<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="review-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Trop Med Infect Dis</journal-id><journal-id journal-id-type="iso-abbrev">Trop Med Infect Dis</journal-id><journal-id journal-id-type="publisher-id">tropicalmed</journal-id><journal-title-group><journal-title>Tropical Medicine and Infectious Disease</journal-title></journal-title-group><issn pub-type="epub">2414-6366</issn><publisher><publisher-name>MDPI</publisher-name></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">39998049</article-id><article-id pub-id-type="pmc">PMC11860496</article-id>
<article-id pub-id-type="doi">10.3390/tropicalmed10020045</article-id><article-id pub-id-type="publisher-id">tropicalmed-10-00045</article-id><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>HIV Cerebrospinal Fluid Escape: Interventions for the Management, Current Evidence and Future Perspectives</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Kelly</surname><given-names>Sophie H.</given-names></name><xref rid="af1-tropicalmed-10-00045" ref-type="aff">1</xref><xref rid="af2-tropicalmed-10-00045" ref-type="aff">2</xref><xref rid="c1-tropicalmed-10-00045" ref-type="corresp">*</xref></contrib><contrib contrib-type="author"><name><surname>Nightingale</surname><given-names>Sam</given-names></name><xref rid="af3-tropicalmed-10-00045" ref-type="aff">3</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0001-9751-1808</contrib-id><name><surname>Gupta</surname><given-names>Ravindra K.</given-names></name><xref rid="af1-tropicalmed-10-00045" ref-type="aff">1</xref><xref rid="af2-tropicalmed-10-00045" ref-type="aff">2</xref><xref rid="af4-tropicalmed-10-00045" ref-type="aff">4</xref><xref rid="af5-tropicalmed-10-00045" ref-type="aff">5</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0001-5446-4423</contrib-id><name><surname>Collier</surname><given-names>Dami A.</given-names></name><xref rid="af1-tropicalmed-10-00045" ref-type="aff">1</xref><xref rid="af6-tropicalmed-10-00045" ref-type="aff">6</xref><xref rid="c1-tropicalmed-10-00045" ref-type="corresp">*</xref></contrib></contrib-group><contrib-group><contrib contrib-type="editor"><name><surname>Ter&#x000e1;n</surname><given-names>Enrique</given-names></name><role>Academic Editor</role></contrib><contrib contrib-type="editor"><name><surname>Izurieta</surname><given-names>Ricardo</given-names></name><role>Academic Editor</role></contrib></contrib-group><aff id="af1-tropicalmed-10-00045"><label>1</label>Cambridge University Hospitals NHS Foundation Trust, Cambridge CB2 0QQ, UK; <email>rkg20@cam.ac.uk</email></aff><aff id="af2-tropicalmed-10-00045"><label>2</label>Department of Medicine, University of Cambridge, Cambridge CB2 1TN, UK</aff><aff id="af3-tropicalmed-10-00045"><label>3</label>Neuroscience Institute, University of Cape Town, Cape Town 7700, South Africa; <email>sam.nightingale@uct.ac.za</email></aff><aff id="af4-tropicalmed-10-00045"><label>4</label>Cambridge Institute of Therapeutic Immunology &#x00026; Infectious Disease (CITIID), Cambridge CB2 0AW, UK</aff><aff id="af5-tropicalmed-10-00045"><label>5</label>Africa Health Research Institute, Durban 4013, South Africa</aff><aff id="af6-tropicalmed-10-00045"><label>6</label>Department of Pathology, University of Cambridge, Cambridge CB2 1TN, UK</aff><author-notes><corresp id="c1-tropicalmed-10-00045"><label>*</label>Correspondence: <email>sk728@cam.ac.uk</email> (S.H.K.); <email>adc82@cam.ac.uk</email> (D.A.C.)</corresp></author-notes><pub-date pub-type="epub"><day>05</day><month>2</month><year>2025</year></pub-date><pub-date pub-type="collection"><month>2</month><year>2025</year></pub-date><volume>10</volume><issue>2</issue><elocation-id>45</elocation-id><history><date date-type="received"><day>19</day><month>11</month><year>2024</year></date><date date-type="rev-recd"><day>22</day><month>1</month><year>2025</year></date><date date-type="accepted"><day>27</day><month>1</month><year>2025</year></date></history><permissions><copyright-statement>&#x000a9; 2025 by the authors.</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><abstract><p>Neurocognitive impairment is an important cause of HIV-associated morbidity. The advent of antiretroviral therapy (ART) has shifted the spectrum of HIV-associated cognitive impairment from HIV-associated dementia to milder forms of cognitive impairment. Independent replication of HIV within the central nervous system in those on effective ART with peripheral suppression is a recognised phenomenon known as cerebrospinal fluid (CSF) HIV RNA escape. CSF HIV RNA escape is independently associated with neurocognitive impairment but has also been detected in asymptomatic persons with HIV. The current consensus for management of CSF HIV RNA escape is based on expert opinion rather than empirical evidence. The current evidence suggests having a low threshold to investigate for CSF HIV RNA escape and optimising ART based on resistance profiles. The use of central nervous system (CNS) penetration effectiveness scores is no longer recommended. The evidence for statins, SSRIs, minocycline, lithium and valproate is limited to small-scale studies. There are potential new developments in the form of nanoparticles, Janus Kinase inhibitors and latency reversal agents.</p></abstract><kwd-group><kwd>HIV</kwd><kwd>cerebrospinal fluid</kwd><kwd>CSF</kwd><kwd>compartmentalization</kwd><kwd>escape</kwd></kwd-group><funding-group><award-group><funding-source>Rosetrees</funding-source><award-id>RCZC/006</award-id></award-group><funding-statement>This research was funded by Rosetrees RCZC/006.</funding-statement></funding-group></article-meta></front><body><sec id="sec1-tropicalmed-10-00045"><title>1. Background</title><sec id="sec1dot1-tropicalmed-10-00045"><title>1.1. Introduction</title><p>Thirty-nine million people are living with human immunodeficiency virus (HIV) globally [<xref rid="B1-tropicalmed-10-00045" ref-type="bibr">1</xref>]. The impact of HIV on the brain was established as early as 1986 with the characterisation of the AIDS dementia complex [<xref rid="B2-tropicalmed-10-00045" ref-type="bibr">2</xref>,<xref rid="B3-tropicalmed-10-00045" ref-type="bibr">3</xref>,<xref rid="B4-tropicalmed-10-00045" ref-type="bibr">4</xref>]. The use of antiretroviral therapy (ART) markedly reduced the prevalence of severe cognitive impairment associated with HIV [<xref rid="B5-tropicalmed-10-00045" ref-type="bibr">5</xref>,<xref rid="B6-tropicalmed-10-00045" ref-type="bibr">6</xref>,<xref rid="B7-tropicalmed-10-00045" ref-type="bibr">7</xref>]. However, there is the persistence of mild cognitive impairment despite adequate treatment with ART [<xref rid="B8-tropicalmed-10-00045" ref-type="bibr">8</xref>]. As HIV treatment and outcomes have improved, there has been a shift in the classification of cognitive impairment in people with HIV away from the Frascati criteria for HIV-associated neurocognitive disorder (HAND) towards one that recognises the multifactorial nature of this condition and differentiates active or legacy HIV-associated brain injury (HABI) from other potential causes of cognitive impairment [<xref rid="B9-tropicalmed-10-00045" ref-type="bibr">9</xref>,<xref rid="B10-tropicalmed-10-00045" ref-type="bibr">10</xref>]. The pathophysiology of HABI is not fully understood. It is thought to occur via multiple mechanisms, including virus-induced neuronal damage, compromised blood&#x02013;brain barrier (BBB) function and chronic immune activation [<xref rid="B9-tropicalmed-10-00045" ref-type="bibr">9</xref>]. Neuroinflammation can occur following viral entry and replication in the brain [<xref rid="B11-tropicalmed-10-00045" ref-type="bibr">11</xref>,<xref rid="B12-tropicalmed-10-00045" ref-type="bibr">12</xref>,<xref rid="B13-tropicalmed-10-00045" ref-type="bibr">13</xref>,<xref rid="B14-tropicalmed-10-00045" ref-type="bibr">14</xref>]. HIV CNS entry occurs in the acute phase of infection and is near universal [<xref rid="B15-tropicalmed-10-00045" ref-type="bibr">15</xref>]. In times of high viral load, either through direct viral toxicity or due to the subsequent inflammatory response, the tight junctions of the BBB are disrupted [<xref rid="B16-tropicalmed-10-00045" ref-type="bibr">16</xref>,<xref rid="B17-tropicalmed-10-00045" ref-type="bibr">17</xref>,<xref rid="B18-tropicalmed-10-00045" ref-type="bibr">18</xref>,<xref rid="B19-tropicalmed-10-00045" ref-type="bibr">19</xref>]. The virus can cross the BBB directly and through infected monocytes and T cells&#x02014;this establishes a reservoir of infection in microglia, perivascular macrophages and astrocytes [<xref rid="B20-tropicalmed-10-00045" ref-type="bibr">20</xref>,<xref rid="B21-tropicalmed-10-00045" ref-type="bibr">21</xref>]. There is evidence that the BBB disruption that occurs in primary CNS infection can persist despite treatment with ART [<xref rid="B22-tropicalmed-10-00045" ref-type="bibr">22</xref>]. Once HIV has entered the CNS, it is exposed to a distinct microenvironment [<xref rid="B23-tropicalmed-10-00045" ref-type="bibr">23</xref>]. This allows for the development of compartmentalised infection and the evolution of genetically distinct quasispecies within the CNS compartment [<xref rid="B24-tropicalmed-10-00045" ref-type="bibr">24</xref>]. Viral populations have been reported to sometimes evolve from R5 T cell-tropic virus to R5 macrophage-tropic virus with a greater ability to infect myeloid-derived cells in the CNS [<xref rid="B24-tropicalmed-10-00045" ref-type="bibr">24</xref>,<xref rid="B25-tropicalmed-10-00045" ref-type="bibr">25</xref>,<xref rid="B26-tropicalmed-10-00045" ref-type="bibr">26</xref>,<xref rid="B27-tropicalmed-10-00045" ref-type="bibr">27</xref>,<xref rid="B28-tropicalmed-10-00045" ref-type="bibr">28</xref>]. Productive infection is predominantly found in perivascular macrophages and microglia. Infection is associated with inflammation and immune activation of glial cells, which contributes to neuronal injury [<xref rid="B13-tropicalmed-10-00045" ref-type="bibr">13</xref>]. Furthermore, some viral proteins, for example Tat and gp120, can directly cause neuronal injury [<xref rid="B29-tropicalmed-10-00045" ref-type="bibr">29</xref>].</p><p>CSF HIV RNA escape is defined as CSF HIV RNA concentration that is higher than plasma HIV RNA concentration [<xref rid="B30-tropicalmed-10-00045" ref-type="bibr">30</xref>]. The reported prevalence of CSF HIV RNA escape varies between studies, with estimates ranging from 1 to 28.6% of PLWH on ART [<xref rid="B31-tropicalmed-10-00045" ref-type="bibr">31</xref>,<xref rid="B32-tropicalmed-10-00045" ref-type="bibr">32</xref>,<xref rid="B33-tropicalmed-10-00045" ref-type="bibr">33</xref>,<xref rid="B34-tropicalmed-10-00045" ref-type="bibr">34</xref>,<xref rid="B35-tropicalmed-10-00045" ref-type="bibr">35</xref>,<xref rid="B36-tropicalmed-10-00045" ref-type="bibr">36</xref>,<xref rid="B37-tropicalmed-10-00045" ref-type="bibr">37</xref>,<xref rid="B38-tropicalmed-10-00045" ref-type="bibr">38</xref>,<xref rid="B39-tropicalmed-10-00045" ref-type="bibr">39</xref>,<xref rid="B40-tropicalmed-10-00045" ref-type="bibr">40</xref>,<xref rid="B41-tropicalmed-10-00045" ref-type="bibr">41</xref>,<xref rid="B42-tropicalmed-10-00045" ref-type="bibr">42</xref>,<xref rid="B43-tropicalmed-10-00045" ref-type="bibr">43</xref>]. However, some of this variation may relate to the population studied, indication for LP and differences in the definitions of CSF HIV RNA escape used. No distinctive clinical characteristics can predict CSF HIV RNA escape, and no biomarkers are in clinical use [<xref rid="B43-tropicalmed-10-00045" ref-type="bibr">43</xref>]. CSF HIV RNA escape is a known cause of HABI [<xref rid="B44-tropicalmed-10-00045" ref-type="bibr">44</xref>,<xref rid="B45-tropicalmed-10-00045" ref-type="bibr">45</xref>].</p></sec><sec id="sec1dot2-tropicalmed-10-00045"><title>1.2. Aims of Review</title><p>There are few consensus guidelines on the treatment of CSF HIV RNA escape. The British HIV Association (BHIVA) and European Aids Clinical Society (EACS) recommend sampling CSF in those with cognitive impairment and an undetectable viral load in the absence of another cause and, if there is a detectable CSF viral load, genotyping this virus for drug resistance mutations [<xref rid="B46-tropicalmed-10-00045" ref-type="bibr">46</xref>,<xref rid="B47-tropicalmed-10-00045" ref-type="bibr">47</xref>]. The BHIVA and EACS recommend avoiding two drug regimens, protease inhibitors and raltegravir, and suggest including a dual nucleoside backbone with consideration of an increased dose of dolutegravir [<xref rid="B46-tropicalmed-10-00045" ref-type="bibr">46</xref>,<xref rid="B47-tropicalmed-10-00045" ref-type="bibr">47</xref>]. Over recent years, there has been growing interest in repurposing already licensed drugs for the treatment of HIV CNS disease and in developing newer technologies such as nanoparticles. This review summarises the currently available evidence for the treatment of CSF HIV RNA escape and directions for future research.</p></sec></sec><sec sec-type="methods" id="sec2-tropicalmed-10-00045"><title>2. Methods and Definitions</title><sec id="sec2dot1-tropicalmed-10-00045"><title>2.1. Methods</title><p>Databases including PubMed, Medline, Embase and Cochrane were searched for the following terms: &#x0201c;HIV&#x0201d; or &#x0201c;Human Immunodeficiency Virus&#x0201d; or &#x0201c;Acquired Immunodeficiency Syndrome&#x0201d; or &#x0201c;AIDS&#x0201d; and &#x0201c;Cerebrospinal fluid&#x0201d; or &#x0201c;CSF&#x0201d; and &#x0201c;escape&#x0201d; or &#x0201c;discordance&#x0201d; or &#x0201c;discordant&#x0201d;; this was performed for texts published up to October 2024. Inclusion criteria were texts available in the English language that included CSF viral load before and after initiation of an intervention or treatment; exclusion criteria were texts that only reported cognitive outcomes. We included all study types, case reports and case series. We assessed the strength of evidence based on the modified the (GRADE) system adopted by BHIVA [<xref rid="B46-tropicalmed-10-00045" ref-type="bibr">46</xref>,<xref rid="B48-tropicalmed-10-00045" ref-type="bibr">48</xref>]; we report recommendations as described in current international guidelines.</p></sec><sec id="sec2dot2-tropicalmed-10-00045"><title>2.2. Definition of CSF HIV RNA Escape</title><p>The consensus on the definition of CSF HIV RNA escape has been most recently agreed upon at the Second Global HIV Cerebrospinal Fluid Escape Consortium in 2019 [<xref rid="B30-tropicalmed-10-00045" ref-type="bibr">30</xref>]. At this meeting, three key recommendations were made: (i) CSF HIV RNA escape should be defined as any detectable CSF RNA level where plasma RNA level is undetectable and any CSF HIV RNA level that is greater than the plasma HIV RNA level when plasma RNA is detectable; (ii) CSF HIV RNA escape should be classified as symptomatic or asymptomatic based on the reported symptoms of the patient rather than the indication for lumbar puncture; and (iii) CSF HIV RNA escape should be actively managed when the patient is symptomatic [<xref rid="B30-tropicalmed-10-00045" ref-type="bibr">30</xref>].</p></sec><sec id="sec2dot3-tropicalmed-10-00045"><title>2.3. Types of Escape</title><p><xref rid="tropicalmed-10-00045-t001" ref-type="table">Table 1</xref> shows a schema for categorising CSF HIV RNA escape. Typically, three types of CSF HIV RNA escape have been described: symptomatic, asymptomatic and secondary [<xref rid="B49-tropicalmed-10-00045" ref-type="bibr">49</xref>]. &#x0201c;Symptomatic&#x0201d; CSF HIV RNA escape refers to primary CSF HIV RNA escape, that occurs in the absence of another CNS opportunistic infection, in people with neurological symptoms. &#x0201c;Asymptomatic&#x0201d; CSF HIV RNA escape refers to primary CSF HIV RNA escape in the absence of neurological symptoms. &#x0201c;Secondary&#x0201d; CSF HIV RNA escape refers to CSF HIV RNA escape that occurs in the context of another cause of CSF pleocytosis, such as a CNS opportunistic infection.</p><p>We have proposed a fourth category of artefactual CSF escape to describe the presence of HIV RNA at higher levels in CSF than plasma at levels within the variability of the HIV RNA assay used (correlation of variation in commonly used assays is 32% to 77% at low viral loads) and maybe related to differential suppression rates between the CSF and plasma compartments [<xref rid="B50-tropicalmed-10-00045" ref-type="bibr">50</xref>]. The inclusion of this category recognises that, within the current accepted classification system, some people who do not have true asymptomatic escape will be classified as having asymptomatic escape due to the variability of the assays. We believe that this is a conceptually distinct entity to true asymptomatic escape and should be recognised in the fourth category of &#x0201c;Artefactual&#x0201d; CSF HIV RNA escape.</p></sec><sec id="sec2dot4-tropicalmed-10-00045"><title>2.4. Epidemiology and Clinical Context</title><p>CSF HIV RNA escape has a broad spectrum of clinical manifestations, ranging from asymptomatic to neurological symptoms such as cognitive impairment, headaches, sleep disturbance, seizures, ataxia, personality disorders, psychosis, coma and death [<xref rid="B43-tropicalmed-10-00045" ref-type="bibr">43</xref>,<xref rid="B49-tropicalmed-10-00045" ref-type="bibr">49</xref>,<xref rid="B51-tropicalmed-10-00045" ref-type="bibr">51</xref>,<xref rid="B52-tropicalmed-10-00045" ref-type="bibr">52</xref>,<xref rid="B53-tropicalmed-10-00045" ref-type="bibr">53</xref>,<xref rid="B54-tropicalmed-10-00045" ref-type="bibr">54</xref>].</p><p>The clinical significance of CSF HIV RNA escape has been reviewed in more detail by this group elsewhere [<xref rid="B14-tropicalmed-10-00045" ref-type="bibr">14</xref>]. Cognitive impairment in people with HIV is often multifactorial and can be caused by opportunistic infection, ART toxicity and other non-HIV related causes [<xref rid="B8-tropicalmed-10-00045" ref-type="bibr">8</xref>,<xref rid="B55-tropicalmed-10-00045" ref-type="bibr">55</xref>]. CSF HIV RNA escape has been associated with poor scores on neuropsychological testing in people with HIV, and HIV-1 RNA transcripts are associated with neuroinflammation and cognitive impairment [<xref rid="B56-tropicalmed-10-00045" ref-type="bibr">56</xref>]. CSF HIV RNA escape is not the most common cause of cognitive impairment in people with HIV; studies have found CSF HIV RNA escape to be present in between 10 and 20% of people presenting with neurological symptoms [<xref rid="B55-tropicalmed-10-00045" ref-type="bibr">55</xref>]. Asymptomatic escape is present in between 1 and 2% of people living with HIV on effective ART [<xref rid="B57-tropicalmed-10-00045" ref-type="bibr">57</xref>,<xref rid="B58-tropicalmed-10-00045" ref-type="bibr">58</xref>,<xref rid="B59-tropicalmed-10-00045" ref-type="bibr">59</xref>]. The significance of asymptomatic escape is not clear, and it is not always associated with HABI. The current consensus opinion on management is to treat those with neurological symptoms and to do so with ART intensification [<xref rid="B9-tropicalmed-10-00045" ref-type="bibr">9</xref>]. In Europe and the UK, testing for CSF HIV viral load is recommended in anyone presenting with cognitive impairment and viral suppression after other causes of the symptoms, including psychiatric causes and opportunistic infections, have been excluded [<xref rid="B10-tropicalmed-10-00045" ref-type="bibr">10</xref>,<xref rid="B46-tropicalmed-10-00045" ref-type="bibr">46</xref>]. This algorithmic protocol is not standardised worldwide and is limited by access and acceptability of CSF testing.</p><table-wrap position="anchor" id="tropicalmed-10-00045-t001"><object-id pub-id-type="pii">tropicalmed-10-00045-t001_Table 1</object-id><label>Table 1</label><caption><p>A schema for categorising CSF HIV RNA escape.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">
</th><th align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Typical Clinical Presentation</th><th align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Prevalence and Relative Frequency</th><th align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Typical CSF Findings</th><th align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Typical Imaging Findings</th></tr></thead><tbody><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><bold>Symptomatic</bold><break/>Primary CSF HIV RNA escape presenting with neurological symptoms</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Variable presentations can include: <break/>Cognitive slowing<break/>Headaches<break/>Sleep disturbance<break/>Seizures<break/>Ataxia<break/>Personality change Psychosis<break/>Reduced level of consciousness [<xref rid="B14-tropicalmed-10-00045" ref-type="bibr">14</xref>]</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">In two large cohort studies of people on ART, the achieved viral suppression overall prevalence was estimated at 0.09&#x02013;2.5% [<xref rid="B35-tropicalmed-10-00045" ref-type="bibr">35</xref>,<xref rid="B36-tropicalmed-10-00045" ref-type="bibr">36</xref>] * <break/>35.1&#x02013;38.2% of aviraemic patients with CSF escape had neurocognitive impairment [<xref rid="B35-tropicalmed-10-00045" ref-type="bibr">35</xref>,<xref rid="B36-tropicalmed-10-00045" ref-type="bibr">36</xref>] ** </td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Lymphocytic pleocytosis<break/>High neuroinflammatory markers<break/>High levels of neurofilament light chain [<xref rid="B60-tropicalmed-10-00045" ref-type="bibr">60</xref>,<xref rid="B61-tropicalmed-10-00045" ref-type="bibr">61</xref>]<break/>High levels of CSF neopterin</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Diffuse white matter signal abnormalities on brain MRI [<xref rid="B33-tropicalmed-10-00045" ref-type="bibr">33</xref>]</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><bold>Asymptomatic</bold><break/>Primary CSF HIV RNA escape presenting without any neurological symptoms</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No symptoms<break/>Can be transient (CSF blips)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">In two large cohort studies of people on ART, the achieved viral suppression overall prevalence was estimated as 2.7&#x02013;4.7% [<xref rid="B35-tropicalmed-10-00045" ref-type="bibr">35</xref>,<xref rid="B36-tropicalmed-10-00045" ref-type="bibr">36</xref>] <break/>61.8&#x02013;64.9% of aviraemic patients with CSF escape had no neurocognitive symptoms [<xref rid="B35-tropicalmed-10-00045" ref-type="bibr">35</xref>,<xref rid="B36-tropicalmed-10-00045" ref-type="bibr">36</xref>] *** </td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Can have mildly raised CSF white cell count [<xref rid="B60-tropicalmed-10-00045" ref-type="bibr">60</xref>,<xref rid="B62-tropicalmed-10-00045" ref-type="bibr">62</xref>]<break/>Lower CSF neurofilament light chain compared to symptomatic escape [<xref rid="B60-tropicalmed-10-00045" ref-type="bibr">60</xref>]<break/>Can have raised neopterin, though typically lower than symptomatic or secondary escape [<xref rid="B32-tropicalmed-10-00045" ref-type="bibr">32</xref>,<xref rid="B60-tropicalmed-10-00045" ref-type="bibr">60</xref>]</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Not associated with changes in brain imaging</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><bold>Secondary</bold><break/>CSF HIV RNA escape in the presence of an alternative cause of CSF pleocytosis</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">May have symptoms in the context of another neurological infection or autoimmune condition</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Limited evidence <break/>In one study, 33.8% of virally suppressed people with CSF escape had a neurological coinfection [<xref rid="B35-tropicalmed-10-00045" ref-type="bibr">35</xref>] </td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Related to the neurological infection <break/>High levels of CSF neopterin </td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Related to the underlying neurological infection</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><bold>Artefactual</bold><break/>CSF HIV RNA viral load higher than HIV RNA plasma viral load within the variability of the assay used</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No symptoms</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Unknown </td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No lymphocytic pleocytosis</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Not associated with changes in brain imaging</td></tr></tbody></table><table-wrap-foot><fn><p>* Mukerji et al.; cohort of 1063 people, the overall prevalence of CSF escape with symptoms reported was 35.1% (<italic toggle="yes">n</italic> = 27) of participants with CSF escape. The authors reported that 33.8% (<italic toggle="yes">n</italic> = 26) of patients with CSF escape have a neurological co-infection, but it is not clear how many of these patients are symptomatic. Therefore, assuming all patients with a neurological co-infection have symptoms and there is only 1 case of true primary symptomatic CSF escape rather than secondary escape, the lowest possible estimate for the overall prevalence of primary symptomatic CSF escape is 1 in 1063, 0.09%, and the highest possible estimate is 27 in 1063, 2.5%. ** Perez Valero et al.; the prevalence of neurocognitive impairment in people with CSF escape was not significantly different to the prevalence of cognitive impairment in those without escape (38.2 vs. 37.7%; <italic toggle="yes">p</italic> = 0.91) [<xref rid="B36-tropicalmed-10-00045" ref-type="bibr">36</xref>]. *** Mukerji et al.; 22.2% of patients with CSF escape were categorised as having &#x0201c;Asymptomatic neurocognitive impairment&#x0201d;, defined as a deficit in neurocognitive testing that did not interfere with activities of daily living. These patients are included in the proportion of asymptomatic escape for the purpose of these prevalence estimates.</p></fn></table-wrap-foot></table-wrap></sec><sec id="sec2dot5-tropicalmed-10-00045"><title>2.5. Mechanisms of CSF HIV RNA Escape</title><p>There are multiple possible mechanisms of CSF HIV RNA escape. One theory is reduced drug penetration of the CNS compartment, allowing for the evolution of drug resistance mutations within this compartment [<xref rid="B53-tropicalmed-10-00045" ref-type="bibr">53</xref>]. Another is that latent virus in the CNS reservoir reactivates. Once in the CNS, the virus infects and integrates proviral DNA into long-lived cells, such as microglia, that are relatively resistant to viral-induced apoptosis [<xref rid="B63-tropicalmed-10-00045" ref-type="bibr">63</xref>]. When activated, these cells maintain the CNS reservoir and can produce infectious virus [<xref rid="B64-tropicalmed-10-00045" ref-type="bibr">64</xref>,<xref rid="B65-tropicalmed-10-00045" ref-type="bibr">65</xref>]. Myeloid cells are intrinsically relatively resistant to productive infection due to the restriction factor sterile alpha motif domain and histidine&#x02013;aspartic domain-containing protein 1 (SAMHD1) that blocks reverse transcription by depletion of deoxynucleotide triphosphate (dNTP) [<xref rid="B66-tropicalmed-10-00045" ref-type="bibr">66</xref>,<xref rid="B67-tropicalmed-10-00045" ref-type="bibr">67</xref>]. However, macrophage cell cycle transitioning can lead to the deactivation of SAMHD1 and render macrophages susceptible [<xref rid="B68-tropicalmed-10-00045" ref-type="bibr">68</xref>]. This transition can occur following various environmental cues, such as low oxygen. Myeloid reservoirs for HIV have become increasingly recognised as significant [<xref rid="B69-tropicalmed-10-00045" ref-type="bibr">69</xref>]. Other mechanisms include increased trafficking of T cells across the BBB in people with low-level viraemia (LLV) and clonal expansion of expanded infected T cells [<xref rid="B65-tropicalmed-10-00045" ref-type="bibr">65</xref>].</p><sec id="sec2dot5dot1-tropicalmed-10-00045"><title>2.5.1. Symptomatic Escape</title><p>Recent work by Kincer et al. has demonstrated that symptomatic CSF HIV RNA escape is driven by ongoing HIV replication in CNS CD4+ T cells [<xref rid="B61-tropicalmed-10-00045" ref-type="bibr">61</xref>]. In the study, there was concordance between the drug resistance mutations in the CSF and plasma virus, suggesting ongoing replication rather than compartmentalised infection [<xref rid="B61-tropicalmed-10-00045" ref-type="bibr">61</xref>]. The authors proposed a model whereby resistance to drugs with high CSF penetration, such as lamivudine, evolves during a period of treatment interruption and is selected on reinitiation of ART. Variants with lamivudine resistance due to the M184V mutation have reduced fitness and are increasingly susceptible to tenofovir, suggesting that they could only survive in an environment where tenofovir levels are not suppressive, such as the CSF [<xref rid="B61-tropicalmed-10-00045" ref-type="bibr">61</xref>]. This theory explains the increased prevalence of M184V mutations in people with CSF HIV RNA escape.</p><p>CSF HIV RNA escape can cause neurological symptoms by triggering CD8 encephalitis, a severe inflammatory disorder characterised by the infiltration of CD8 T-lymphocytes into the CNS. This rare but life-threatening disorder typically presents when HIV is well controlled on ART. The pathophysiology of CD8 encephalitis is unclear, but CSF HIV RNA escape is a common finding present in 68% of patients with CD8 encephalitis [<xref rid="B70-tropicalmed-10-00045" ref-type="bibr">70</xref>]. It has been suggested that ongoing and potentially compartmentalised CNS HIV replication induces a widespread CD8+ T cell response, CNS infiltration and encephalitis.</p></sec><sec id="sec2dot5dot2-tropicalmed-10-00045"><title>2.5.2. Asymptomatic Escape</title><p>Asymptomatic CSF HIV RNA escape has been identified in patients who have had lumbar puncture for research purposes. Eden et al. found a CSF HIV RNA escape prevalence of 10% amongst 69 asymptomatic, virologically suppressed individuals [<xref rid="B32-tropicalmed-10-00045" ref-type="bibr">32</xref>]. A follow-up retrospective longitudinal study in a group in 75 asymptomatic individuals found a prevalence of 36% [<xref rid="B71-tropicalmed-10-00045" ref-type="bibr">71</xref>]. However, this is at a viral load limit of detection of 20 copies/mL compared with 50 copies/mL in the prior study. Upon repeat sampling, CSF HIV RNA escape persisted at a rate of 3%. It is thought that the other cases were due to CSF viral blips. In larger cohorts, including CHARTER, National NeuroAids Tissue Consortium (NNTC) and HIV Neurobehavioural Research Centre (HNRC), the prevalence of asymptomatic CSF HIV RNA escape amongst aviraemic individuals was between 2.7 and 4.7% (c.f. 0.09&#x02013;2.5% symptomatic CSF HIV RNA escape) (<xref rid="tropicalmed-10-00045-t001" ref-type="table">Table 1</xref>) [<xref rid="B35-tropicalmed-10-00045" ref-type="bibr">35</xref>,<xref rid="B36-tropicalmed-10-00045" ref-type="bibr">36</xref>]. These were based on a limit of quantification of 50 copies/mL. It is likely that the true prevalence of asymptomatic CSF HIV RNA escape is greater than that of symptomatic CSF HIV RNA escape; however it is affected by the limit of detection of the assay used, the population from which the sample is drawn and the CSF sample volume used.</p><p>Asymptomatic CSF HIV RNA escape has been found to be associated with pleocytosis and biomarkers of intrathecal immune activation and BBB dysfunction, although not in all cases [<xref rid="B32-tropicalmed-10-00045" ref-type="bibr">32</xref>,<xref rid="B57-tropicalmed-10-00045" ref-type="bibr">57</xref>,<xref rid="B72-tropicalmed-10-00045" ref-type="bibr">72</xref>,<xref rid="B73-tropicalmed-10-00045" ref-type="bibr">73</xref>]. In contrast to symptomatic CSF HIV RNA escape, which involves active replication of HIV-1, asymptomatic CSF HIV RNA escape can be produced by virus expression from clonally expanded CD4+ T cells in the absence of replication or by replication in reactivated macrophages [<xref rid="B65-tropicalmed-10-00045" ref-type="bibr">65</xref>]. Eden et al., in a cohort of asymptomatic CSF HIV RNA escape, found raised neopterin, a marker of macrophage activation, which suggests that the source can be the CNS reservoir [<xref rid="B32-tropicalmed-10-00045" ref-type="bibr">32</xref>].</p><p>The concept of a plasma blip, an isolated detectable HIV RNA viral load followed by a return to viral suppression, is well recognised. Longitudinal analysis of neurologically asymptomatic and virally suppressed cohorts demonstrates that transient low-level detectable viraemia also occurs in the CSF [<xref rid="B71-tropicalmed-10-00045" ref-type="bibr">71</xref>]. This was not sustained in most patients and was associated with a plasma blip at one of the time points and a higher CSF neopterin [<xref rid="B71-tropicalmed-10-00045" ref-type="bibr">71</xref>]. This suggests that in well-controlled virologically suppressed patients, CSF viraemia may reflect low-level variations in the release of virus into the CSF compartment rather than ongoing replication within the CNS. The significance of asymptomatic CSF HIV RNA escape in terms of the impact on cognitive function or progression to symptomatic escape is currently unclear.</p></sec><sec id="sec2dot5dot3-tropicalmed-10-00045"><title>2.5.3. Secondary CSF HIV RNA Escape</title><p><xref rid="tropicalmed-10-00045-f001" ref-type="fig">Figure 1</xref> illustrates the mechanisms of secondary CSF HIV RNA escape. HIV can increase the risk of CNS opportunistic infections (OIs), including <italic toggle="yes">Mycobacterium tuberculosis</italic>, <italic toggle="yes">Toxoplasma gondii</italic>, herpes viruses, JC virus, Epstein-Barr virus (EBV) and <italic toggle="yes">Cryptococcus neoformans</italic>, by facilitating entry, enhancing transcription and causing reactivation [<xref rid="B74-tropicalmed-10-00045" ref-type="bibr">74</xref>]. In turn, opportunistic infections can generate inflammation and increase the translocation of HIV-infected lymphocytes across the BBB [<xref rid="B74-tropicalmed-10-00045" ref-type="bibr">74</xref>]. OIs, particularly those that cause macrophage activation such as Cryptococcus neoformans, tuberculosis and toxoplasmosis, can help to sustain local HIV replication in the CNS and the development of a distinct CNS virus [<xref rid="B75-tropicalmed-10-00045" ref-type="bibr">75</xref>,<xref rid="B76-tropicalmed-10-00045" ref-type="bibr">76</xref>]. Those with CNS OIs can have increased CSF HIV RNA viral loads and are at increased risk of escape, the significance of which is not known.</p><p>Persons with HIV are less likely to be able to completely control DNA viruses such as EBV. EBV is known to infect endothelial cells and, upon reactivation, increase the expression of proinflammatory cytokines CCL-2 and CCL-5 and adhesion molecules [<xref rid="B77-tropicalmed-10-00045" ref-type="bibr">77</xref>]. It is thought that this can lead to alteration of the BBB and that a chronic subclinical EBV infection could increase immune cell trafficking and thus the migration of HIV into the CNS [<xref rid="B49-tropicalmed-10-00045" ref-type="bibr">49</xref>,<xref rid="B78-tropicalmed-10-00045" ref-type="bibr">78</xref>]. A cohort study of 297 persons with HIV found that EBV was detected in the CSF of 9.2% of peripherally suppressed patients [<xref rid="B79-tropicalmed-10-00045" ref-type="bibr">79</xref>]. The presence of EBV was independently associated with CSF HIV RNA escape, CSF pleocytosis and markers of inflammation. A study using next-generation sequencing with immunostaining and multiplexed self-antigen serology demonstrated that EBV was more frequently present in the CSF of symptomatic CSF HIV RNA escape patients than in asymptomatic controls, suggesting that EBV may be playing a role in HABI [<xref rid="B79-tropicalmed-10-00045" ref-type="bibr">79</xref>].</p></sec><sec id="sec2dot5dot4-tropicalmed-10-00045"><title>2.5.4. Artefactual&#x02014;Differential Suppression and Limitations of the Assay</title><p>The pharmacodynamics of ART are such that in some cases, plasma viral load can suppress more quickly than CSF HIV RNA, particularly in those with HABI symptoms, low peripheral CD4 counts and reduced CSF pleocytosis [<xref rid="B64-tropicalmed-10-00045" ref-type="bibr">64</xref>,<xref rid="B80-tropicalmed-10-00045" ref-type="bibr">80</xref>,<xref rid="B81-tropicalmed-10-00045" ref-type="bibr">81</xref>]. It has been proposed that in some patients with advanced disease, T-tropic variants in the blood are rapidly suppressed, whereas M-tropic variants maintained in the CNS are suppressed more slowly [<xref rid="B73-tropicalmed-10-00045" ref-type="bibr">73</xref>]. Therefore, if the lumbar puncture is taken early in treatment, after treatment interruption and reinitiation or change in treatment, the CSF viral load may be greater than the plasma viral load, but this does not represent ongoing replication in the CNS. For example, in a recent CONNECT study, transient CSF escape was observed in a participant switching from efavirenz to dolutegravir, which was proposed to be due to differential viral decay between the CSF and plasma compartments [<xref rid="B82-tropicalmed-10-00045" ref-type="bibr">82</xref>]. Ellis et al. demonstrated that CSF viral decay following treatment initiation is much slower than the decrease in plasma viral load in people with advanced HIV disease (defined as a CD4 count &#x0003c;400/&#x003bc;L) and in those with cognitive impairment when compared with those who start treatment with a CD4 count &#x0003e;400/&#x003bc;L [<xref rid="B80-tropicalmed-10-00045" ref-type="bibr">80</xref>]. This suggests that in advanced HIV disease, there can be ongoing replication in the CNS compartment, which may take longer to respond to ART [<xref rid="B80-tropicalmed-10-00045" ref-type="bibr">80</xref>].</p><p>Particularly at low copy numbers, there is significant variation within and between HIV RNA assays. Intra-assay variability can be high and can be affected by many factors, including sample preparation, the operator&#x02019;s experience and automaticity of the assay [<xref rid="B50-tropicalmed-10-00045" ref-type="bibr">50</xref>,<xref rid="B83-tropicalmed-10-00045" ref-type="bibr">83</xref>,<xref rid="B84-tropicalmed-10-00045" ref-type="bibr">84</xref>]. For example, at 50 copies/mL, precision has been estimated to be around 0.33 log10 or 23&#x02013;110 copies/mL [<xref rid="B85-tropicalmed-10-00045" ref-type="bibr">85</xref>]. Given the sensitivity of novel tests, which can detect viral loads down to 20 copies/mL, a proportion of people will have CSF escape based on these results that would not have been classified as having escape with standard assays. For example, in Eden&#x02019;s cohort, 27 participants (36%) were classified as having escape based on a limit of 20 copies/mL, whilst this reduced to 17 participants (20%) when the limit of 50 copies/mL was used [<xref rid="B71-tropicalmed-10-00045" ref-type="bibr">71</xref>]. The significance of this low-level CSF viral load is debated [<xref rid="B86-tropicalmed-10-00045" ref-type="bibr">86</xref>,<xref rid="B87-tropicalmed-10-00045" ref-type="bibr">87</xref>].</p></sec></sec><sec id="sec2dot6-tropicalmed-10-00045"><title>2.6. Biomarkers for Early Detection</title><p>Gissl&#x000e9;n et al. showed that neurofilament light protein (NFL), a marker of axonal injury, was a useful biomarker for predicting the onset of neurocognitive impairment in people with HIV [<xref rid="B88-tropicalmed-10-00045" ref-type="bibr">88</xref>]. However, there are currently no biomarkers used in clinical practice to predict the onset of either symptomatic, asymptomatic or secondary CSF HIV RNA escape. NFL has the potential to be a useful marker for assessing treatment response. It is raised in symptomatic escape but normalises on CSF viral suppression; furthermore, as the plasma concentration correlates strongly with the CSF concentration, this has the potential to be a less invasive marker to monitor treatment response and to distinguish between legacy and active HIV-induced neuronal damage [<xref rid="B60-tropicalmed-10-00045" ref-type="bibr">60</xref>,<xref rid="B89-tropicalmed-10-00045" ref-type="bibr">89</xref>,<xref rid="B90-tropicalmed-10-00045" ref-type="bibr">90</xref>]. Hu et al. recently examined the role of over 1000 CSF proteins in HIV associated disease and found that for a panel of 10 proteins that were most useful in differentiating the different phenotypes of CSF HIV RNA escape, most of these proteins were involved in neuroinflammatory processes [<xref rid="B60-tropicalmed-10-00045" ref-type="bibr">60</xref>]. The role of these tools in detecting early CSF HIV RNA escape has yet to be established.</p></sec></sec><sec id="sec3-tropicalmed-10-00045"><title>3. Existing Treatment for CSF HIV RNA Escape</title><p>Treatment for CSF HIV RNA escape is determined by the underlying cause and the symptomology. Secondary CSF HIV RNA escape is managed by treating the underlying cause. Treatment is currently only recommended for primary CSF HIV RNA escape when there are symptoms [<xref rid="B30-tropicalmed-10-00045" ref-type="bibr">30</xref>]. Therefore, the rest of this review will focus on the treatments for symptomatic CSF HIV RNA escape. <xref rid="tropicalmed-10-00045-t002" ref-type="table">Table 2</xref> shows the strengths and limitations of each treatment, the current recommendations based on BHIVA and EACS guidelines and the level of evidence that supports the recommendation.</p><sec id="sec3dot1-tropicalmed-10-00045"><title>3.1. Optimising Antiretroviral Therapy</title><p>A potential issue in the treatment of HIV in the CNS may be the variability in the penetration of some antiretrovirals across the BBB to reach optimal concentrations in the CNS [<xref rid="B35-tropicalmed-10-00045" ref-type="bibr">35</xref>,<xref rid="B91-tropicalmed-10-00045" ref-type="bibr">91</xref>,<xref rid="B92-tropicalmed-10-00045" ref-type="bibr">92</xref>,<xref rid="B93-tropicalmed-10-00045" ref-type="bibr">93</xref>]. The BBB is a selective and highly impermeable barrier formed by a monolayer of microvascular endothelial cells connected by tight junction proteins [<xref rid="B23-tropicalmed-10-00045" ref-type="bibr">23</xref>]. The BBB serves an important purpose in the preservation of the microenvironment of the brain [<xref rid="B23-tropicalmed-10-00045" ref-type="bibr">23</xref>].</p><p>ART does not easily cross the BBB and, when it does, is susceptible to removal via ATP-binding efflux pumps embedded within the endothelial monolayer [<xref rid="B94-tropicalmed-10-00045" ref-type="bibr">94</xref>]. It is thought that some drugs, such as abacavir and protease inhibitors, are unable to reach therapeutic concentrations in the brain due to high efflux [<xref rid="B94-tropicalmed-10-00045" ref-type="bibr">94</xref>]. A multitude of factors contribute to the bioavailability of a drug in the CNS, including weight, molecular size, lipophilicity, interaction with molecular pumps and other proteins. For example, some drugs, such as the relatively new non-nucleoside reverse transcriptase inhibitor doravirine, reach very high unbound concentrations in the CSF and have been proposed as a potential useful addition in people with neurocognitive impairment [<xref rid="B95-tropicalmed-10-00045" ref-type="bibr">95</xref>].</p><p>There has been debate about the utility of a CNS penetration effectiveness (CPE) score to optimise ART in cognitive impairment. The CPE score ranks individual ART drugs from 1 to 4, with 4 reflecting the highest CNS penetration [<xref rid="B96-tropicalmed-10-00045" ref-type="bibr">96</xref>]. The score is derived from the chemical properties of the drug, the concentration of the drug in the CSF in human or animal studies and demonstrated effectiveness in improving CSF viral load in clinical studies [<xref rid="B80-tropicalmed-10-00045" ref-type="bibr">80</xref>,<xref rid="B96-tropicalmed-10-00045" ref-type="bibr">96</xref>,<xref rid="B97-tropicalmed-10-00045" ref-type="bibr">97</xref>,<xref rid="B98-tropicalmed-10-00045" ref-type="bibr">98</xref>]. The use of this score in clinical practice is limited, and cohort studies report conflicting findings. One small (<italic toggle="yes">n</italic> = 49) prospective randomised control trial found no difference in cognitive outcomes in those assigned to the higher CPE-score ART regimes and lower levels of plasma viral suppression [<xref rid="B99-tropicalmed-10-00045" ref-type="bibr">99</xref>]. There are some clear issues with the assumption that CSF drug levels are comparable with brain parenchymal levels; indeed, a recent study performed on the brains of recently deceased people with HIV found that for some drugs, such as efavirenz, parenchymal levels were much higher than CSF levels [<xref rid="B100-tropicalmed-10-00045" ref-type="bibr">100</xref>]. Therefore, using the CPE score to guide clinical practice is not recommended.</p><p>Whilst viral suppression is neuroprotective, there has recently been more recognition of the neurotoxicity of antiretroviral therapy [<xref rid="B101-tropicalmed-10-00045" ref-type="bibr">101</xref>]. Whilst some drugs, such as efavirenz, are well known to be neurotoxic, there are several questions about the potential toxicity of multiple ART drugs [<xref rid="B102-tropicalmed-10-00045" ref-type="bibr">102</xref>]. Treatment of patients with HABI and CSF HIV RNA escape needs to consider the potential neurotoxicity of the treatment itself.</p></sec><sec id="sec3dot2-tropicalmed-10-00045"><title>3.2. Optimising ART to Target Resistant Viruses</title><p>Certain HIV drug resistance mutations, such as M184V/I mutations and thymidine analogue mutations, are more common in people with HIV and CSF HIV RNA escape [<xref rid="B35-tropicalmed-10-00045" ref-type="bibr">35</xref>,<xref rid="B39-tropicalmed-10-00045" ref-type="bibr">39</xref>]. This has informed the recommendation to adjust ART regimes based on resistance genotype [<xref rid="B46-tropicalmed-10-00045" ref-type="bibr">46</xref>,<xref rid="B47-tropicalmed-10-00045" ref-type="bibr">47</xref>]. Canestri et al. reported a case series in which CSF HIV RNA escape was present in 8/11 patients who had acute or subacute neurological symptoms [<xref rid="B53-tropicalmed-10-00045" ref-type="bibr">53</xref>]. Most (seven out of eight) of the patients with CSF HIV RNA escape had drug resistance mutations in the CSF virus. Following ART adjustment based on genotyping, all patients improved, and their CSF normalised [<xref rid="B53-tropicalmed-10-00045" ref-type="bibr">53</xref>]. This finding has been replicated in further retrospective case reviews and series and incorporated into international guidelines and is the standard of care [<xref rid="B10-tropicalmed-10-00045" ref-type="bibr">10</xref>,<xref rid="B103-tropicalmed-10-00045" ref-type="bibr">103</xref>].</p></sec><sec id="sec3dot3-tropicalmed-10-00045"><title>3.3. Integrase Inhibitors Can Be Used to Intensify ART Regimens in CSF HIV RNA Escape</title><p>Henderson (2023) carried out a retrospective cohort study of 114 patients undergoing CSF analysis for clinical indications over a 5-year period between 2017 and 2022. Nineteen of these patients had CSF HIV RNA escape [<xref rid="B55-tropicalmed-10-00045" ref-type="bibr">55</xref>]. Of these 19 patients, only 17% (3 patients) were on an integrase inhibitor-based regime compared with 48% (36 patients) of those who did have CSF HIV RNA escape, and this was statistically significant, with <italic toggle="yes">p</italic> = 0.017. In contrast, over half (55%) of those with CSF HIV RNA escape were on a PI-based regimen compared with 36% of those who did not have CSF HIV RNA escape. In 10 of the 19 patients with CSF HIV RNA escape, the clinician thought escape was the cause of their neurological symptoms. In eight cases, an integrase inhibitor was added to the ART regimen (dolutegravir in seven cases and raltegravir in one case), and in three cases, boosted PIs were added (darunavir/ritonavir in two cases, and lopinavir/ritonavir in one case). Two participants had no change in their ART regimen. All 10 participants had symptomatic resolution. The numbers are small, but the optimisation of ART following resistance testing by adding integrase inhibitors may be useful in the management of CSF HIV RNA escape, given that currently, integrase inhibitor resistance is rare. Currently, the EACS guidelines recommends avoiding once daily dosing of raltegravir in CSF HIV RNA escape due to a lack of evidence in this cohort. A randomised open-label pilot study found that raltegravir intensification did not reduce CSF HIV viral load in people with symptomatic escape [<xref rid="B104-tropicalmed-10-00045" ref-type="bibr">104</xref>]. There is high inter-person variability in CSF concentrations and raltegravir, and there have been case reports of CSF raltegravir resistance [<xref rid="B105-tropicalmed-10-00045" ref-type="bibr">105</xref>,<xref rid="B106-tropicalmed-10-00045" ref-type="bibr">106</xref>]. Therefore, the use of raltegravir in CSF HIV RNA escape is not recommended.</p></sec><sec id="sec3dot4-tropicalmed-10-00045"><title>3.4. Protease Inhibitors, Particularly Atazanavir, Are Associated with CSF HIV RNA Escape</title><p>In a large prospective study of 1063 participants on ART, Mukherji et al. examined the association between ART regimen and CSF HIV RNA escape [<xref rid="B35-tropicalmed-10-00045" ref-type="bibr">35</xref>]. In this study, with a median follow-up time of 4.4 years, 65% of patients were on a PI-based regimen, and CSF HIV RNA escape occurred in 7.2% of participants (<italic toggle="yes">n</italic> = 77). There was no significant difference in the CPE scores between those with and without CSF HIV RNA escape (<italic toggle="yes">p</italic> = 0.3). In adjusted analyses, regimens containing protease inhibitors were independent predictors of CSF HIV RNA escape (OR 3.1, (95% CI 1.8&#x02013;5.0)), with regimens containing atazanavir being most associated with escape compared with non-ATV + nucleoside reverse transcriptase inhibitor (NRTI) regimens (OR 3.1 95% CI 1.9&#x02013;5.3). In a cohort of 513 people with HIV in India, symptomatic CSF HIV RNA escape was present in 10.5% of the cohort; the most common ART regimen was tenofovir disoproxil (TDF)/emtricitabine (FTC) and atazanavir/r [<xref rid="B107-tropicalmed-10-00045" ref-type="bibr">107</xref>]. Participants either underwent intensification with the addition of zidovudine (AZT) (23 cases) or replacement of the boosted protease inhibitor (PI) (mostly AZT) with a more CNS penetrating PI such as lopinavir/ritonavir or darunavir/ritonavir plus the addition of an integrase inhibitor (9 cases); the third option was replacing the PI with a better CNS penetrating PI plus addition of AZT/3TC and TDF (4 cases). Follow-up CSF viral loads were suppressed in 18/24 patients who underwent PI/INSTI intensification and 15/23 patients in the AZT intensification group. All patients who had drug resistance mutation testing had viruses with the M184V mutation in their CSF.</p></sec><sec id="sec3dot5-tropicalmed-10-00045"><title>3.5. CCR5 Inhibitors</title><p>Maraviroc inhibits entry of HIV-1 by binding to and modifying the CCR5 extracellular loops&#x02019; conformation so that they cannot bind to gp120. CCR5 is expressed on neurons, macrophages, microglia and glial cells. It plays a role in brain development and neuroimmunology [<xref rid="B108-tropicalmed-10-00045" ref-type="bibr">108</xref>]. It is thought that HIV infection can disrupt normal synaptic functions by altering cytokine and chemokine levels, activating aberrant intracellular signalling and leading to neuroinflammation and neuronal death [<xref rid="B109-tropicalmed-10-00045" ref-type="bibr">109</xref>]. Neuronal activation via numerous CD4-independent pathways, including p38-MAPK, neuronal nicotinic receptor &#x003b1;7 and NMDA receptors, are shown to lead to increased calcium ion influx and apoptosis [<xref rid="B108-tropicalmed-10-00045" ref-type="bibr">108</xref>].</p><p>Maraviroc penetrates the BBB well and achieves concentrations well above the concentration required to inhibit viral replication by 90% (IC90) in the CSF [<xref rid="B110-tropicalmed-10-00045" ref-type="bibr">110</xref>,<xref rid="B111-tropicalmed-10-00045" ref-type="bibr">111</xref>,<xref rid="B112-tropicalmed-10-00045" ref-type="bibr">112</xref>]. As previously discussed, viruses within the CNS are more likely to be macrophage-tropic and utilise the CCR5 co-receptor [<xref rid="B28-tropicalmed-10-00045" ref-type="bibr">28</xref>,<xref rid="B113-tropicalmed-10-00045" ref-type="bibr">113</xref>,<xref rid="B114-tropicalmed-10-00045" ref-type="bibr">114</xref>]. In macaques, maraviroc monotherapy has been shown to reduce both replicating and latent SIV in the brain [<xref rid="B115-tropicalmed-10-00045" ref-type="bibr">115</xref>]. One study of six patients with symptomatic CSF HIV RNA escape found significant improvement in CSF viral load one month after starting maraviroc [<xref rid="B111-tropicalmed-10-00045" ref-type="bibr">111</xref>]. Whilst pilot studies have shown a signal towards improvement in neurocognitive performance with maraviroc [<xref rid="B116-tropicalmed-10-00045" ref-type="bibr">116</xref>,<xref rid="B117-tropicalmed-10-00045" ref-type="bibr">117</xref>], a larger (<italic toggle="yes">n</italic> = 49) randomised placebo-controlled trial showed no effect [<xref rid="B118-tropicalmed-10-00045" ref-type="bibr">118</xref>].</p><p>CCR2+ monocytes are thought to be associated with the degree of cognitive impairment [<xref rid="B119-tropicalmed-10-00045" ref-type="bibr">119</xref>,<xref rid="B120-tropicalmed-10-00045" ref-type="bibr">120</xref>]. This is thought to be due to the preferential trafficking of these cells into the brain, contributing to neuroinflammation and reduced cognitive function [<xref rid="B119-tropicalmed-10-00045" ref-type="bibr">119</xref>,<xref rid="B121-tropicalmed-10-00045" ref-type="bibr">121</xref>,<xref rid="B122-tropicalmed-10-00045" ref-type="bibr">122</xref>]. An open-label trial of a CCR2 and CCR5 inhibitor cenicriviroc (<italic toggle="yes">n</italic> = 17) showed some improvement in cognitive impairment and decreased levels of biomarkers associated with inflammation (sCD163, sCD14 and neopterin); the study did not explore the effect on CSF viral load [<xref rid="B123-tropicalmed-10-00045" ref-type="bibr">123</xref>].</p></sec><sec id="sec3dot6-tropicalmed-10-00045"><title>3.6. Two Drug Regimens and Long-Acting Antivirals</title><p>It is recommended to avoid two drug regimens in people with CSF HIV RNA escape. This recommendation is based on data from a Swiss cohort of 25 people with CSF HIV RNA escape and 263 without, in which there was a slightly higher proportion of participants on two drug regimens including dolutegravir and rilpirivine or lamivudine in the group with CSF HIV RNA escape compared with those without (4.0% vs. 1.5%, <italic toggle="yes">p</italic> = 0.07) [<xref rid="B43-tropicalmed-10-00045" ref-type="bibr">43</xref>].</p><p>At present, there is no recommendation on the use of long acting antiretrovirals in cases of CSF HIV RNA escape. Initial data suggest that the long-acting injectable drugs cabotegravir and rilpirivine reach good concentrations in the CSF [<xref rid="B124-tropicalmed-10-00045" ref-type="bibr">124</xref>]; but there is insufficient data on the use of long-acting ART in cases of known CSF HIV RNA escape. Long-acting ART may be a useful tool in managing patients with poor ART adherence due to cognitive impairment [<xref rid="B125-tropicalmed-10-00045" ref-type="bibr">125</xref>].</p></sec><sec id="sec3dot7-tropicalmed-10-00045"><title>3.7. Preventing CSF HIV RNA Escape Before It Occurs</title><p>Whilst the bulk of this review focuses on the treatment of CSF HIV RNA escape, it is crucial to recognise that escape is more likely to occur in those who have had disruptions in ART, multiple different drug regimens and resistance. Therefore, an important step in preventing escape is optimising the ART regimen and adherence to avoid the development of resistance.</p></sec></sec><sec id="sec4-tropicalmed-10-00045"><title>4. Repurposing Licensed Drugs for CSF HIV RNA Escape</title><sec id="sec4dot1-tropicalmed-10-00045"><title>4.1. Lithium</title><p>Early studies in murine models of HIV showed that lithium reduced the development of lymphadenopathy, splenomegaly and lymphoma associated with immunodeficiency; lithium also increased survival [<xref rid="B126-tropicalmed-10-00045" ref-type="bibr">126</xref>]. Four small-scale trials have looked at the utility of lithium in treating cognitive impairment defined using the HAND criteria [<xref rid="B127-tropicalmed-10-00045" ref-type="bibr">127</xref>,<xref rid="B128-tropicalmed-10-00045" ref-type="bibr">128</xref>,<xref rid="B129-tropicalmed-10-00045" ref-type="bibr">129</xref>,<xref rid="B130-tropicalmed-10-00045" ref-type="bibr">130</xref>]. The results of these trials are mixed; all trials report that lithium was safe and well tolerated, but the evidence of an effect on neurocognitive outcomes or CNS biomarkers of neuroinflammation was minimal [<xref rid="B27-tropicalmed-10-00045" ref-type="bibr">27</xref>,<xref rid="B107-tropicalmed-10-00045" ref-type="bibr">107</xref>]. Only one of these studies looked directly at the impact on CSF viral load and found that whilst there was a significant improvement in neuropsychological (NP) performance following treatment with 12 weeks of oral lithium at a dose of 300 mg per day, there was no effect on plasma or CSF viral load from baseline. This suggests that the effect of lithium on NP performance in these participants was independent of CNS viral replication. This study was limited in size (<italic toggle="yes">n</italic> = 8), duration and lack of a control group [<xref rid="B127-tropicalmed-10-00045" ref-type="bibr">127</xref>].</p></sec><sec id="sec4dot2-tropicalmed-10-00045"><title>4.2. Valproic Acid</title><p>Sodium valproate and lithium are known to inhibit glycogen synthase kinase-3 beta (GSK3B), a serine/threonine kinase upregulated by the HIV proteins Tat and gp120. GSK3B inhibitors, such as valproate, have been shown in vitro to reduce HIV-1-mediated neurotoxicity, though this has yet to be demonstrated in vivo [<xref rid="B131-tropicalmed-10-00045" ref-type="bibr">131</xref>].</p><p>Valproate acts as a histone deacetylase (HDAC) inhibitor. HDAC is a chromatin remodelling enzyme that maintains latency of integrated HIV provirus; inhibiting this enzyme leads to re-activation of the virus and can be used in shock and kill strategies. A proof-of-concept study in four volunteers by Lehrman et al. (2005) used valproate with enfuvirtide and demonstrated a potential acceleration in the clearance of HIV from resting T cells [<xref rid="B132-tropicalmed-10-00045" ref-type="bibr">132</xref>]. However, larger studies have not replicated these results [<xref rid="B133-tropicalmed-10-00045" ref-type="bibr">133</xref>,<xref rid="B134-tropicalmed-10-00045" ref-type="bibr">134</xref>].</p><p>Whilst a small-scale pilot study suggested a trend towards cognitive improvement in people with HIV treated with valproate as an adjunctive therapy, the opposite was the case in a larger clinical observational study using higher doses of valproate (850 mg/day) and with a longer follow-up period [<xref rid="B135-tropicalmed-10-00045" ref-type="bibr">135</xref>,<xref rid="B136-tropicalmed-10-00045" ref-type="bibr">136</xref>]. Retrospective cohort reviews, although small in size, have shown no evidence that valproate affects CSF viral load when given for 12 weeks [<xref rid="B137-tropicalmed-10-00045" ref-type="bibr">137</xref>]. Given the potential neurotoxicity of valproate and the efficacy of ART optimisation for symptomatic CSF HIV RNA escape, it is not recommended.</p></sec><sec id="sec4dot3-tropicalmed-10-00045"><title>4.3. Statins</title><p>HMG Co-A reductase inhibitors have both beneficial cardiovascular and immunomodulatory effects. There is some in vitro work suggesting that statins may inhibit HIV replication by reducing membrane lipid rafts that are rich in chemokine receptors, reducing adhesion molecule expression and reducing Rho guanosine triphosphatase activity [<xref rid="B138-tropicalmed-10-00045" ref-type="bibr">138</xref>,<xref rid="B139-tropicalmed-10-00045" ref-type="bibr">139</xref>,<xref rid="B140-tropicalmed-10-00045" ref-type="bibr">140</xref>,<xref rid="B141-tropicalmed-10-00045" ref-type="bibr">141</xref>].</p><p>In one large cross-sectional study, Letendre et al. (2007) analysed the impact of statin use on HIV viral load in the CSF [<xref rid="B142-tropicalmed-10-00045" ref-type="bibr">142</xref>]. A minority, 10%, of the 658 people with HIV in the CHARTER cohort who had baseline NP testing, plasma and CSF HIV viral load testing were using a statin. Amongst those taking ART, participants taking a statin were less likely to have a detectable CSF viral load (OR = 0.09, <italic toggle="yes">p</italic> &#x0003c; 0.001). However, statin use was not significantly associated with CSF viral load in the multivariate logistic regression analysis adjusted for AIDS diagnosis, ART use, CD4 count, HIV RNA plasma level, depression scores, education, age, gender and ethnicity. This cohort study has the benefit of relatively large numbers but is limited by the cross-sectional design and pretreatment difference between the groups; furthermore, the dose and class of statin varied between participants with five different drugs used, each of which had different lipophilicity and doses not reported. The power of this study to detect associations is limited, but given the trend towards significance, further research is warranted.</p></sec><sec id="sec4dot4-tropicalmed-10-00045"><title>4.4. Selective Serotonin Reuptake Inhibitors</title><p>In the CHARTER cohort, 195/658 (30%) of the participants were taking selective serotonin reuptake inhibitors (SSRIs) [<xref rid="B142-tropicalmed-10-00045" ref-type="bibr">142</xref>]. Selective serotonin reuptake inhibitors were associated with a lower risk of having detectable HIV RNA in the CSF (odds ratio: 0.69, <italic toggle="yes">p</italic> = 0.05) [<xref rid="B142-tropicalmed-10-00045" ref-type="bibr">142</xref>]. The authors combined those taking three drugs&#x02014;citalopram (<italic toggle="yes">n</italic> = 24), trazodone (<italic toggle="yes">n</italic> = 64) and sertraline (<italic toggle="yes">n</italic> = 37)&#x02014;that were trending towards significance into one category, the so-called &#x0201c;antiviral serotine reuptake inhibitors&#x0201d; and found that there was greater protection from detectable HIV RNA in the CSF (OR: 0.56, <italic toggle="yes">p</italic> = 0.02). This effect was more significant in those not taking ART; the authors, therefore, concluded that this effect cannot be attributed to improved mood and ART adherence when taking SSRIs.</p><p>Those using both an SSRI and a statin had a lower proportion of detectable HIV RNA in the CSF compared with those taking either of the drugs individually or neither. The authors comment that ART use was similar between the two groups, but given the low numbers and multiple potential confounders, it is difficult to know whether this is a true reflection of the therapeutic effect. This analysis is limited by the potential for multiple confounders, the grouping of many different drugs and the artificial grouping of proposed antiviral SSRIs. The analysis does not separate those with and without peripheral viral suppression, which makes it difficult to ascertain whether SSRIs would be genuinely useful in those with CSF HIV RNA escape. There is little understanding of a potential mechanism by which SSRIs would reduce HIV replication, and further work is required [<xref rid="B142-tropicalmed-10-00045" ref-type="bibr">142</xref>,<xref rid="B143-tropicalmed-10-00045" ref-type="bibr">143</xref>].</p></sec><sec id="sec4dot5-tropicalmed-10-00045"><title>4.5. Minocycline</title><p>Minocycline, a tetracycline antibiotic, has known immunomodulatory effects, and in animal models of CNS HIV, minocycline has been demonstrated to reduce lentiviral infection in microglia [<xref rid="B144-tropicalmed-10-00045" ref-type="bibr">144</xref>,<xref rid="B145-tropicalmed-10-00045" ref-type="bibr">145</xref>,<xref rid="B146-tropicalmed-10-00045" ref-type="bibr">146</xref>,<xref rid="B147-tropicalmed-10-00045" ref-type="bibr">147</xref>]. There is in vitro evidence that minocycline has antiviral effects on human CD4+ T cells in the context of HIV infection [<xref rid="B148-tropicalmed-10-00045" ref-type="bibr">148</xref>]. One open-labelled pilot study in humans tests the hypothesis that minocycline will reduce HIV CNS viral load both absolutely and in relation to plasma viral load [<xref rid="B149-tropicalmed-10-00045" ref-type="bibr">149</xref>]. Seven participants, none of whom were taking ART, were included in the final analysis. There was no change in the CSF or plasma HIV-1 RNA level [<xref rid="B149-tropicalmed-10-00045" ref-type="bibr">149</xref>].</p></sec><sec id="sec4dot6-tropicalmed-10-00045"><title>4.6. Janus Kinase (Jak 1/2) Inhibitors</title><p>Ruxolitinib has been investigated in preclinical and early clinical studies and was found to reduce markers of immune activation and the peripheral HIV reservoir [<xref rid="B150-tropicalmed-10-00045" ref-type="bibr">150</xref>]. Baricitinib has a favourable safety profile and reaches therapeutic CNS concentrations in humans. It has shown promise in murine models, non-human primates and humans [<xref rid="B151-tropicalmed-10-00045" ref-type="bibr">151</xref>,<xref rid="B152-tropicalmed-10-00045" ref-type="bibr">152</xref>]. It is currently undergoing evaluation in Phase II clinical trial therapy to determine if it decreases the HIV CNS reservoir in PLWH with durable virologic suppression on ART.</p></sec></sec><sec id="sec5-tropicalmed-10-00045"><title>5. Novel Therapeutics for Treating CSF HIV RNA Escape</title><sec id="sec5dot1-tropicalmed-10-00045"><title>5.1. The Use of Nanoparticles to Cross the BBB</title><p>We have discussed the optimisation of CNS penetrance of antiretroviral therapy. However, this is not the magic bullet for CSF HIV RNA escape. Taking ART which penetrates the CNS is associated with neurovascular toxicity [<xref rid="B153-tropicalmed-10-00045" ref-type="bibr">153</xref>,<xref rid="B154-tropicalmed-10-00045" ref-type="bibr">154</xref>,<xref rid="B155-tropicalmed-10-00045" ref-type="bibr">155</xref>]. If adequate concentrations are not reached, then clonal expansion of these HIV reservoirs will continue. This clonal expansion allows for the development of multidrug-resistant strains of HIV, which are more difficult to target with conventional ART regimens. Any treatment interruption leads to the expansion of this viral reservoir and rebound viraemia [<xref rid="B156-tropicalmed-10-00045" ref-type="bibr">156</xref>,<xref rid="B157-tropicalmed-10-00045" ref-type="bibr">157</xref>].</p><p>Nanotechnology has been proposed as a solution to design drugs that can cross the BBB whilst preserving its integrity [<xref rid="B158-tropicalmed-10-00045" ref-type="bibr">158</xref>]. Nanoparticles are materials with overall dimensions less than 100 nm; those designed for brain specific drugs are typically administered intranasally for direct delivery [<xref rid="B159-tropicalmed-10-00045" ref-type="bibr">159</xref>]. There has been some progress in using nanotechnology to achieve a nanoparticle delivery of conventional ART drugs to solve the problems associated with delivering ART across the BBB [<xref rid="B160-tropicalmed-10-00045" ref-type="bibr">160</xref>,<xref rid="B161-tropicalmed-10-00045" ref-type="bibr">161</xref>]. Nanoparticles can be adapted with surface moieties to increase specificity to desired cells. One study used a poloxamer-PGLA-based nanocarrier for elvitegravir (an integrase inhibitor) and showed that, in vitro, this carrier crossed the BBB and achieved viral suppression in HIV-1 infected macrophages [<xref rid="B162-tropicalmed-10-00045" ref-type="bibr">162</xref>]. Another in vitro model utilised surface modified nanodiamonds to deliver efavirenz across the BBB [<xref rid="B163-tropicalmed-10-00045" ref-type="bibr">163</xref>]. This technology has also been used in rodent models to demonstrate improvement in macrophage-mediated uptake of ART [<xref rid="B164-tropicalmed-10-00045" ref-type="bibr">164</xref>,<xref rid="B165-tropicalmed-10-00045" ref-type="bibr">165</xref>]. There are currently no clinical trials in nanomedicine for the treatment of HIV, but this remains an exciting future perspective for both better treatment of CNS disease and elimination of the HIV reservoir [<xref rid="B166-tropicalmed-10-00045" ref-type="bibr">166</xref>].</p></sec><sec id="sec5dot2-tropicalmed-10-00045"><title>5.2. Elimination of the CNS Reservoir</title><p>We have discussed a few approaches to achieve reduced viral replication in the CNS. One approach discussed by N&#x000fc;hn et al. in their comprehensive 2022 review is that of &#x0201c;shock and kill&#x0201d; [<xref rid="B167-tropicalmed-10-00045" ref-type="bibr">167</xref>]. This approach aims to reactivate the latent reservoir with latency reversal agents, including epigenetic modifiers, intracellular signalling modulators, cytokine or immune receptor agonists and transcription elongation factors, which will then be eliminated by the immune system or by viral cytolysis, achieving viral cure. Very few latency reversal agents have been studied in vivo, but it is thought that some degree of immune stimulation will be required to stimulate clearance [<xref rid="B168-tropicalmed-10-00045" ref-type="bibr">168</xref>]. The CNS reservoir, likely composed of microglia, astrocytes and CD4+ T cells, provides a unique challenge. There are pharmacokinetic challenges as LRAs need to be able to cross the blood&#x02013;brain barrier; but more importantly, we need to consider whether viral reactivation within the CNS is a tolerable side effect. One in vivo study in a macaque SIV model showed that the administration of ingenol-B and vorinostat led to a reactivation of the CNS reservoir, but there were also signs of increased neuronal degradation, inflammation and encephalitis [<xref rid="B169-tropicalmed-10-00045" ref-type="bibr">169</xref>]. The neuronal damage provoked by HIV reactivation is unlikely to be a tolerable side effect in humans.</p><p>There are also specific challenges in the &#x0201c;kill&#x0201d; stage in the CNS. As discussed, myeloid cells that make up the CNS reservoir are more resistant to virus-induced cytopathy, and viral infection further upregulates gene expression associated with apoptosis-resistance [<xref rid="B170-tropicalmed-10-00045" ref-type="bibr">170</xref>]. CD8+ T cell-mediated killing of infected macrophages requires high concentrations of interferon gamma and long cell-to-cell contact times [<xref rid="B171-tropicalmed-10-00045" ref-type="bibr">171</xref>,<xref rid="B172-tropicalmed-10-00045" ref-type="bibr">172</xref>]. In vitro work suggests a level of resistance to virus-induced apoptosis in primary CNS cells [<xref rid="B173-tropicalmed-10-00045" ref-type="bibr">173</xref>,<xref rid="B174-tropicalmed-10-00045" ref-type="bibr">174</xref>]. Immune-mediated clearance of infected cells in the CNS is unlikely to occur without causing inflammation and encephalitis and neuronal damage [<xref rid="B175-tropicalmed-10-00045" ref-type="bibr">175</xref>]. This is unlikely to be an acceptable cost for an unproven benefit.</p><table-wrap position="anchor" id="tropicalmed-10-00045-t002"><object-id pub-id-type="pii">tropicalmed-10-00045-t002_Table 2</object-id><label>Table 2</label><caption><p>Summaries of the treatment strategies for CSF HIV RNA escape, their advantages and limitations and the strength of evidence and recommendations based on current guidelines.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Treatment</th><th align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Advantages </th><th align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Limitations </th><th align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Strength of Evidence </th><th align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Recommendation<break/>(Strength of Recommendation)</th></tr></thead><tbody><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ART optimisation based on resistance profiles </td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Tailored regimen for each patient </td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Resource intensive <break/>Access to genotyping is limited in low-resource settings</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Low<break/>Case series <break/>[<xref rid="B39-tropicalmed-10-00045" ref-type="bibr">39</xref>,<xref rid="B53-tropicalmed-10-00045" ref-type="bibr">53</xref>,<xref rid="B61-tropicalmed-10-00045" ref-type="bibr">61</xref>,<xref rid="B107-tropicalmed-10-00045" ref-type="bibr">107</xref>]</td><td align="left" valign="middle" style="border-bottom:solid thin;background:#E2EFD9" rowspan="1" colspan="1">Recommended <break/>(Strong) </td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ART optimisation by adding a second generationintegrase strand inhibitor (INSTI)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cost effective; easily available <break/>Second generation INSTI&#x02019;s now recommended in most first line regimes <break/>Guidelines suggest doubling dose of DTG if concerned re INSTI resistance </td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Neurocognitive side effects with dolutegravir in some patients <break/><break/>Raltegravir should be avoided in suspected CSF escape</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Low<break/>Case series [<xref rid="B43-tropicalmed-10-00045" ref-type="bibr">43</xref>,<xref rid="B107-tropicalmed-10-00045" ref-type="bibr">107</xref>]<break/>Expert opinion</td><td align="left" valign="middle" style="border-bottom:solid thin;background:#FBE4D5" rowspan="1" colspan="1">Recommended<break/>(Weak) </td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ART optimisation based on CNS penetration effectiveness (CPE) scores </td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cost effective as does not require resistance testing. </td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Relies on the assumption that CSF drug levels are comparable with parenchymal levels. <break/>Not backed up by evidence from autopsy studies showing much higher levels in parenchyma than CSF [<xref rid="B102-tropicalmed-10-00045" ref-type="bibr">102</xref>]. <break/>Need to consider the potential neurotoxicity of ART itself [<xref rid="B104-tropicalmed-10-00045" ref-type="bibr">104</xref>]</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Low <break/>Case series and retrospective cohort studies <break/>[<xref rid="B176-tropicalmed-10-00045" ref-type="bibr">176</xref>,<xref rid="B177-tropicalmed-10-00045" ref-type="bibr">177</xref>,<xref rid="B178-tropicalmed-10-00045" ref-type="bibr">178</xref>,<xref rid="B179-tropicalmed-10-00045" ref-type="bibr">179</xref>]. </td><td align="left" valign="middle" style="border-bottom:solid thin;background:#F2C5BD" rowspan="1" colspan="1">Not recommended </td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ART optimisation&#x02014;avoiding PI based regimens</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cost effective </td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PI-based regimes are the only option for second-line treatment in some contexts. </td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Low<break/>A large retrospective cohort study (n = 1063)<break/>[<xref rid="B35-tropicalmed-10-00045" ref-type="bibr">35</xref>]. </td><td align="left" valign="middle" style="border-bottom:solid thin;background:#E2EFD9" rowspan="1" colspan="1">Recommended (Strong)</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ART optimisation&#x02014;adding CCR5 inhibitors</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Good BBB penetration </td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No effect in larger randomised controlled trials </td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Low<break/>Case series [<xref rid="B114-tropicalmed-10-00045" ref-type="bibr">114</xref>]<break/>One randomised controlled trial (<italic toggle="yes">n</italic> = 49) [<xref rid="B118-tropicalmed-10-00045" ref-type="bibr">118</xref>]</td><td align="left" valign="middle" style="border-bottom:solid thin;background:#F2C5BD" rowspan="1" colspan="1">Not Recommended</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ART optimisation&#x02014;avoiding dual ART regimens </td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cost effective </td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Dual ART regimens are a simpler option for those with cognitive impairment</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Low<break/><break/>Retrospective cohort [<xref rid="B43-tropicalmed-10-00045" ref-type="bibr">43</xref>]</td><td align="left" valign="middle" style="border-bottom:solid thin;background:#E2EFD9" rowspan="1" colspan="1">Recommended (Strong)</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Lithium </td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Already licensed<break/>Safe and well tolerated </td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Risk of neurotoxic side effects, difficult to dose. </td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Low <break/>Pilot studies, no control group [<xref rid="B127-tropicalmed-10-00045" ref-type="bibr">127</xref>]</td><td align="left" valign="middle" style="border-bottom:solid thin;background:#F2C5BD" rowspan="1" colspan="1">Not recommended </td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Valproic acid </td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Already licensed </td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Neurotoxic side effects <break/>Teratogenic </td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Low<break/>Retrospective cohort studies<break/>[<xref rid="B137-tropicalmed-10-00045" ref-type="bibr">137</xref>] </td><td align="left" valign="middle" style="border-bottom:solid thin;background:#F2C5BD" rowspan="1" colspan="1">Not recommended </td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Statins</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Easily available <break/>Cost effective <break/>Other cardiovascular and immunomodulatory benefits </td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Evidence from cross-sectional studies only.<break/>Pretreatment difference between the groups. <break/>Dose and class of statin varied in CHARTER. </td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Low<break/>Retrospective cohort studies [<xref rid="B142-tropicalmed-10-00045" ref-type="bibr">142</xref>] </td><td align="left" valign="middle" style="border-bottom:solid thin;background:#F2C5BD" rowspan="1" colspan="1">Not recommended </td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Selective serotonin reuptake inhibitors</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cheap and easily available </td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Evidence from cross-sectional studies only. <break/>Multiple different SSRIs grouped together. <break/>Not all patients in CHARTER on ART; not necessarily generalisable to this population. </td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Low<break/>Retrospective cohort studies<break/>[<xref rid="B142-tropicalmed-10-00045" ref-type="bibr">142</xref>]</td><td align="left" valign="middle" style="border-bottom:solid thin;background:#F2C5BD" rowspan="1" colspan="1">Not recommended </td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Minocycline </td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cheap<break/>Already licensed </td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Only evidence from a small, open-labelled, pilot study <break/>No participants taking ART&#x02014;not applicable to current population. </td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Low<break/>Open-labelled pilot study<break/>[<xref rid="B147-tropicalmed-10-00045" ref-type="bibr">147</xref>]</td><td align="left" valign="middle" style="border-bottom:solid thin;background:#F2C5BD" rowspan="1" colspan="1">Not recommended </td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Baricitinib</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Licensed</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Currently in Phase II clinical studies</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Preclinical studies in rodents and non-human primates [<xref rid="B151-tropicalmed-10-00045" ref-type="bibr">151</xref>,<xref rid="B152-tropicalmed-10-00045" ref-type="bibr">152</xref>]</td><td align="left" valign="middle" style="border-bottom:solid thin;background:#F2C5BD" rowspan="1" colspan="1">Not recommended</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Nanoparticles </td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Optimise concentration in CNS <break/>Could both treat CSF escape and help with elimination of the reservoir </td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Not yet in clinical trials</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Insufficient<break/>in vitro and rodent models<break/>[<xref rid="B162-tropicalmed-10-00045" ref-type="bibr">162</xref>,<xref rid="B163-tropicalmed-10-00045" ref-type="bibr">163</xref>,<xref rid="B164-tropicalmed-10-00045" ref-type="bibr">164</xref>,<xref rid="B165-tropicalmed-10-00045" ref-type="bibr">165</xref>,<xref rid="B166-tropicalmed-10-00045" ref-type="bibr">166</xref>] </td><td align="left" valign="middle" style="border-bottom:solid thin;background:#F2C5BD" rowspan="1" colspan="1">Not recommended </td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Elimination of the CNS reservoir with &#x0201c;shock and kill&#x0201d; strategies </td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Elimination of the CNS reservoir essential to achieve HIV cure </td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Neuronal damage provoked by HIV reactivation and immune mediated clearance is unlikely to be a tolerable side effect in humans</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Insufficient<break/>In vitro and rodent models<break/>[<xref rid="B167-tropicalmed-10-00045" ref-type="bibr">167</xref>] </td><td align="left" valign="middle" style="border-bottom:solid thin;background:#F2C5BD" rowspan="1" colspan="1">Not recommended </td></tr></tbody></table><table-wrap-foot><fn><p>Strong recommendations are shown in green, weak recommendations in orange and interventions that are not recommended are shown in red.</p></fn></table-wrap-foot></table-wrap></sec></sec><sec sec-type="conclusions" id="sec6-tropicalmed-10-00045"><title>6. Conclusions</title><p>Whilst ongoing HIV replication in the CSF is not the only cause of cognitive impairment in people living with HIV, it is an important factor and is known to contribute to HABI. CSF HIV RNA escape can be difficult to manage and can recur following mild infection or change in antiretroviral treatment [<xref rid="B180-tropicalmed-10-00045" ref-type="bibr">180</xref>]. Antiretroviral therapy optimisation to target resistant virus is the only recommended strategy for treatment, though the evidence for this comes from relatively small studies. There has been some exploration into licensed drugs to explore their effect on CNS disease; the evidence is limited to poorly controlled pilot studies and case series. Given the evidence of immune activation in CSF HIV RNA escape, ongoing Phase II clinical trials utilising Janus kinase (Jak 1/2) inhibitors to decrease the HIV CNS reservoir and immune activation are promising. Newer treatments using nanotechnology to facilitate crossing the BBB have the potential to change the management of CSF HIV RNA escape but have yet to be studied in clinical trials.</p><p>Uncertainly remains around the implications of asymptomatic CSF HIV RNA escape and its clinical significance. Longitudinal follow up cohorts with asymptomatic CSF HIV RNA escape will be invaluable in clarifying their clinical outcomes. In addition, research on the dynamics of biomarkers of CNS immune activation and neuroinflammation in this cohort is required. It is important to note that very few studies have examined CSF HIV RNA escape in sub-Saharan Africa, where the burden of HIV is greatest. Therefore, research into the prevalence and clinical spectrum is warranted in this setting.</p><p>The current recommended approach for managing CSF HIV RNA escape in symptomatic PLWH involves sequencing the CSF virus, targeting ART to overcome resistance and intensifying the ART regimen. It is also important to recognise that whilst whole genome sequencing for HIV is widely available in high-resource settings, access to HIV viral loads and genotypic resistance testing is limited in low-resource setting; this limits the ability to both diagnose and treat CSF HIV RNA escape. In recent years, the World Health Organization has worked to increase access to HIV drug resistance testing by increasing laboratory capacity. Point mutation assays have been developed for key mutations, which allow for more cost-effective access [<xref rid="B181-tropicalmed-10-00045" ref-type="bibr">181</xref>,<xref rid="B182-tropicalmed-10-00045" ref-type="bibr">182</xref>]. However, the cost effectiveness of this approach versus the intensification of ART regimens (for example, commencing twice daily dolutegravir in the context of low-population INSTI resistance) needs to be evaluated. If the BHIVA and EACS recommendation that all patients with suppressed viral load and new cognitive impairment should have their CSF taken for HIV viral load and resistance testing is to be deployed globally, it is essential that the logistical and financial barriers in implementing this recommendation in low-resource settings are addressed.</p></sec></body><back><fn-group><fn><p><bold>Disclaimer/Publisher&#x02019;s Note:</bold> The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.</p></fn></fn-group><notes><title>Author Contributions</title><p>Conceptualization, D.A.C.; methodology, D.A.C., S.H.K., S.N.; writing&#x02014;original draft preparation, S.H.K.; writing&#x02014;review and editing, D.A.C., S.N., R.K.G. All authors have read and agreed to the published version of the manuscript.</p></notes><notes><title>Institutional Review Board Statement</title><p>Not applicable.</p></notes><notes><title>Informed Consent Statement</title><p>Not applicable.</p></notes><notes notes-type="data-availability"><title>Data Availability Statement</title><p>No new data were created or analyzed in this study. Data sharing is not applicable to this paper.</p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>The authors declare no conflict of interest.</p></notes><ref-list><title>References</title><ref id="B1-tropicalmed-10-00045"><label>1.</label><element-citation publication-type="webpage"><person-group person-group-type="author">
<collab>UNAIDS</collab>
</person-group><article-title>UNAIDS Fact Sheet&#x02014;Global HIV Statistics [Internet]</article-title><year>2023</year><comment>Available online: <ext-link xlink:href="https://www.unaids.org/sites/default/files/media_asset/UNAIDS_FactSheet_en.pdf" ext-link-type="uri">https://www.unaids.org/sites/default/files/media_asset/UNAIDS_FactSheet_en.pdf</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-03-28">(accessed on 28 March 2024)</date-in-citation></element-citation></ref><ref id="B2-tropicalmed-10-00045"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Navia</surname><given-names>B.A.</given-names></name>
<name><surname>Jordan</surname><given-names>B.D.</given-names></name>
<name><surname>Price</surname><given-names>R.W.</given-names></name>
</person-group><article-title>The AIDS dementia complex: I. Clinical features</article-title><source>Ann. Neurol.</source><year>1986</year><volume>19</volume><fpage>517</fpage><lpage>524</lpage><pub-id pub-id-type="doi">10.1002/ana.410190602</pub-id><pub-id pub-id-type="pmid">3729308</pub-id>
</element-citation></ref><ref id="B3-tropicalmed-10-00045"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Popovic</surname><given-names>M.</given-names></name>
<name><surname>Sarngadharan</surname><given-names>M.G.</given-names></name>
<name><surname>Read</surname><given-names>E.</given-names></name>
<name><surname>Gallo</surname><given-names>R.C.</given-names></name>
</person-group><article-title>Detection, isolation, and continuous production of cytopathic retroviruses (HTLV-III) from patients with AIDS and pre-AIDS</article-title><source>Science</source><year>1984</year><volume>224</volume><fpage>497</fpage><lpage>500</lpage><pub-id pub-id-type="doi">10.1126/science.6200935</pub-id><pub-id pub-id-type="pmid">6200935</pub-id>
</element-citation></ref><ref id="B4-tropicalmed-10-00045"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Barr&#x000e9;-Sinoussi</surname><given-names>F.</given-names></name>
<name><surname>Chermann</surname><given-names>J.C.</given-names></name>
<name><surname>Rey</surname><given-names>F.</given-names></name>
<name><surname>Nugeyre</surname><given-names>M.T.</given-names></name>
<name><surname>Chamaret</surname><given-names>S.</given-names></name>
<name><surname>Gruest</surname><given-names>J.</given-names></name>
<name><surname>Dauguet</surname><given-names>C.</given-names></name>
<name><surname>Axler-Blin</surname><given-names>C.</given-names></name>
<name><surname>V&#x000e9;zinet-Brun</surname><given-names>F.</given-names></name>
<name><surname>Rouzioux</surname><given-names>C.</given-names></name>
<etal/>
</person-group><article-title>Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS)</article-title><source>Science</source><year>1983</year><volume>220</volume><fpage>868</fpage><lpage>871</lpage><pub-id pub-id-type="doi">10.1126/science.6189183</pub-id><pub-id pub-id-type="pmid">6189183</pub-id>
</element-citation></ref><ref id="B5-tropicalmed-10-00045"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Dore</surname><given-names>G.J.</given-names></name>
<name><surname>McDonald</surname><given-names>A.</given-names></name>
<name><surname>Li</surname><given-names>Y.</given-names></name>
<name><surname>Kaldor</surname><given-names>J.M.</given-names></name>
<name><surname>Brew</surname><given-names>B.J.</given-names></name>
</person-group><article-title>Marked improvement in survival following AIDS dementia complex in the era of highly active antiretroviral therapy</article-title><source>AIDS</source><year>2003</year><volume>17</volume><fpage>1539</fpage><lpage>1545</lpage><pub-id pub-id-type="doi">10.1097/00002030-200307040-00015</pub-id><pub-id pub-id-type="pmid">12824792</pub-id>
</element-citation></ref><ref id="B6-tropicalmed-10-00045"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sacktor</surname><given-names>N.</given-names></name>
<name><surname>McDermott</surname><given-names>M.P.</given-names></name>
<name><surname>Marder</surname><given-names>K.</given-names></name>
<name><surname>Schifitto</surname><given-names>G.</given-names></name>
<name><surname>Selnes</surname><given-names>O.A.</given-names></name>
<name><surname>McArthur</surname><given-names>J.C.</given-names></name>
<name><surname>Stern</surname><given-names>Y.</given-names></name>
<name><surname>Albert</surname><given-names>S.</given-names></name>
<name><surname>Palumbo</surname><given-names>D.</given-names></name>
<name><surname>Kieburtz</surname><given-names>K.</given-names></name>
<etal/>
</person-group><article-title>HIV-associated cognitive impairment before and after the advent of combination therapy</article-title><source>J. NeuroVirology</source><year>2002</year><volume>8</volume><fpage>136</fpage><lpage>142</lpage><pub-id pub-id-type="doi">10.1080/13550280290049615</pub-id><pub-id pub-id-type="pmid">11935465</pub-id>
</element-citation></ref><ref id="B7-tropicalmed-10-00045"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Robertson</surname><given-names>K.R.</given-names></name>
<name><surname>Smurzynski</surname><given-names>M.</given-names></name>
<name><surname>Parsons</surname><given-names>T.D.</given-names></name>
<name><surname>Wu</surname><given-names>K.</given-names></name>
<name><surname>Bosch</surname><given-names>R.J.</given-names></name>
<name><surname>Wu</surname><given-names>J.</given-names></name>
<name><surname>McArthur</surname><given-names>J.C.</given-names></name>
<name><surname>Collier</surname><given-names>A.C.</given-names></name>
<name><surname>Evans</surname><given-names>S.R.</given-names></name>
<name><surname>Ellis</surname><given-names>R.J.</given-names></name>
</person-group><article-title>The prevalence and incidence of neurocognitive impairment in the HAART era</article-title><source>AIDS</source><year>2007</year><volume>21</volume><fpage>1915</fpage><lpage>1921</lpage><pub-id pub-id-type="doi">10.1097/QAD.0b013e32828e4e27</pub-id><pub-id pub-id-type="pmid">17721099</pub-id>
</element-citation></ref><ref id="B8-tropicalmed-10-00045"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Heaton</surname><given-names>R.K.</given-names></name>
<name><surname>Franklin</surname><given-names>D.R.</given-names></name>
<name><surname>Ellis</surname><given-names>R.J.</given-names></name>
<name><surname>McCutchan</surname><given-names>J.A.</given-names></name>
<name><surname>Letendre</surname><given-names>S.L.</given-names></name>
<name><surname>Leblanc</surname><given-names>S.</given-names></name>
<name><surname>Corkran</surname><given-names>S.H.</given-names></name>
<name><surname>Duarte</surname><given-names>N.A.</given-names></name>
<name><surname>Clifford</surname><given-names>D.B.</given-names></name>
<name><surname>Woods</surname><given-names>S.P.</given-names></name>
<etal/>
</person-group><article-title>HIV-associated neurocognitive disorders before and during the era of combination antiretroviral therapy: Differences in rates, nature, and predictors</article-title><source>J. NeuroVirol.</source><year>2011</year><volume>17</volume><fpage>3</fpage><lpage>16</lpage><pub-id pub-id-type="doi">10.1007/s13365-010-0006-1</pub-id><pub-id pub-id-type="pmid">21174240</pub-id>
</element-citation></ref><ref id="B9-tropicalmed-10-00045"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Nightingale</surname><given-names>S.</given-names></name>
<name><surname>Ances</surname><given-names>B.</given-names></name>
<name><surname>Cinque</surname><given-names>P.</given-names></name>
<name><surname>Dravid</surname><given-names>A.</given-names></name>
<name><surname>Dreyer</surname><given-names>A.J.</given-names></name>
<name><surname>Gissl&#x000e9;n</surname><given-names>M.</given-names></name>
<name><surname>Joska</surname><given-names>J.A.</given-names></name>
<name><surname>Kwasa</surname><given-names>J.</given-names></name>
<name><surname>Meyer</surname><given-names>A.-C.</given-names></name>
<name><surname>Mpongo</surname><given-names>N.</given-names></name>
<etal/>
</person-group><article-title>Cognitive impairment in people living with HIV: Consensus recommendations for a new approach</article-title><source>Nat. Rev. Neurol.</source><year>2023</year><volume>19</volume><fpage>424</fpage><lpage>433</lpage><pub-id pub-id-type="pmid">37311873</pub-id>
</element-citation></ref><ref id="B10-tropicalmed-10-00045"><label>10.</label><element-citation publication-type="webpage"><article-title>European AIDS Clinical Society Guidelines 12.0 [Internet]</article-title><year>2023</year><comment>Available online: <ext-link xlink:href="https://www.eacsociety.org/media/guidelines-12.0.pdf" ext-link-type="uri">https://www.eacsociety.org/media/guidelines-12.0.pdf</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-10-25">(accessed on 25 October 2024)</date-in-citation></element-citation></ref><ref id="B11-tropicalmed-10-00045"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>McArthur</surname><given-names>J.C.</given-names></name>
<name><surname>Steiner</surname><given-names>J.</given-names></name>
<name><surname>Sacktor</surname><given-names>N.</given-names></name>
<name><surname>Nath</surname><given-names>A.</given-names></name>
</person-group><article-title>Human immunodeficiency virus-associated neurocognitive disorders mind the gap</article-title><source>Ann. Neurol.</source><year>2010</year><volume>67</volume><fpage>699</fpage><lpage>714</lpage><pub-id pub-id-type="doi">10.1002/ana.22053</pub-id><pub-id pub-id-type="pmid">20517932</pub-id>
</element-citation></ref><ref id="B12-tropicalmed-10-00045"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kaul</surname><given-names>M.</given-names></name>
</person-group><article-title>HIV-1 associated dementia: Update on pathological mechanisms and therapeutic approaches</article-title><source>Curr. Opin. Neurol.</source><year>2009</year><volume>22</volume><fpage>315</fpage><lpage>320</lpage><pub-id pub-id-type="doi">10.1097/WCO.0b013e328329cf3c</pub-id><pub-id pub-id-type="pmid">19300249</pub-id>
</element-citation></ref><ref id="B13-tropicalmed-10-00045"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Gannon</surname><given-names>P.</given-names></name>
<name><surname>Khan</surname><given-names>M.Z.</given-names></name>
<name><surname>Kolson</surname><given-names>D.L.</given-names></name>
</person-group><article-title>Current understanding of HIV-associated neurocognitive disorders pathogenesis</article-title><source>Curr. Opin. Neurol.</source><year>2011</year><volume>24</volume><fpage>275</fpage><lpage>283</lpage><pub-id pub-id-type="doi">10.1097/WCO.0b013e32834695fb</pub-id><pub-id pub-id-type="pmid">21467932</pub-id>
</element-citation></ref><ref id="B14-tropicalmed-10-00045"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Collier</surname><given-names>D.A.</given-names></name>
<name><surname>Haddow</surname><given-names>L.</given-names></name>
<name><surname>Brijkumar</surname><given-names>J.</given-names></name>
<name><surname>Moosa</surname><given-names>M.Y.S.</given-names></name>
<name><surname>Benjamin</surname><given-names>L.</given-names></name>
<name><surname>Gupta</surname><given-names>R.K.</given-names></name>
</person-group><article-title>HIV cerebrospinal fluid escape and neurocognitive pathology in the era of combined antiretroviral therapy: What lies beneath the tip of the Iceberg in Sub-Saharan Africa?</article-title><source>Brain Sci.</source><year>2018</year><volume>8</volume><elocation-id>190</elocation-id><pub-id pub-id-type="doi">10.3390/brainsci8100190</pub-id><pub-id pub-id-type="pmid">30347806</pub-id>
</element-citation></ref><ref id="B15-tropicalmed-10-00045"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Valcour</surname><given-names>V.</given-names></name>
<name><surname>Chalermchai</surname><given-names>T.</given-names></name>
<name><surname>Sailasuta</surname><given-names>N.</given-names></name>
<name><surname>Marovich</surname><given-names>M.</given-names></name>
<name><surname>Lerdlum</surname><given-names>S.</given-names></name>
<name><surname>Suttichom</surname><given-names>D.</given-names></name>
<name><surname>Suwanwela</surname><given-names>N.C.</given-names></name>
<name><surname>Jagodzinski</surname><given-names>L.</given-names></name>
<name><surname>Michael</surname><given-names>N.</given-names></name>
<name><surname>Spudich</surname><given-names>S.</given-names></name>
<etal/>
</person-group><article-title>Central nervous system viral invasion and inflammation during acute HIV infection</article-title><source>J. Infect. Dis.</source><year>2012</year><volume>206</volume><fpage>275</fpage><lpage>282</lpage><pub-id pub-id-type="doi">10.1093/infdis/jis326</pub-id><pub-id pub-id-type="pmid">22551810</pub-id>
</element-citation></ref><ref id="B16-tropicalmed-10-00045"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kanmogne</surname><given-names>G.D.</given-names></name>
<name><surname>Schall</surname><given-names>K.</given-names></name>
<name><surname>Leibhart</surname><given-names>J.</given-names></name>
<name><surname>Knipe</surname><given-names>B.</given-names></name>
<name><surname>E Gendelman</surname><given-names>H.</given-names></name>
<name><surname>Persidsky</surname><given-names>Y.</given-names></name>
</person-group><article-title>HIV-1 gp120 compromises blood-brain barrier integrity and enhance monocyte migration across blood-brain barrier: Implication for viral neuropathogenesis</article-title><source>J. Cereb. Blood Flow. Metab.</source><year>2006</year><volume>27</volume><fpage>123</fpage><lpage>134</lpage><pub-id pub-id-type="doi">10.1038/sj.jcbfm.9600330</pub-id><pub-id pub-id-type="pmid">16685256</pub-id>
</element-citation></ref><ref id="B17-tropicalmed-10-00045"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Eugenin</surname><given-names>E.A.</given-names></name>
<name><surname>Clements</surname><given-names>J.E.</given-names></name>
<name><surname>Christine Zink</surname><given-names>M.</given-names></name>
<name><surname>Berman</surname><given-names>J.W.</given-names></name>
</person-group><article-title>Human immunodeficiency virus infection of human astrocytes disrupts blood-brain barrier integrity by a gap junction-dependent mechanism</article-title><source>J. Neurosci.</source><year>2011</year><volume>31</volume><fpage>9456</fpage><lpage>9465</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.1460-11.2011</pub-id><pub-id pub-id-type="pmid">21715610</pub-id>
</element-citation></ref><ref id="B18-tropicalmed-10-00045"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Toborek</surname><given-names>M.</given-names></name>
<name><surname>Lee</surname><given-names>Y.W.</given-names></name>
<name><surname>Flora</surname><given-names>G.</given-names></name>
<name><surname>Pu</surname><given-names>H.</given-names></name>
<name><surname>Andr&#x000e1;s</surname><given-names>I.E.</given-names></name>
<name><surname>Wylegala</surname><given-names>E.</given-names></name>
<name><surname>Hennig</surname><given-names>B.</given-names></name>
<name><surname>Nath</surname><given-names>A.</given-names></name>
</person-group><article-title>Mechanisms of the blood-brain barrier disruption in HIV-1 infection</article-title><source>Cell. Mol. Neurobiol.</source><year>2005</year><volume>25</volume><fpage>181</fpage><lpage>199</lpage><pub-id pub-id-type="doi">10.1007/s10571-004-1383-x</pub-id><pub-id pub-id-type="pmid">15962513</pub-id>
</element-citation></ref><ref id="B19-tropicalmed-10-00045"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Dallasta</surname><given-names>L.M.</given-names></name>
<name><surname>Pisarov</surname><given-names>L.A.</given-names></name>
<name><surname>Esplen</surname><given-names>J.E.</given-names></name>
<name><surname>Werley</surname><given-names>J.V.</given-names></name>
<name><surname>Moses</surname><given-names>A.V.</given-names></name>
<name><surname>Nelson</surname><given-names>J.A.</given-names></name>
<name><surname>Achim</surname><given-names>C.L.</given-names></name>
</person-group><article-title>Blood-brain barrier tight junction disruption in human immunodeficiency virus-1 encephalitis</article-title><source>Am. J. Pathol.</source><year>1999</year><volume>155</volume><fpage>1915</fpage><lpage>1927</lpage><pub-id pub-id-type="doi">10.1016/S0002-9440(10)65511-3</pub-id><pub-id pub-id-type="pmid">10595922</pub-id>
</element-citation></ref><ref id="B20-tropicalmed-10-00045"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Eugenin</surname><given-names>E.A.</given-names></name>
<name><surname>Osiecki</surname><given-names>K.</given-names></name>
<name><surname>Lopez</surname><given-names>L.</given-names></name>
<name><surname>Goldstein</surname><given-names>H.</given-names></name>
<name><surname>Calderon</surname><given-names>T.M.</given-names></name>
<name><surname>Berman</surname><given-names>J.W.</given-names></name>
</person-group><article-title>CCL2/monocyte chemoattractant protein-1 mediates enhanced transmigration of human immunodeficiency virus (HIV)-infected leukocytes across the blood-brain barrier: A potential mechanism of HIV-CNS invasion and NeuroAIDS</article-title><source>J. Neurosci.</source><year>2006</year><volume>26</volume><fpage>1098</fpage><lpage>1106</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.3863-05.2006</pub-id><pub-id pub-id-type="pmid">16436595</pub-id>
</element-citation></ref><ref id="B21-tropicalmed-10-00045"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Atluri</surname><given-names>V.S.R.</given-names></name>
<name><surname>Hidalgo</surname><given-names>M.</given-names></name>
<name><surname>Samikkannu</surname><given-names>T.</given-names></name>
<name><surname>Kurapati</surname><given-names>K.R.V.</given-names></name>
<name><surname>Jayant</surname><given-names>R.D.</given-names></name>
<name><surname>Sagar</surname><given-names>V.</given-names></name>
<name><surname>Nair</surname><given-names>M.P.N.</given-names></name>
</person-group><article-title>Effect of human immunodeficiency virus on blood-brain barrier integrity and function: An update</article-title><source>Front. Cell. Neurosci.</source><year>2015</year><volume>9</volume><elocation-id>212</elocation-id><pub-id pub-id-type="doi">10.3389/fncel.2015.00212</pub-id><pub-id pub-id-type="pmid">26113810</pub-id>
</element-citation></ref><ref id="B22-tropicalmed-10-00045"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Rahimy</surname><given-names>E.</given-names></name>
<name><surname>Li</surname><given-names>F.-Y.</given-names></name>
<name><surname>Hagberg</surname><given-names>L.</given-names></name>
<name><surname>Fuchs</surname><given-names>D.</given-names></name>
<name><surname>Robertson</surname><given-names>K.</given-names></name>
<name><surname>Meyerhoff</surname><given-names>D.J.</given-names></name>
<name><surname>Zetterberg</surname><given-names>H.</given-names></name>
<name><surname>Price</surname><given-names>R.W.</given-names></name>
<name><surname>Gissl&#x000e9;n</surname><given-names>M.</given-names></name>
<name><surname>Spudich</surname><given-names>S.</given-names></name>
</person-group><article-title>Blood-brain barrier disruption is initiated during primary HIV infection and not rapidly altered by antiretroviral therapy</article-title><source>J. Infect. Dis.</source><year>2017</year><volume>215</volume><fpage>1132</fpage><lpage>1140</lpage><pub-id pub-id-type="doi">10.1093/infdis/jix013</pub-id><pub-id pub-id-type="pmid">28368497</pub-id>
</element-citation></ref><ref id="B23-tropicalmed-10-00045"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Weiss</surname><given-names>N.</given-names></name>
<name><surname>Miller</surname><given-names>F.</given-names></name>
<name><surname>Cazaubon</surname><given-names>S.</given-names></name>
<name><surname>Couraud</surname><given-names>P.O.</given-names></name>
</person-group><article-title>The blood-brain barrier in brain homeostasis and neurological diseases</article-title><source>Biochim. Et. Biophys. Acta (BBA)-Biomembr.</source><year>2009</year><volume>1788</volume><fpage>842</fpage><lpage>857</lpage><pub-id pub-id-type="doi">10.1016/j.bbamem.2008.10.022</pub-id></element-citation></ref><ref id="B24-tropicalmed-10-00045"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Schnell</surname><given-names>G.</given-names></name>
<name><surname>Price</surname><given-names>R.W.</given-names></name>
<name><surname>Swanstrom</surname><given-names>R.</given-names></name>
<name><surname>Spudich</surname><given-names>S.</given-names></name>
</person-group><article-title>Compartmentalization and Clonal Amplification of HIV-1 Variants in the Cerebrospinal Fluid during Primary Infection</article-title><source>J. Virol.</source><year>2010</year><volume>84</volume><fpage>2395</fpage><lpage>2407</lpage><pub-id pub-id-type="doi">10.1128/JVI.01863-09</pub-id><pub-id pub-id-type="pmid">20015984</pub-id>
</element-citation></ref><ref id="B25-tropicalmed-10-00045"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Pillai</surname><given-names>S.K.</given-names></name>
<name><surname>Pond</surname><given-names>S.L.K.</given-names></name>
<name><surname>Liu</surname><given-names>Y.</given-names></name>
<name><surname>Good</surname><given-names>B.M.</given-names></name>
<name><surname>Strain</surname><given-names>M.C.</given-names></name>
<name><surname>Ellis</surname><given-names>R.J.</given-names></name>
<name><surname>Letendre</surname><given-names>S.</given-names></name>
<name><surname>Smith</surname><given-names>D.M.</given-names></name>
<name><surname>G&#x000fc;nthard</surname><given-names>H.F.</given-names></name>
<name><surname>Grant</surname><given-names>I.</given-names></name>
<etal/>
</person-group><article-title>Genetic attributes of cerebrospinal fluid-derived HIV-1 env</article-title><source>Brain</source><year>2006</year><volume>129</volume><fpage>1872</fpage><lpage>1883</lpage><pub-id pub-id-type="doi">10.1093/brain/awl136</pub-id><pub-id pub-id-type="pmid">16735456</pub-id>
</element-citation></ref><ref id="B26-tropicalmed-10-00045"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Tang</surname><given-names>Y.W.</given-names></name>
<name><surname>Huong</surname><given-names>J.T.J.</given-names></name>
<name><surname>Lloyd</surname><given-names>J.</given-names></name>
<name><surname>Spearman</surname><given-names>P.</given-names></name>
<name><surname>Haas</surname><given-names>D.W.</given-names></name>
</person-group><article-title>Comparison of human immunodeficiency virus type 1 RNA sequence heterogeneity in cerebrospinal fluid and plasma</article-title><source>J. Clin. Microbiol.</source><year>2000</year><volume>38</volume><fpage>4637</fpage><lpage>4639</lpage><pub-id pub-id-type="doi">10.1128/JCM.38.12.4637-4639.2000</pub-id><pub-id pub-id-type="pmid">11101610</pub-id>
</element-citation></ref><ref id="B27-tropicalmed-10-00045"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Rossi</surname><given-names>F.</given-names></name>
<name><surname>Querido</surname><given-names>B.</given-names></name>
<name><surname>Nimmagadda</surname><given-names>M.</given-names></name>
<name><surname>Cocklin</surname><given-names>S.</given-names></name>
<name><surname>Navas-Mart&#x000ed;n</surname><given-names>S.</given-names></name>
<name><surname>Mart&#x000ed;n-Garc&#x000ed;a</surname><given-names>J.</given-names></name>
</person-group><article-title>The V1-V3 region of a brain-derived HIV-1 envelope glycoprotein determines macrophage tropism, low CD4 dependence, increased fusogenicity and altered sensitivity to entry inhibitors</article-title><source>Retrovirology</source><year>2008</year><volume>5</volume><fpage>89</fpage><pub-id pub-id-type="doi">10.1186/1742-4690-5-89</pub-id><pub-id pub-id-type="pmid">18837996</pub-id>
</element-citation></ref><ref id="B28-tropicalmed-10-00045"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sturdevant</surname><given-names>C.B.</given-names></name>
<name><surname>Joseph</surname><given-names>S.B.</given-names></name>
<name><surname>Schnell</surname><given-names>G.</given-names></name>
<name><surname>Price</surname><given-names>R.W.</given-names></name>
<name><surname>Swanstrom</surname><given-names>R.</given-names></name>
<name><surname>Spudich</surname><given-names>S.</given-names></name>
</person-group><article-title>Compartmentalized Replication of R5 T Cell-Tropic HIV-1 in the Central Nervous System Early in the Course of Infection</article-title><source>PLoS Pathog.</source><year>2015</year><volume>11</volume><elocation-id>e1004720</elocation-id><pub-id pub-id-type="doi">10.1371/journal.ppat.1004720</pub-id><pub-id pub-id-type="pmid">25811757</pub-id>
</element-citation></ref><ref id="B29-tropicalmed-10-00045"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Maggirwar</surname><given-names>S.B.</given-names></name>
<name><surname>Tong</surname><given-names>N.</given-names></name>
<name><surname>Ramirez</surname><given-names>S.</given-names></name>
<name><surname>Gelbard</surname><given-names>H.A.</given-names></name>
<name><surname>Dewhurst</surname><given-names>S.</given-names></name>
</person-group><article-title>HIV-1 Tat-mediated activation of glycogen synthase kinase-3&#x003b2; contributes to Tat-mediated neurotoxicity</article-title><source>J. Neurochem.</source><year>1999</year><volume>73</volume><fpage>578</fpage><lpage>586</lpage><pub-id pub-id-type="doi">10.1046/j.1471-4159.1999.0730578.x</pub-id><pub-id pub-id-type="pmid">10428053</pub-id>
</element-citation></ref><ref id="B30-tropicalmed-10-00045"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Winston</surname><given-names>A.</given-names></name>
<name><surname>Antinori</surname><given-names>A.</given-names></name>
<name><surname>Cinque</surname><given-names>P.</given-names></name>
<name><surname>Fox</surname><given-names>H.S.</given-names></name>
<name><surname>Gisslen</surname><given-names>M.</given-names></name>
<name><surname>Henrich</surname><given-names>T.J.</given-names></name>
<name><surname>Letendre</surname><given-names>S.</given-names></name>
<name><surname>Persaud</surname><given-names>D.</given-names></name>
<name><surname>Price</surname><given-names>R.W.</given-names></name>
<name><surname>Spudich</surname><given-names>S.</given-names></name>
</person-group><article-title>Defining cerebrospinal fluid HIV RNA escape: Editorial review</article-title><source>Aids</source><year>2019</year><volume>33</volume><fpage>S107</fpage><lpage>S111</lpage><pub-id pub-id-type="doi">10.1097/QAD.0000000000002252</pub-id><pub-id pub-id-type="pmid">31790376</pub-id>
</element-citation></ref><ref id="B31-tropicalmed-10-00045"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Di Carlofelice</surname><given-names>M.</given-names></name>
<name><surname>Everitt</surname><given-names>A.</given-names></name>
<name><surname>Muir</surname><given-names>D.</given-names></name>
<name><surname>Winston</surname><given-names>A.</given-names></name>
</person-group><article-title>Cerebrospinal fluid HIV RNA in persons living with HIV</article-title><source>HIV Med.</source><year>2018</year><volume>19</volume><fpage>365</fpage><lpage>368</lpage><pub-id pub-id-type="doi">10.1111/hiv.12594</pub-id><pub-id pub-id-type="pmid">29368400</pub-id>
</element-citation></ref><ref id="B32-tropicalmed-10-00045"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ed&#x000e9;n</surname><given-names>A.</given-names></name>
<name><surname>Fuchs</surname><given-names>D.</given-names></name>
<name><surname>Hagberg</surname><given-names>L.</given-names></name>
<name><surname>Nilsson</surname><given-names>S.</given-names></name>
<name><surname>Spudich</surname><given-names>S.</given-names></name>
<name><surname>Svennerholm</surname><given-names>B.</given-names></name>
<name><surname>Price</surname><given-names>R.W.</given-names></name>
<name><surname>Gissl&#x000e9;n</surname><given-names>M.</given-names></name>
</person-group><article-title>HIV-1 viral escape in cerebrospinal fluid of subjects on suppressive antiretroviral treatment</article-title><source>J. Infect. Dis.</source><year>2010</year><volume>202</volume><fpage>1819</fpage><lpage>1825</lpage><pub-id pub-id-type="doi">10.1086/657342</pub-id><pub-id pub-id-type="pmid">21050119</pub-id>
</element-citation></ref><ref id="B33-tropicalmed-10-00045"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kugathasan</surname><given-names>R.</given-names></name>
<name><surname>Collier</surname><given-names>D.A.</given-names></name>
<name><surname>Haddow</surname><given-names>L.J.</given-names></name>
<name><surname>El Bouzidi</surname><given-names>K.</given-names></name>
<name><surname>Edwards</surname><given-names>S.G.</given-names></name>
<name><surname>Cartledge</surname><given-names>J.D.</given-names></name>
<name><surname>Miller</surname><given-names>R.F.</given-names></name>
<name><surname>Gupta</surname><given-names>R.K.</given-names></name>
</person-group><article-title>Diffuse white matter signal abnormalities on magnetic resonance imaging are associated with human immunodeficiency virus type 1 viral escape in the central nervous system among patients with neurological symptoms</article-title><source>Clin. Infect. Dis.</source><year>2017</year><volume>64</volume><fpage>1059</fpage><lpage>1065</lpage><pub-id pub-id-type="doi">10.1093/cid/cix035</pub-id><pub-id pub-id-type="pmid">28329096</pub-id>
</element-citation></ref><ref id="B34-tropicalmed-10-00045"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Mukerji</surname><given-names>S.S.</given-names></name>
<name><surname>Misra</surname><given-names>V.</given-names></name>
<name><surname>Lorenz</surname><given-names>D.</given-names></name>
<name><surname>Cervantes-Arslanian</surname><given-names>A.M.</given-names></name>
<name><surname>Lyons</surname><given-names>J.</given-names></name>
<name><surname>Chalkias</surname><given-names>S.</given-names></name>
<name><surname>Wurcel</surname><given-names>A.</given-names></name>
<name><surname>Burke</surname><given-names>D.</given-names></name>
<name><surname>Venna</surname><given-names>N.</given-names></name>
<name><surname>Morgello</surname><given-names>S.</given-names></name>
<etal/>
</person-group><article-title>Temporal Patterns and Drug Resistance in CSF Viral Escape among ART-Experienced HIV-1 Infected Adults</article-title><source>J. Acquir. Immune Defic. Syndr.</source><year>2017</year><volume>75</volume><fpage>246</fpage><lpage>255</lpage><pub-id pub-id-type="doi">10.1097/QAI.0000000000001362</pub-id><pub-id pub-id-type="pmid">28328546</pub-id>
</element-citation></ref><ref id="B35-tropicalmed-10-00045"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Mukerji</surname><given-names>S.S.</given-names></name>
<name><surname>Misra</surname><given-names>V.</given-names></name>
<name><surname>Lorenz</surname><given-names>D.R.</given-names></name>
<name><surname>Uno</surname><given-names>H.</given-names></name>
<name><surname>Morgello</surname><given-names>S.</given-names></name>
<name><surname>Franklin</surname><given-names>D.</given-names></name>
<name><surname>Ellis</surname><given-names>R.J.</given-names></name>
<name><surname>Letendre</surname><given-names>S.</given-names></name>
<name><surname>Gabuzda</surname><given-names>D.</given-names></name>
</person-group><article-title>Impact of Antiretroviral Regimens on Cerebrospinal Fluid Viral Escape in a Prospective Multicohort Study of Antiretroviral Therapy-Experienced Human Immunodeficiency Virus-1-Infected Adults in the United States</article-title><source>Clin. Infect. Dis.</source><year>2018</year><volume>67</volume><fpage>1182</fpage><lpage>1190</lpage><pub-id pub-id-type="doi">10.1093/cid/ciy267</pub-id><pub-id pub-id-type="pmid">29617912</pub-id>
</element-citation></ref><ref id="B36-tropicalmed-10-00045"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>P&#x000e9;rez-Valero</surname><given-names>I.</given-names></name>
<name><surname>Ellis</surname><given-names>R.</given-names></name>
<name><surname>Heaton</surname><given-names>R.</given-names></name>
<name><surname>Deutsch</surname><given-names>R.</given-names></name>
<name><surname>Franklin</surname><given-names>D.</given-names></name>
<name><surname>Clifford</surname><given-names>D.B.</given-names></name>
<name><surname>Collier</surname><given-names>A.</given-names></name>
<name><surname>Gelman</surname><given-names>B.</given-names></name>
<name><surname>Marra</surname><given-names>C.</given-names></name>
<name><surname>McCutchan</surname><given-names>J.A.</given-names></name>
<etal/>
</person-group><article-title>Cerebrospinal fluid viral escape in aviremic HIV-infected patients receiving antiretroviral therapy: Prevalence, risk factors and neurocognitive effects</article-title><source>AIDS</source><year>2019</year><volume>33</volume><fpage>475</fpage><lpage>481</lpage><pub-id pub-id-type="doi">10.1097/QAD.0000000000002074</pub-id><pub-id pub-id-type="pmid">30702516</pub-id>
</element-citation></ref><ref id="B37-tropicalmed-10-00045"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Rawson</surname><given-names>T.</given-names></name>
<name><surname>Muir</surname><given-names>D.</given-names></name>
<name><surname>Mackie</surname><given-names>N.E.</given-names></name>
<name><surname>Garvey</surname><given-names>L.J.</given-names></name>
<name><surname>Everitt</surname><given-names>A.</given-names></name>
<name><surname>Winston</surname><given-names>A.</given-names></name>
</person-group><article-title>Factors associated with cerebrospinal fluid HIV RNA in HIV infected subjects undergoing lumbar puncture examination in a clinical setting</article-title><source>J. Infect.</source><year>2012</year><volume>65</volume><fpage>239</fpage><lpage>245</lpage><pub-id pub-id-type="doi">10.1016/j.jinf.2012.04.007</pub-id><pub-id pub-id-type="pmid">22522289</pub-id>
</element-citation></ref><ref id="B38-tropicalmed-10-00045"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Trunfio</surname><given-names>M.</given-names></name>
<name><surname>Rugge</surname><given-names>W.</given-names></name>
<name><surname>Mighetto</surname><given-names>L.</given-names></name>
<name><surname>Vai</surname><given-names>D.</given-names></name>
<name><surname>Atzori</surname><given-names>C.</given-names></name>
<name><surname>Nigra</surname><given-names>M.</given-names></name>
<name><surname>Domini</surname><given-names>S.</given-names></name>
<name><surname>Borgogno</surname><given-names>E.</given-names></name>
<name><surname>Guastamacchia</surname><given-names>G.</given-names></name>
<name><surname>Bonora</surname><given-names>S.</given-names></name>
<etal/>
</person-group><article-title>Dual antiretroviral therapies are effective and safe regimens in the central nervous system of neurologically symptomatic people living with HIV</article-title><source>AIDS</source><year>2020</year><volume>34</volume><fpage>1899</fpage><lpage>1906</lpage><pub-id pub-id-type="doi">10.1097/QAD.0000000000002601</pub-id><pub-id pub-id-type="pmid">32701580</pub-id>
</element-citation></ref><ref id="B39-tropicalmed-10-00045"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Dravid</surname><given-names>A.N.</given-names></name>
<name><surname>Natrajan</surname><given-names>K.</given-names></name>
<name><surname>Kulkarni</surname><given-names>M.M.</given-names></name>
<name><surname>Saraf</surname><given-names>C.K.</given-names></name>
<name><surname>Mahajan</surname><given-names>U.S.</given-names></name>
<name><surname>Kore</surname><given-names>S.D.</given-names></name>
<name><surname>Rathod</surname><given-names>N.M.</given-names></name>
<name><surname>Mahajan</surname><given-names>U.S.</given-names></name>
<name><surname>Wadia</surname><given-names>R.S.</given-names></name>
</person-group><article-title>Discordant CSF/plasma HIV-1 RNA in individuals on virologically suppressive antiretroviral therapy in Western India</article-title><source>Medicine</source><year>2018</year><volume>97</volume><fpage>e9969</fpage><pub-id pub-id-type="doi">10.1097/MD.0000000000009969</pub-id><pub-id pub-id-type="pmid">29465595</pub-id>
</element-citation></ref><ref id="B40-tropicalmed-10-00045"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>de Almeida</surname><given-names>S.M.</given-names></name>
<name><surname>Rotta</surname><given-names>I.</given-names></name>
<name><surname>de Pereira</surname><given-names>A.P.</given-names></name>
<name><surname>Tang</surname><given-names>B.</given-names></name>
<name><surname>Umlauf</surname><given-names>A.</given-names></name>
<name><surname>Ribeiro</surname><given-names>C.E.</given-names></name>
<name><surname>Letendre</surname><given-names>S.</given-names></name>
<name><surname>Ellis</surname><given-names>R.J.</given-names></name>
<collab>HIV Neurobehavioral Research Center (HNRC) Group</collab>
</person-group><article-title>Cerebrospinal fluid pleocytosis as a predictive factor for CSF and plasma HIV RNA discordance and escape</article-title><source>J. Neurovirol.</source><year>2020</year><volume>26</volume><fpage>241</fpage><lpage>251</lpage><pub-id pub-id-type="doi">10.1007/s13365-020-00828-1</pub-id><pub-id pub-id-type="pmid">32002817</pub-id>
</element-citation></ref><ref id="B41-tropicalmed-10-00045"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Calcagno</surname><given-names>A.</given-names></name>
<name><surname>Simiele</surname><given-names>M.</given-names></name>
<name><surname>Alberione</surname><given-names>M.C.</given-names></name>
<name><surname>Bracchi</surname><given-names>M.</given-names></name>
<name><surname>Marinaro</surname><given-names>L.</given-names></name>
<name><surname>Ecclesia</surname><given-names>S.</given-names></name>
<name><surname>Di Perri</surname><given-names>G.</given-names></name>
<name><surname>D&#x02019;Avolio</surname><given-names>A.</given-names></name>
<name><surname>Bonora</surname><given-names>S.</given-names></name>
</person-group><article-title>Cerebrospinal fluid inhibitory quotients of antiretroviral drugs in HIV-infected patients are associated with compartmental viral control</article-title><source>Clin. Infect. Dis.</source><year>2015</year><volume>60</volume><fpage>311</fpage><lpage>317</lpage><pub-id pub-id-type="doi">10.1093/cid/ciu773</pub-id><pub-id pub-id-type="pmid">25281609</pub-id>
</element-citation></ref><ref id="B42-tropicalmed-10-00045"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bavaro</surname><given-names>D.F.</given-names></name>
<name><surname>Calamo</surname><given-names>A.</given-names></name>
<name><surname>Lepore</surname><given-names>L.</given-names></name>
<name><surname>Fabrizio</surname><given-names>C.</given-names></name>
<name><surname>Saracino</surname><given-names>A.</given-names></name>
<name><surname>Angarano</surname><given-names>G.</given-names></name>
<name><surname>Monno</surname><given-names>L.</given-names></name>
</person-group><article-title>Cerebrospinal fluid compartmentalization of HIV-1 and correlation with plasma viral load and blood&#x02013;brain barrier damage</article-title><source>Infection</source><year>2019</year><volume>47</volume><fpage>441</fpage><lpage>446</lpage><pub-id pub-id-type="doi">10.1007/s15010-019-01268-8</pub-id><pub-id pub-id-type="pmid">30649685</pub-id>
</element-citation></ref><ref id="B43-tropicalmed-10-00045"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Filippidis</surname><given-names>P.</given-names></name>
<name><surname>Damas</surname><given-names>J.</given-names></name>
<name><surname>Viala</surname><given-names>B.</given-names></name>
<name><surname>Assal</surname><given-names>F.</given-names></name>
<name><surname>Tshikung</surname><given-names>O.N.</given-names></name>
<name><surname>Tarr</surname><given-names>P.</given-names></name>
<name><surname>Derfuss</surname><given-names>T.</given-names></name>
<name><surname>Oberholzer</surname><given-names>M.</given-names></name>
<name><surname>Jelcic</surname><given-names>I.</given-names></name>
<name><surname>Hundsberger</surname><given-names>T.</given-names></name>
<etal/>
</person-group><article-title>Cerebrospinal Fluid HIV-1 Escape in Patients with Neurocognitive Symptoms: Pooled Data from a Neuro-HIV Platform and the NAMACO Study</article-title><source>J. Acquir. Immune Defic. Syndr.</source><year>2023</year><volume>93</volume><fpage>219</fpage><lpage>228</lpage><pub-id pub-id-type="doi">10.1097/QAI.0000000000003189</pub-id><pub-id pub-id-type="pmid">36927958</pub-id>
</element-citation></ref><ref id="B44-tropicalmed-10-00045"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Letendre</surname><given-names>S.L.</given-names></name>
<name><surname>Ellis</surname><given-names>R.J.</given-names></name>
<name><surname>Ances</surname><given-names>B.M.</given-names></name>
<name><surname>McCutchan</surname><given-names>J.A.</given-names></name>
</person-group><article-title>Neurologic complications of HIV disease and their treatment</article-title><source>Top. HIV Med.</source><year>2010</year><volume>18</volume><fpage>45</fpage><lpage>55</lpage><pub-id pub-id-type="pmid">20516524</pub-id>
</element-citation></ref><ref id="B45-tropicalmed-10-00045"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Garvey</surname><given-names>L.J.</given-names></name>
<name><surname>Everitt</surname><given-names>A.</given-names></name>
<name><surname>Winston</surname><given-names>A.</given-names></name>
<name><surname>MacKie</surname><given-names>N.E.</given-names></name>
<name><surname>Benzie</surname><given-names>A.</given-names></name>
</person-group><article-title>Detectable cerebrospinal fluid HIV RNA with associated neurological deficits, despite suppression of HIV replication in the plasma compartment</article-title><source>AIDS</source><year>2009</year><volume>23</volume><fpage>1443</fpage><lpage>1444</lpage><pub-id pub-id-type="doi">10.1097/QAD.0b013e32832d077c</pub-id><pub-id pub-id-type="pmid">19564723</pub-id>
</element-citation></ref><ref id="B46-tropicalmed-10-00045"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Waters</surname><given-names>L.</given-names></name>
<name><surname>Winston</surname><given-names>A.</given-names></name>
<name><surname>Reeves</surname><given-names>I.</given-names></name>
<name><surname>Boffito</surname><given-names>M.</given-names></name>
<name><surname>Churchill</surname><given-names>D.</given-names></name>
<name><surname>Cromarty</surname><given-names>B.</given-names></name>
<name><surname>Dunn</surname><given-names>D.</given-names></name>
<name><surname>Fink</surname><given-names>D.</given-names></name>
<name><surname>Fidler</surname><given-names>S.</given-names></name>
<name><surname>Foster</surname><given-names>C.</given-names></name>
<etal/>
</person-group><article-title>BHIVA guidelines on antiretroviral treatment for adults living with HIV-1 2022</article-title><source>HIV Med.</source><year>2022</year><volume>23</volume><fpage>3</fpage><lpage>115</lpage><pub-id pub-id-type="doi">10.1111/hiv.13446</pub-id><pub-id pub-id-type="pmid">36504313</pub-id>
</element-citation></ref><ref id="B47-tropicalmed-10-00045"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ambrosioni</surname><given-names>J.</given-names></name>
<name><surname>Levi</surname><given-names>L.</given-names></name>
<name><surname>Alagaratnam</surname><given-names>J.</given-names></name>
<name><surname>Van Bremen</surname><given-names>K.</given-names></name>
<name><surname>Mastrangelo</surname><given-names>A.</given-names></name>
<name><surname>Waalewijn</surname><given-names>H.</given-names></name>
<name><surname>Molina</surname><given-names>J.</given-names></name>
<name><surname>Guaraldi</surname><given-names>G.</given-names></name>
<name><surname>Winston</surname><given-names>A.</given-names></name>
<name><surname>Boesecke</surname><given-names>C.</given-names></name>
<etal/>
</person-group><article-title>Major revision version 12.0 of the European AIDS Clinical Society guidelines 2023</article-title><source>HIV Med.</source><year>2023</year><volume>24</volume><fpage>1126</fpage><lpage>1136</lpage><pub-id pub-id-type="doi">10.1111/hiv.13542</pub-id><pub-id pub-id-type="pmid">37849432</pub-id>
</element-citation></ref><ref id="B48-tropicalmed-10-00045"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Guyatt</surname><given-names>G.H.</given-names></name>
<name><surname>Oxman</surname><given-names>A.D.</given-names></name>
<name><surname>Kunz</surname><given-names>R.</given-names></name>
<name><surname>Falck-Ytter</surname><given-names>Y.</given-names></name>
<name><surname>Vist</surname><given-names>G.E.</given-names></name>
<name><surname>Liberati</surname><given-names>A.</given-names></name>
<name><surname>Sch&#x000fc;nemann</surname><given-names>H.J.</given-names></name>
</person-group><article-title>GRADE: Going from evidence to recommendations</article-title><source>Bmj</source><year>2008</year><volume>336</volume><fpage>1049</fpage><lpage>1051</lpage><pub-id pub-id-type="doi">10.1136/bmj.39493.646875.AE</pub-id><pub-id pub-id-type="pmid">18467413</pub-id>
</element-citation></ref><ref id="B49-tropicalmed-10-00045"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ferretti</surname><given-names>F.</given-names></name>
<name><surname>Gisslen</surname><given-names>M.</given-names></name>
<name><surname>Cinque</surname><given-names>P.</given-names></name>
<name><surname>Price</surname><given-names>R.W.</given-names></name>
</person-group><article-title>Cerebrospinal Fluid HIV Escape from Antiretroviral Therapy</article-title><source>Curr. HIV/AIDS Rep.</source><year>2015</year><volume>12</volume><fpage>280</fpage><lpage>288</lpage><pub-id pub-id-type="doi">10.1007/s11904-015-0267-7</pub-id><pub-id pub-id-type="pmid">25860317</pub-id>
</element-citation></ref><ref id="B50-tropicalmed-10-00045"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ruelle</surname><given-names>J.</given-names></name>
<name><surname>Debaisieux</surname><given-names>L.</given-names></name>
<name><surname>Vancutsem</surname><given-names>E.</given-names></name>
<name><surname>De Bel</surname><given-names>A.</given-names></name>
<name><surname>Delforge</surname><given-names>M.-L.</given-names></name>
<name><surname>Pi&#x000e9;rard</surname><given-names>D.</given-names></name>
<name><surname>Goubau</surname><given-names>P.</given-names></name>
</person-group><article-title>HIV-1 low-level viraemia assessed with 3 commercial real-time PCR assays show high variability</article-title><source>BMC Infect. Dis.</source><year>2012</year><volume>12</volume><elocation-id>100</elocation-id><pub-id pub-id-type="doi">10.1186/1471-2334-12-100</pub-id><pub-id pub-id-type="pmid">22530816</pub-id>
</element-citation></ref><ref id="B51-tropicalmed-10-00045"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Barakat</surname><given-names>E.</given-names></name>
<name><surname>Oren</surname><given-names>N.C.</given-names></name>
<name><surname>Vaysberg</surname><given-names>A.</given-names></name>
</person-group><article-title>Symptomatic cerebrospinal fluid HIV escape syndrome in a patient on highly active antiretroviral therapy and suppressed plasma viral load</article-title><source>AIDS</source><year>2019</year><volume>33</volume><fpage>2444</fpage><lpage>2446</lpage><pub-id pub-id-type="doi">10.1097/QAD.0000000000002370</pub-id><pub-id pub-id-type="pmid">31764112</pub-id>
</element-citation></ref><ref id="B52-tropicalmed-10-00045"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>B&#x000e9;guelin</surname><given-names>C.</given-names></name>
<name><surname>V&#x000e1;zquez</surname><given-names>M.</given-names></name>
<name><surname>Bertschi</surname><given-names>M.</given-names></name>
<name><surname>Yerly</surname><given-names>S.</given-names></name>
<name><surname>de Jong</surname><given-names>D.</given-names></name>
<name><surname>Gutbrod</surname><given-names>K.</given-names></name>
<name><surname>Rauch</surname><given-names>A.</given-names></name>
<name><surname>Cusini</surname><given-names>A.</given-names></name>
</person-group><article-title>Viral escape in the central nervous system with multidrug-resistant human immunodeficiency virus-1</article-title><source>Open Forum Infect. Dis.</source><year>2016</year><volume>3</volume><fpage>ofv210</fpage><pub-id pub-id-type="doi">10.1093/ofid/ofv210</pub-id><pub-id pub-id-type="pmid">26885540</pub-id>
</element-citation></ref><ref id="B53-tropicalmed-10-00045"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Canestri</surname><given-names>A.</given-names></name>
<name><surname>Lescure</surname><given-names>F.</given-names></name>
<name><surname>Jaureguiberry</surname><given-names>S.</given-names></name>
<name><surname>Moulignier</surname><given-names>A.</given-names></name>
<name><surname>Amiel</surname><given-names>C.</given-names></name>
<name><surname>Marcelin</surname><given-names>A.G.</given-names></name>
<name><surname>Peytavin</surname><given-names>G.</given-names></name>
<name><surname>Tubiana</surname><given-names>R.</given-names></name>
<name><surname>Pialoux</surname><given-names>G.</given-names></name>
<name><surname>Katlama</surname><given-names>C.</given-names></name>
</person-group><article-title>Discordance between cerebral spinal fluid and plasma HIV replication in patients with neurological symptoms who are receiving suppressive antiretroviral therapy</article-title><source>Clin. Infect. Dis.</source><year>2010</year><volume>50</volume><fpage>773</fpage><lpage>778</lpage><pub-id pub-id-type="doi">10.1086/650538</pub-id><pub-id pub-id-type="pmid">20100092</pub-id>
</element-citation></ref><ref id="B54-tropicalmed-10-00045"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Peluso</surname><given-names>M.J.</given-names></name>
<name><surname>Ferretti</surname><given-names>F.</given-names></name>
<name><surname>Peterson</surname><given-names>J.</given-names></name>
<name><surname>Lee</surname><given-names>E.</given-names></name>
<name><surname>Fuchs</surname><given-names>D.</given-names></name>
<name><surname>Boschini</surname><given-names>A.</given-names></name>
<name><surname>Gissl&#x000e9;n</surname><given-names>M.</given-names></name>
<name><surname>Angoff</surname><given-names>N.</given-names></name>
<name><surname>Price</surname><given-names>R.W.</given-names></name>
<name><surname>Cinque</surname><given-names>P.</given-names></name>
<etal/>
</person-group><article-title>Cerebrospinal fluid HIV escape associated with progressive neurologic dysfunction in patients on antiretroviral therapy with well controlled plasma viral load</article-title><source>AIDS</source><year>2012</year><volume>26</volume><fpage>1765</fpage><lpage>1774</lpage><pub-id pub-id-type="doi">10.1097/QAD.0b013e328355e6b2</pub-id><pub-id pub-id-type="pmid">22614889</pub-id>
</element-citation></ref><ref id="B55-tropicalmed-10-00045"><label>55.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Henderson</surname><given-names>M.</given-names></name>
<name><surname>Pepper</surname><given-names>N.</given-names></name>
<name><surname>Bawa</surname><given-names>M.</given-names></name>
<name><surname>Muir</surname><given-names>D.</given-names></name>
<name><surname>Everitt</surname><given-names>A.</given-names></name>
<name><surname>Mackie</surname><given-names>N.E.</given-names></name>
<name><surname>Winston</surname><given-names>A.</given-names></name>
</person-group><article-title>Cerebrospinal fluid virology in people with HIV</article-title><source>HIV Med.</source><year>2023</year><volume>24</volume><fpage>838</fpage><lpage>844</lpage><pub-id pub-id-type="doi">10.1111/hiv.13471</pub-id><pub-id pub-id-type="pmid">36895097</pub-id>
</element-citation></ref><ref id="B56-tropicalmed-10-00045"><label>56.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Spudich</surname><given-names>S.</given-names></name>
<name><surname>Robertson</surname><given-names>K.R.</given-names></name>
<name><surname>Bosch</surname><given-names>R.J.</given-names></name>
<name><surname>Gandhi</surname><given-names>R.T.</given-names></name>
<name><surname>Cyktor</surname><given-names>J.C.</given-names></name>
<name><surname>Mar</surname><given-names>H.</given-names></name>
<name><surname>Macatangay</surname><given-names>B.J.</given-names></name>
<name><surname>Lalama</surname><given-names>C.M.</given-names></name>
<name><surname>Rinaldo</surname><given-names>C.</given-names></name>
<name><surname>Collier</surname><given-names>A.C.</given-names></name>
<etal/>
</person-group><article-title>Persistent HIV-infected cells in cerebrospinal fluid are associated with poorer neurocognitive performance</article-title><source>J. Clin. Investig.</source><year>2019</year><volume>129</volume><fpage>3339</fpage><lpage>3346</lpage><pub-id pub-id-type="doi">10.1172/JCI127413</pub-id><pub-id pub-id-type="pmid">31305262</pub-id>
</element-citation></ref><ref id="B57-tropicalmed-10-00045"><label>57.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ulfhammer</surname><given-names>G.</given-names></name>
<name><surname>Yilmaz</surname><given-names>A.</given-names></name>
<name><surname>Mellgren</surname><given-names>&#x000c5;.</given-names></name>
<name><surname>Tyrberg</surname><given-names>E.</given-names></name>
<name><surname>S&#x000f6;rstedt</surname><given-names>E.</given-names></name>
<name><surname>Hagberg</surname><given-names>L.</given-names></name>
<name><surname>Gostner</surname><given-names>J.</given-names></name>
<name><surname>Fuchs</surname><given-names>D.</given-names></name>
<name><surname>Zetterberg</surname><given-names>H.</given-names></name>
<name><surname>Nilsson</surname><given-names>S.</given-names></name>
<etal/>
</person-group><article-title>Asymptomatic Cerebrospinal Fluid HIV-1 Escape: Incidence and Consequences</article-title><source>J. Infect. Dis.</source><year>2024</year><pub-id pub-id-type="doi">10.1093/infdis/jiae555</pub-id><pub-id pub-id-type="pmid">39531854</pub-id>
</element-citation></ref><ref id="B58-tropicalmed-10-00045"><label>58.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Underwood</surname><given-names>J.</given-names></name>
<name><surname>Cole</surname><given-names>J.H.</given-names></name>
<name><surname>Leech</surname><given-names>R.</given-names></name>
<name><surname>Sharp</surname><given-names>D.J.</given-names></name>
<name><surname>Winston</surname><given-names>A.</given-names></name>
<collab>for the CHARTER group</collab>
</person-group><article-title>Multivariate pattern analysis of volumetric neuroimaging data and its relationship with cognitive function in treated HIV disease</article-title><source>J. Acquir. Immune Defic. Syndr.</source><year>2018</year><volume>78</volume><fpage>429</fpage><lpage>436</lpage><pub-id pub-id-type="doi">10.1097/QAI.0000000000001687</pub-id><pub-id pub-id-type="pmid">29608444</pub-id>
</element-citation></ref><ref id="B59-tropicalmed-10-00045"><label>59.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>A van Zoest</surname><given-names>R.</given-names></name>
<name><surname>Underwood</surname><given-names>J.</given-names></name>
<name><surname>De Francesco</surname><given-names>D.</given-names></name>
<name><surname>A Sabin</surname><given-names>C.</given-names></name>
<name><surname>Cole</surname><given-names>J.H.</given-names></name>
<name><surname>Wit</surname><given-names>F.W.</given-names></name>
<name><surname>A Caan</surname><given-names>M.W.</given-names></name>
<name><surname>A Kootstra</surname><given-names>N.</given-names></name>
<name><surname>Fuchs</surname><given-names>D.</given-names></name>
<name><surname>Zetterberg</surname><given-names>H.</given-names></name>
<etal/>
</person-group><article-title>Structural Brain Abnormalities in Successfully Treated HIV Infection: Associations with Disease and Cerebrospinal Fluid Biomarkers</article-title><source>J. Infect. Dis.</source><year>2018</year><volume>217</volume><fpage>69</fpage><lpage>81</lpage><pub-id pub-id-type="doi">10.1093/infdis/jix553</pub-id></element-citation></ref><ref id="B60-tropicalmed-10-00045"><label>60.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hu</surname><given-names>Z.</given-names></name>
<name><surname>Cinque</surname><given-names>P.</given-names></name>
<name><surname>Dravid</surname><given-names>A.</given-names></name>
<name><surname>Hagberg</surname><given-names>L.</given-names></name>
<name><surname>Yilmaz</surname><given-names>A.</given-names></name>
<name><surname>Zetterberg</surname><given-names>H.</given-names></name>
<name><surname>Fuchs</surname><given-names>D.</given-names></name>
<name><surname>Gostner</surname><given-names>J.</given-names></name>
<name><surname>Blennow</surname><given-names>K.</given-names></name>
<name><surname>Spudich</surname><given-names>S.S.</given-names></name>
<etal/>
</person-group><article-title>Changes in cerebrospinal fluid proteins across the spectrum of untreated and treated chronic HIV-1 infection. Silvestri G, editor</article-title><source>PLoS Pathog.</source><year>2024</year><volume>20</volume><elocation-id>e1012470</elocation-id><pub-id pub-id-type="doi">10.1371/journal.ppat.1012470</pub-id><pub-id pub-id-type="pmid">39316609</pub-id>
</element-citation></ref><ref id="B61-tropicalmed-10-00045"><label>61.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kincer</surname><given-names>L.P.</given-names></name>
<name><surname>Dravid</surname><given-names>A.</given-names></name>
<name><surname>Trunfio</surname><given-names>M.</given-names></name>
<name><surname>Calcagno</surname><given-names>A.</given-names></name>
<name><surname>Zhou</surname><given-names>S.</given-names></name>
<name><surname>Vercesi</surname><given-names>R.</given-names></name>
<name><surname>Spudich</surname><given-names>S.</given-names></name>
<name><surname>Gisslen</surname><given-names>M.</given-names></name>
<name><surname>Price</surname><given-names>R.W.</given-names></name>
<name><surname>Cinque</surname><given-names>P.</given-names></name>
<etal/>
</person-group><article-title>Neurosymptomatic HIV-1 CSF escape is associated with replication in CNS T cells and inflammation</article-title><source>J. Clin. Investig.</source><year>2024</year><volume>134</volume><fpage>e176358</fpage><pub-id pub-id-type="doi">10.1172/JCI176358</pub-id><pub-id pub-id-type="pmid">39352388</pub-id>
</element-citation></ref><ref id="B62-tropicalmed-10-00045"><label>62.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Guha</surname><given-names>D.</given-names></name>
<name><surname>Misra</surname><given-names>V.</given-names></name>
<name><surname>Yin</surname><given-names>J.</given-names></name>
<name><surname>Gabuzda</surname><given-names>D.</given-names></name>
</person-group><article-title>CSF Inflammation Markers Associated with Asymptomatic Viral Escape in Cerebrospinal Fluid of HIV-Positive Individuals on Antiretroviral Therapy</article-title><source>Viruses</source><year>2023</year><volume>15</volume><elocation-id>1829</elocation-id><pub-id pub-id-type="doi">10.3390/v15091829</pub-id><pub-id pub-id-type="pmid">37766236</pub-id>
</element-citation></ref><ref id="B63-tropicalmed-10-00045"><label>63.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Castellano</surname><given-names>P.</given-names></name>
<name><surname>Prevedel</surname><given-names>L.</given-names></name>
<name><surname>Eugenin</surname><given-names>E.A.</given-names></name>
</person-group><article-title>HIV-infected macrophages and microglia that survive acute infection become viral reservoirs by a mechanism involving Bim</article-title><source>Sci. Rep.</source><year>2017</year><volume>7</volume><elocation-id>12866</elocation-id><pub-id pub-id-type="doi">10.1038/s41598-017-12758-w</pub-id><pub-id pub-id-type="pmid">28993666</pub-id>
</element-citation></ref><ref id="B64-tropicalmed-10-00045"><label>64.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Schnell</surname><given-names>G.</given-names></name>
<name><surname>Spudich</surname><given-names>S.</given-names></name>
<name><surname>Harrington</surname><given-names>P.</given-names></name>
<name><surname>Price</surname><given-names>R.W.</given-names></name>
<name><surname>Swanstrom</surname><given-names>R.</given-names></name>
</person-group><article-title>Compartmentalized Human Immunodeficiency Virus Type 1 Originates from Long-Lived Cells in Some Subjects with HIV-1-Associated Dementia</article-title><source>PLoS Pathog.</source><year>2009</year><volume>5</volume><elocation-id>e1000395</elocation-id><pub-id pub-id-type="doi">10.1371/journal.ppat.1000395</pub-id><pub-id pub-id-type="pmid">19390619</pub-id>
</element-citation></ref><ref id="B65-tropicalmed-10-00045"><label>65.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Joseph</surname><given-names>S.B.</given-names></name>
<name><surname>Kincer</surname><given-names>L.P.</given-names></name>
<name><surname>Bowman</surname><given-names>N.M.</given-names></name>
<name><surname>Evans</surname><given-names>C.</given-names></name>
<name><surname>Vinikoor</surname><given-names>M.J.</given-names></name>
<name><surname>Lippincott</surname><given-names>C.K.</given-names></name>
<name><surname>Gissl&#x000e9;n</surname><given-names>M.</given-names></name>
<name><surname>Spudich</surname><given-names>S.</given-names></name>
<name><surname>Menezes</surname><given-names>P.</given-names></name>
<name><surname>Robertson</surname><given-names>K.</given-names></name>
<etal/>
</person-group><article-title>Human Immunodeficiency Virus Type 1 RNA Detected in the Central Nervous System (CNS) after Years of Suppressive Antiretroviral Therapy Can Originate from a Replicating CNS Reservoir or Clonally Expanded Cells</article-title><source>Clin. Infect. Dis.</source><year>2019</year><volume>69</volume><fpage>1345</fpage><lpage>1352</lpage><pub-id pub-id-type="doi">10.1093/cid/ciy1066</pub-id><pub-id pub-id-type="pmid">30561541</pub-id>
</element-citation></ref><ref id="B66-tropicalmed-10-00045"><label>66.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lahouassa</surname><given-names>H.</given-names></name>
<name><surname>Daddacha</surname><given-names>W.</given-names></name>
<name><surname>Hofmann</surname><given-names>H.</given-names></name>
<name><surname>Ayinde</surname><given-names>D.</given-names></name>
<name><surname>Logue</surname><given-names>E.C.</given-names></name>
<name><surname>Dragin</surname><given-names>L.</given-names></name>
<name><surname>Bloch</surname><given-names>N.</given-names></name>
<name><surname>Maudet</surname><given-names>C.</given-names></name>
<name><surname>Bertrand</surname><given-names>M.</given-names></name>
<name><surname>Gramberg</surname><given-names>T.</given-names></name>
<etal/>
</person-group><article-title>SAMHD1 restricts the replication of human immunodeficiency virus type 1 by depleting the intracellular pool of deoxynucleoside triphosphates</article-title><source>Nat. Immunol.</source><year>2012</year><volume>13</volume><fpage>223</fpage><lpage>228</lpage><pub-id pub-id-type="doi">10.1038/ni.2236</pub-id><pub-id pub-id-type="pmid">22327569</pub-id>
</element-citation></ref><ref id="B67-tropicalmed-10-00045"><label>67.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Laguette</surname><given-names>N.</given-names></name>
<name><surname>Sobhian</surname><given-names>B.</given-names></name>
<name><surname>Casartelli</surname><given-names>N.</given-names></name>
<name><surname>Ringeard</surname><given-names>M.</given-names></name>
<name><surname>Chable-Bessia</surname><given-names>C.</given-names></name>
<name><surname>S&#x000e9;g&#x000e9;ral</surname><given-names>E.</given-names></name>
<name><surname>Yatim</surname><given-names>A.</given-names></name>
<name><surname>Emiliani</surname><given-names>S.</given-names></name>
<name><surname>Schwartz</surname><given-names>O.</given-names></name>
<name><surname>Benkirane</surname><given-names>M.</given-names></name>
</person-group><article-title>SAMHD1 is the dendritic- and myeloid-cell-specific HIV-1 restriction factor counteracted by Vpx</article-title><source>Nature</source><year>2011</year><volume>474</volume><fpage>654</fpage><lpage>657</lpage><pub-id pub-id-type="doi">10.1038/nature10117</pub-id><pub-id pub-id-type="pmid">21613998</pub-id>
</element-citation></ref><ref id="B68-tropicalmed-10-00045"><label>68.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Mlcochova</surname><given-names>P.</given-names></name>
<name><surname>Sutherland</surname><given-names>K.A.</given-names></name>
<name><surname>Watters</surname><given-names>S.A.</given-names></name>
<name><surname>Bertoli</surname><given-names>C.</given-names></name>
<name><surname>de Bruin</surname><given-names>R.A.</given-names></name>
<name><surname>Rehwinkel</surname><given-names>J.</given-names></name>
<name><surname>Neil</surname><given-names>S.J.</given-names></name>
<name><surname>Lenzi</surname><given-names>G.M.</given-names></name>
<name><surname>Kim</surname><given-names>B.</given-names></name>
<name><surname>Khwaja</surname><given-names>A.</given-names></name>
<etal/>
</person-group><article-title>A G1-like state allows HIV -1 to bypass SAMHD 1 restriction in macrophages</article-title><source>EMBO J.</source><year>2017</year><volume>36</volume><fpage>604</fpage><lpage>616</lpage><pub-id pub-id-type="doi">10.15252/embj.201696025</pub-id><pub-id pub-id-type="pmid">28122869</pub-id>
</element-citation></ref><ref id="B69-tropicalmed-10-00045"><label>69.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Mlcochova</surname><given-names>P.</given-names></name>
<name><surname>Heilig</surname><given-names>R.</given-names></name>
<name><surname>Fischer</surname><given-names>R.</given-names></name>
<name><surname>Gupta</surname><given-names>R.K.</given-names></name>
</person-group><article-title>CD4 T cell contact drives macrophage cell cycle progression and susceptibility to lentiviral transduction</article-title><source>Sig. Transduct. Target Ther.</source><year>2024</year><volume>9</volume><fpage>348</fpage><pub-id pub-id-type="doi">10.1038/s41392-024-02053-2</pub-id></element-citation></ref><ref id="B70-tropicalmed-10-00045"><label>70.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lucas</surname><given-names>S.B.</given-names></name>
<name><surname>Wong</surname><given-names>K.T.</given-names></name>
<name><surname>Nightingale</surname><given-names>S.</given-names></name>
<name><surname>Miller</surname><given-names>R.F.</given-names></name>
</person-group><article-title>HIV-Associated CD8 Encephalitis: A UK Case Series and Review of Histopathologically Confirmed Cases</article-title><source>Front. Neurol.</source><year>2021</year><volume>12</volume><elocation-id>628296</elocation-id><pub-id pub-id-type="doi">10.3389/fneur.2021.628296</pub-id><pub-id pub-id-type="pmid">33868143</pub-id>
</element-citation></ref><ref id="B71-tropicalmed-10-00045"><label>71.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ed&#x000e9;n</surname><given-names>A.</given-names></name>
<name><surname>Nilsson</surname><given-names>S.</given-names></name>
<name><surname>Hagberg</surname><given-names>L.</given-names></name>
<name><surname>Fuchs</surname><given-names>D.</given-names></name>
<name><surname>Zetterberg</surname><given-names>H.</given-names></name>
<name><surname>Svennerholm</surname><given-names>B.</given-names></name>
<name><surname>Gissl&#x000e9;n</surname><given-names>M.</given-names></name>
</person-group><article-title>Asymptomatic cerebrospinal fluid HIV-1 viral blips and viral escape during antiretroviral therapy: A longitudinal study</article-title><source>J. Infect. Dis.</source><year>2016</year><volume>214</volume><fpage>1822</fpage><lpage>1825</lpage><pub-id pub-id-type="doi">10.1093/infdis/jiw454</pub-id><pub-id pub-id-type="pmid">27683820</pub-id>
</element-citation></ref><ref id="B72-tropicalmed-10-00045"><label>72.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Spudich</surname><given-names>S.S.</given-names></name>
<name><surname>Nilsson</surname><given-names>A.C.</given-names></name>
<name><surname>Lollo</surname><given-names>N.D.</given-names></name>
<name><surname>Liegler</surname><given-names>T.J.</given-names></name>
<name><surname>Petropoulos</surname><given-names>C.J.</given-names></name>
<name><surname>Deeks</surname><given-names>S.G.</given-names></name>
<name><surname>E Paxinos</surname><given-names>E.</given-names></name>
<name><surname>Price</surname><given-names>R.W.</given-names></name>
</person-group><article-title>Cerebrospinal fluid HIV infection and pleocytosis: Relation to systemic infection and antiretroviral treatment</article-title><source>BMC Infect. Dis.</source><year>2005</year><volume>5</volume><elocation-id>98</elocation-id><pub-id pub-id-type="doi">10.1186/1471-2334-5-98</pub-id><pub-id pub-id-type="pmid">16266436</pub-id>
</element-citation></ref><ref id="B73-tropicalmed-10-00045"><label>73.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Marra</surname><given-names>C.M.</given-names></name>
<name><surname>Maxwell</surname><given-names>C.L.</given-names></name>
<name><surname>Collier</surname><given-names>A.C.</given-names></name>
<name><surname>Robertson</surname><given-names>K.R.</given-names></name>
<name><surname>Imrie</surname><given-names>A.</given-names></name>
</person-group><article-title>Interpreting cerebrospinal fluid pleocytosis in HIV in the era of potent antiretroviral therapy</article-title><source>BMC Infect. Dis.</source><year>2007</year><volume>7</volume><elocation-id>37</elocation-id><pub-id pub-id-type="doi">10.1186/1471-2334-7-37</pub-id><pub-id pub-id-type="pmid">17475004</pub-id>
</element-citation></ref><ref id="B74-tropicalmed-10-00045"><label>74.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Antinori</surname><given-names>A.</given-names></name>
<name><surname>Giancola</surname><given-names>M.L.</given-names></name>
<name><surname>Grisetti</surname><given-names>S.</given-names></name>
<name><surname>Soldani</surname><given-names>F.</given-names></name>
<name><surname>Alba</surname><given-names>L.</given-names></name>
<name><surname>Liuzzi</surname><given-names>G.</given-names></name>
<name><surname>Amendola</surname><given-names>A.</given-names></name>
<name><surname>Capobianchi</surname><given-names>M.</given-names></name>
<name><surname>Tozzi</surname><given-names>V.</given-names></name>
<name><surname>Perno</surname><given-names>C.F.</given-names></name>
</person-group><article-title>Factors influencing virological response to antiretroviral drugs in cerebrospinal fluid of advanced HIV-1-infected patients</article-title><source>AIDS</source><year>2002</year><volume>16</volume><fpage>1867</fpage><lpage>1876</lpage><pub-id pub-id-type="doi">10.1097/00002030-200209270-00003</pub-id><pub-id pub-id-type="pmid">12351946</pub-id>
</element-citation></ref><ref id="B75-tropicalmed-10-00045"><label>75.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Cecchini</surname><given-names>D.M.</given-names></name>
<name><surname>Ca&#x000f1;izal</surname><given-names>A.M.</given-names></name>
<name><surname>Rojas</surname><given-names>H.</given-names></name>
<name><surname>Arechavala</surname><given-names>A.</given-names></name>
<name><surname>Negroni</surname><given-names>R.</given-names></name>
<name><surname>Bouzas</surname><given-names>M.B.</given-names></name>
<name><surname>A Benetucci</surname><given-names>J.</given-names></name>
</person-group><article-title>Variables that influence HIV-1 cerebrospinal fluid viral load in cryptococcal meningitis: A linear regression analysis</article-title><source>J. Int. AIDS Soc.</source><year>2009</year><volume>12</volume><fpage>33</fpage><pub-id pub-id-type="doi">10.1186/1758-2652-12-33</pub-id><pub-id pub-id-type="pmid">19906308</pub-id>
</element-citation></ref><ref id="B76-tropicalmed-10-00045"><label>76.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Christo</surname><given-names>P.P.</given-names></name>
<name><surname>Greco</surname><given-names>D.B.</given-names></name>
<name><surname>Aleixo</surname><given-names>A.W.</given-names></name>
<name><surname>Livramento</surname><given-names>J.A.</given-names></name>
</person-group><article-title>HIV-1 RNA levels in cerebrospinal fluid and plasma and their correlation with opportunistic neurological diseases in a Brazilian aids reference hospital</article-title><source>Arq. Neuropsiquiatr.</source><year>2005</year><volume>63</volume><fpage>907</fpage><lpage>913</lpage><pub-id pub-id-type="doi">10.1590/S0004-282X2005000600001</pub-id><pub-id pub-id-type="pmid">16400403</pub-id>
</element-citation></ref><ref id="B77-tropicalmed-10-00045"><label>77.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Jones</surname><given-names>K.</given-names></name>
<name><surname>Rivera</surname><given-names>C.</given-names></name>
<name><surname>Sgadari</surname><given-names>C.</given-names></name>
<name><surname>Franklin</surname><given-names>J.</given-names></name>
<name><surname>E Max</surname><given-names>E.</given-names></name>
<name><surname>Bhatia</surname><given-names>K.</given-names></name>
<name><surname>Tosato</surname><given-names>G.</given-names></name>
</person-group><article-title>Infection of human endothelial cells with Epstein-Barr virus</article-title><source>J. Exp. Med.</source><year>1995</year><volume>182</volume><fpage>1213</fpage><lpage>1221</lpage><pub-id pub-id-type="doi">10.1084/jem.182.5.1213</pub-id><pub-id pub-id-type="pmid">7595192</pub-id>
</element-citation></ref><ref id="B78-tropicalmed-10-00045"><label>78.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lupia</surname><given-names>T.</given-names></name>
<name><surname>Milia</surname><given-names>M.G.</given-names></name>
<name><surname>Atzori</surname><given-names>C.</given-names></name>
<name><surname>Gianella</surname><given-names>S.</given-names></name>
<name><surname>Audagnotto</surname><given-names>S.</given-names></name>
<name><surname>Imperiale</surname><given-names>D.</given-names></name>
<name><surname>Mighetto</surname><given-names>L.</given-names></name>
<name><surname>Pirriatore</surname><given-names>V.</given-names></name>
<name><surname>Gregori</surname><given-names>G.</given-names></name>
<name><surname>Lipani</surname><given-names>F.</given-names></name>
<etal/>
</person-group><article-title>Presence of Epstein-Barr virus DNA in cerebrospinal fluid is associated with greater HIV RNA and inflammation</article-title><source>AIDS</source><year>2020</year><volume>34</volume><fpage>373</fpage><lpage>380</lpage><pub-id pub-id-type="doi">10.1097/QAD.0000000000002442</pub-id><pub-id pub-id-type="pmid">31764071</pub-id>
</element-citation></ref><ref id="B79-tropicalmed-10-00045"><label>79.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hawes</surname><given-names>I.</given-names></name>
<name><surname>Alvarenga</surname><given-names>B.</given-names></name>
<name><surname>Browne</surname><given-names>W.</given-names></name>
<name><surname>Wapniarski</surname><given-names>A.</given-names></name>
<name><surname>Dandekar</surname><given-names>R.</given-names></name>
<name><surname>Bartley</surname><given-names>C.</given-names></name>
<name><surname>Sowa</surname><given-names>G.</given-names></name>
<name><surname>DeRisi</surname><given-names>J.</given-names></name>
<name><surname>Cinque</surname><given-names>P.</given-names></name>
<name><surname>Dravid</surname><given-names>A.</given-names></name>
<etal/>
</person-group><article-title>Viral co-infection, autoimmunity, and CSF HIV antibody profiles in HIV central nervous system escape</article-title><source>J. Neuroimmunol.</source><year>2023</year><volume>381</volume><fpage>578141</fpage><pub-id pub-id-type="doi">10.1016/j.jneuroim.2023.578141</pub-id><pub-id pub-id-type="pmid">37418948</pub-id>
</element-citation></ref><ref id="B80-tropicalmed-10-00045"><label>80.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ellis</surname><given-names>R.</given-names></name>
<name><surname>Gamst</surname><given-names>A.</given-names></name>
<name><surname>Capparelli</surname><given-names>E.</given-names></name>
<name><surname>Spector</surname><given-names>S.</given-names></name>
<name><surname>Hsia</surname><given-names>K.</given-names></name>
<name><surname>Wolfson</surname><given-names>T.</given-names></name>
<name><surname>Abramson</surname><given-names>I.</given-names></name>
<name><surname>Grant</surname><given-names>I.</given-names></name>
<name><surname>McCutchan</surname><given-names>J.</given-names></name>
</person-group><article-title>Cerebrospinal fluid HIV RNA originates from both local CNS and systemic sources</article-title><source>Neurology</source><year>2000</year><volume>54</volume><fpage>927</fpage><lpage>936</lpage><pub-id pub-id-type="doi">10.1212/WNL.54.4.927</pub-id><pub-id pub-id-type="pmid">10690988</pub-id>
</element-citation></ref><ref id="B81-tropicalmed-10-00045"><label>81.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Schnell</surname><given-names>G.</given-names></name>
<name><surname>Joseph</surname><given-names>S.</given-names></name>
<name><surname>Spudich</surname><given-names>S.</given-names></name>
<name><surname>Price</surname><given-names>R.W.</given-names></name>
<name><surname>Swanstrom</surname><given-names>R.</given-names></name>
</person-group><article-title>HIV-1 replication in the central nervous system occurs in two distinct cell types</article-title><source>PLoS Pathog.</source><year>2011</year><volume>7</volume><elocation-id>e1002286</elocation-id><pub-id pub-id-type="doi">10.1371/journal.ppat.1002286</pub-id><pub-id pub-id-type="pmid">22007152</pub-id>
</element-citation></ref><ref id="B82-tropicalmed-10-00045"><label>82.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Nightingale</surname><given-names>S.</given-names></name>
<name><surname>Dreyer</surname><given-names>A.J.</given-names></name>
<name><surname>Thomas</surname><given-names>K.G.F.</given-names></name>
<name><surname>van Zyl</surname><given-names>G.</given-names></name>
<name><surname>Decloedt</surname><given-names>E.</given-names></name>
<name><surname>Naude</surname><given-names>P.J.W.</given-names></name>
<name><surname>Orrell</surname><given-names>C.</given-names></name>
<name><surname>Sinxadi</surname><given-names>P.</given-names></name>
<name><surname>Winston</surname><given-names>A.</given-names></name>
<name><surname>Khoo</surname><given-names>S.</given-names></name>
<etal/>
</person-group><article-title>Cognitive performance, neuropsychiatric symptoms, and cerebrospinal fluid viral control following programmatic switch from efavirenz-based to dolutegravir-based antiretroviral therapy in South Africa (CONNECT): A prospective cohort study</article-title><source>Lancet HIV</source><year>2024</year><volume>11</volume><fpage>e680</fpage><lpage>e689</lpage><pub-id pub-id-type="doi">10.1016/S2352-3018(24)00209-1</pub-id><pub-id pub-id-type="pmid">39284338</pub-id>
</element-citation></ref><ref id="B83-tropicalmed-10-00045"><label>83.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Swenson</surname><given-names>L.C.</given-names></name>
<name><surname>Cobb</surname><given-names>B.</given-names></name>
<name><surname>Geretti</surname><given-names>A.M.</given-names></name>
<name><surname>Harrigan</surname><given-names>P.R.</given-names></name>
<name><surname>Poljak</surname><given-names>M.</given-names></name>
<name><surname>Seguin-Devaux</surname><given-names>C.</given-names></name>
<name><surname>Verhofstede</surname><given-names>C.</given-names></name>
<name><surname>Wirden</surname><given-names>M.</given-names></name>
<name><surname>Amendola</surname><given-names>A.</given-names></name>
<name><surname>Boni</surname><given-names>J.</given-names></name>
<etal/>
</person-group><article-title>Comparative performances of HIV-1 RNA load assays at low viral load levels: Results of an international collaboration</article-title><source>J. Clin. Microbiol.</source><year>2014</year><volume>52</volume><fpage>517</fpage><lpage>523</lpage><pub-id pub-id-type="doi">10.1128/JCM.02461-13</pub-id><pub-id pub-id-type="pmid">24478482</pub-id>
</element-citation></ref><ref id="B84-tropicalmed-10-00045"><label>84.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sollis</surname><given-names>K.A.</given-names></name>
<name><surname>Smit</surname><given-names>P.W.</given-names></name>
<name><surname>Fiscus</surname><given-names>S.</given-names></name>
<name><surname>Ford</surname><given-names>N.</given-names></name>
<name><surname>Vitoria</surname><given-names>M.</given-names></name>
<name><surname>Essajee</surname><given-names>S.</given-names></name>
<name><surname>Barnett</surname><given-names>D.</given-names></name>
<name><surname>Cheng</surname><given-names>B.</given-names></name>
<name><surname>Crowe</surname><given-names>S.M.</given-names></name>
<name><surname>Denny</surname><given-names>T.</given-names></name>
<etal/>
</person-group><article-title>Systematic review of the performance of HIV viral load technologies on plasma samples</article-title><source>PLoS ONE</source><year>2014</year><volume>9</volume><elocation-id>e85869</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0085869</pub-id><pub-id pub-id-type="pmid">24558359</pub-id>
</element-citation></ref><ref id="B85-tropicalmed-10-00045"><label>85.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Chernoff</surname><given-names>D.N.</given-names></name>
</person-group><article-title>The significance of HIV viral load assay precision: A review of the package insert specifications of two commercial kits</article-title><source>J. Int. Assoc. Physicians AIDS Care</source><year>2002</year><volume>1</volume><fpage>134</fpage><lpage>140</lpage><pub-id pub-id-type="doi">10.1177/154510970200100405</pub-id></element-citation></ref><ref id="B86-tropicalmed-10-00045"><label>86.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Doyle</surname><given-names>T.</given-names></name>
<name><surname>Geretti</surname><given-names>A.M.</given-names></name>
</person-group><article-title>Low-level viraemia on HAART: Significance and management</article-title><source>Curr. Opin. Infect. Dis.</source><year>2012</year><volume>25</volume><fpage>17</fpage><lpage>25</lpage><pub-id pub-id-type="doi">10.1097/QCO.0b013e32834ef5d9</pub-id><pub-id pub-id-type="pmid">22156900</pub-id>
</element-citation></ref><ref id="B87-tropicalmed-10-00045"><label>87.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Letendre</surname><given-names>S.</given-names></name>
<name><surname>McClernon</surname><given-names>D.</given-names></name>
<name><surname>Ellis</surname><given-names>R.J.</given-names></name>
<name><surname>Mu&#x000f1;oz-Moreno</surname><given-names>J.</given-names></name>
<name><surname>Way</surname><given-names>L.</given-names></name>
<name><surname>Clifford</surname><given-names>D.</given-names></name>
<name><surname>Collier</surname><given-names>A.</given-names></name>
<name><surname>Gelman</surname><given-names>B.</given-names></name>
<name><surname>Marra</surname><given-names>C.</given-names></name>
<name><surname>McArthur</surname><given-names>J.</given-names></name>
<etal/>
</person-group><article-title>Persistent HIV in the central nervous system during treatment is associated with worse antiretroviral therapy penetration and cognitive impairment</article-title><source>J. Neurovirol.</source><year>2009</year><volume>15</volume><issue>(Suppl. S1)</issue><fpage>74</fpage></element-citation></ref><ref id="B88-tropicalmed-10-00045"><label>88.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Gissl&#x000e9;n</surname><given-names>M.</given-names></name>
<name><surname>Hagberg</surname><given-names>L.</given-names></name>
<name><surname>Brew</surname><given-names>B.J.</given-names></name>
<name><surname>Cinque</surname><given-names>P.</given-names></name>
<name><surname>Price</surname><given-names>R.W.</given-names></name>
<name><surname>Rosengren</surname><given-names>L.</given-names></name>
</person-group><article-title>Elevated Cerebrospinal Fluid Neurofilament Light Protein Concentrations Predict the Development of AIDS Dementia Complex</article-title><source>J. Infect. Dis.</source><year>2007</year><volume>195</volume><fpage>1774</fpage><lpage>1778</lpage><pub-id pub-id-type="doi">10.1086/518043</pub-id><pub-id pub-id-type="pmid">17492593</pub-id>
</element-citation></ref><ref id="B89-tropicalmed-10-00045"><label>89.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>de Almeida</surname><given-names>S.M.</given-names></name>
<name><surname>Rotta</surname><given-names>I.</given-names></name>
<name><surname>Ribeiro</surname><given-names>C.E.</given-names></name>
<name><surname>Oliveira</surname><given-names>M.F.</given-names></name>
<name><surname>Chaillon</surname><given-names>A.</given-names></name>
<name><surname>de Pereira</surname><given-names>A.P.</given-names></name>
<name><surname>Cunha</surname><given-names>A.P.</given-names></name>
<name><surname>Zonta</surname><given-names>M.</given-names></name>
<name><surname>Bents</surname><given-names>J.F.</given-names></name>
<name><surname>Raboni</surname><given-names>S.M.</given-names></name>
<etal/>
</person-group><article-title>Dynamic of CSF and serum biomarkers in HIV-1 subtype C encephalitis with CNS genetic compartmentalization&#x02014;Case study</article-title><source>J. NeuroVirology</source><year>2017</year><volume>23</volume><fpage>460</fpage><lpage>473</lpage><pub-id pub-id-type="doi">10.1007/s13365-017-0518-z</pub-id><pub-id pub-id-type="pmid">28247269</pub-id>
</element-citation></ref><ref id="B90-tropicalmed-10-00045"><label>90.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Gissl&#x000e9;n</surname><given-names>M.</given-names></name>
<name><surname>Price</surname><given-names>R.W.</given-names></name>
<name><surname>Andreasson</surname><given-names>U.</given-names></name>
<name><surname>Norgren</surname><given-names>N.</given-names></name>
<name><surname>Nilsson</surname><given-names>S.</given-names></name>
<name><surname>Hagberg</surname><given-names>L.</given-names></name>
<name><surname>Fuchs</surname><given-names>D.</given-names></name>
<name><surname>Spudich</surname><given-names>S.</given-names></name>
<name><surname>Blennow</surname><given-names>K.</given-names></name>
<name><surname>Zetterberg</surname><given-names>H.</given-names></name>
</person-group><article-title>Plasma Concentration of the Neurofilament Light Protein (NFL) is a Biomarker of CNS Injury in HIV Infection: A Cross-Sectional Study</article-title><source>EBioMedicine</source><year>2016</year><volume>3</volume><fpage>135</fpage><lpage>140</lpage><pub-id pub-id-type="doi">10.1016/j.ebiom.2015.11.036</pub-id><pub-id pub-id-type="pmid">26870824</pub-id>
</element-citation></ref><ref id="B91-tropicalmed-10-00045"><label>91.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lustig</surname><given-names>G.</given-names></name>
<name><surname>Cele</surname><given-names>S.</given-names></name>
<name><surname>Karim</surname><given-names>F.</given-names></name>
<name><surname>Derache</surname><given-names>A.</given-names></name>
<name><surname>Ngoepe</surname><given-names>A.</given-names></name>
<name><surname>Khan</surname><given-names>K.</given-names></name>
<name><surname>Gosnell</surname><given-names>B.I.</given-names></name>
<name><surname>Moosa</surname><given-names>M.-Y.S.</given-names></name>
<name><surname>Ntshuba</surname><given-names>N.</given-names></name>
<name><surname>Marais</surname><given-names>S.</given-names></name>
<etal/>
</person-group><article-title>T cell derived HIV-1 is present in the CSF in the face of suppressive antiretroviral therapy</article-title><source>PLoS Pathog.</source><year>2021</year><volume>17</volume><elocation-id>e1009871</elocation-id><pub-id pub-id-type="doi">10.1371/journal.ppat.1009871</pub-id><pub-id pub-id-type="pmid">34555123</pub-id>
</element-citation></ref><ref id="B92-tropicalmed-10-00045"><label>92.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bertrand</surname><given-names>L.</given-names></name>
<name><surname>Nair</surname><given-names>M.</given-names></name>
<name><surname>Toborek</surname><given-names>M.</given-names></name>
</person-group><article-title>Solving the Blood-Brain Barrier Challenge for the Effective Treatment of HIV Replication in the Central Nervous System</article-title><source>Curr. Pharm. Des.</source><year>2016</year><volume>22</volume><fpage>5477</fpage><lpage>5486</lpage><pub-id pub-id-type="doi">10.2174/1381612822666160726113001</pub-id><pub-id pub-id-type="pmid">27464720</pub-id>
</element-citation></ref><ref id="B93-tropicalmed-10-00045"><label>93.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ene</surname><given-names>L.</given-names></name>
<name><surname>Duiculescu</surname><given-names>D.</given-names></name>
<name><surname>Ruta</surname><given-names>S.M.</given-names></name>
</person-group><article-title>How much do antiretroviral drugs penetrate into the central nervous system?</article-title><source>J. Med. Life</source><year>2011</year><volume>4</volume><fpage>432</fpage><pub-id pub-id-type="pmid">22514580</pub-id>
</element-citation></ref><ref id="B94-tropicalmed-10-00045"><label>94.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Harder</surname><given-names>B.G.</given-names></name>
<name><surname>Blomquist</surname><given-names>M.R.</given-names></name>
<name><surname>Wang</surname><given-names>J.</given-names></name>
<name><surname>Kim</surname><given-names>A.J.</given-names></name>
<name><surname>Woodworth</surname><given-names>G.F.</given-names></name>
<name><surname>Winkles</surname><given-names>J.A.</given-names></name>
<name><surname>Loftus</surname><given-names>J.C.</given-names></name>
<name><surname>Tran</surname><given-names>N.L.</given-names></name>
</person-group><article-title>Developments in Blood-Brain Barrier Penetrance and Drug Repurposing for Improved Treatment of Glioblastoma</article-title><source>Front. Oncol.</source><year>2018</year><volume>8</volume><elocation-id>462</elocation-id><pub-id pub-id-type="doi">10.3389/fonc.2018.00462</pub-id><pub-id pub-id-type="pmid">30406029</pub-id>
</element-citation></ref><ref id="B95-tropicalmed-10-00045"><label>95.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Tiraboschi</surname><given-names>J.</given-names></name>
<name><surname>Sc&#x000e9;vola</surname><given-names>S.</given-names></name>
<name><surname>Penchala</surname><given-names>S.D.</given-names></name>
<name><surname>Challenger</surname><given-names>E.</given-names></name>
<name><surname>Else</surname><given-names>L.</given-names></name>
<name><surname>Prieto</surname><given-names>P.</given-names></name>
<name><surname>Saumoy</surname><given-names>M.</given-names></name>
<name><surname>Imaz</surname><given-names>A.</given-names></name>
<name><surname>Silva-Klug</surname><given-names>A.</given-names></name>
<name><surname>Niub&#x000f3;</surname><given-names>J.</given-names></name>
<etal/>
</person-group><article-title>Total and Unbound Doravirine Concentrations and Viral Suppression in CSF</article-title><source>Clin. Infect. Dis.</source><year>2021</year><volume>74</volume><fpage>1855</fpage><lpage>1858</lpage><pub-id pub-id-type="doi">10.1093/cid/ciab835</pub-id><pub-id pub-id-type="pmid">34549268</pub-id>
</element-citation></ref><ref id="B96-tropicalmed-10-00045"><label>96.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Letendre</surname><given-names>S.</given-names></name>
<name><surname>Marquie-Beck</surname><given-names>J.</given-names></name>
<name><surname>Capparelli</surname><given-names>E.</given-names></name>
<name><surname>Best</surname><given-names>B.</given-names></name>
<name><surname>Clifford</surname><given-names>D.</given-names></name>
<name><surname>Collier</surname><given-names>A.C.</given-names></name>
<name><surname>Gelman</surname><given-names>B.B.</given-names></name>
<name><surname>McArthur</surname><given-names>J.C.</given-names></name>
<name><surname>McCutchan</surname><given-names>J.A.</given-names></name>
<name><surname>Morgello</surname><given-names>S.</given-names></name>
<etal/>
</person-group><article-title>Validation of the CNS penetration-effectiveness rank for quantifying antiretroviral penetration into the central nervous system</article-title><source>Arch. Neurol.</source><year>2008</year><volume>65</volume><fpage>65</fpage><lpage>70</lpage><pub-id pub-id-type="doi">10.1001/archneurol.2007.31</pub-id><pub-id pub-id-type="pmid">18195140</pub-id>
</element-citation></ref><ref id="B97-tropicalmed-10-00045"><label>97.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Cusini</surname><given-names>A.</given-names></name>
<name><surname>Vernazza</surname><given-names>P.L.</given-names></name>
<name><surname>Yerly</surname><given-names>S.</given-names></name>
<name><surname>Decosterd</surname><given-names>L.A.</given-names></name>
<name><surname>Ledergerber</surname><given-names>B.</given-names></name>
<name><surname>Fux</surname><given-names>C.A.</given-names></name>
<name><surname>Rohrbach</surname><given-names>J.</given-names></name>
<name><surname>Widmer</surname><given-names>N.</given-names></name>
<name><surname>Hirschel</surname><given-names>B.</given-names></name>
<name><surname>Gaudenz</surname><given-names>R.</given-names></name>
<etal/>
</person-group><article-title>Higher CNS penetration-effectiveness of long-term combination antiretroviral therapy is associated with better hiv-1 viral suppression in cerebrospinal fluid</article-title><source>J. Acquir. Immune Defic. Syndr.</source><year>2013</year><volume>62</volume><fpage>28</fpage><lpage>35</lpage><pub-id pub-id-type="doi">10.1097/QAI.0b013e318274e2b0</pub-id><pub-id pub-id-type="pmid">23018371</pub-id>
</element-citation></ref><ref id="B98-tropicalmed-10-00045"><label>98.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Varatharajan</surname><given-names>L.</given-names></name>
<name><surname>Thomas</surname><given-names>S.A.</given-names></name>
</person-group><article-title>The transport of anti-HIV drugs across blood-CNS interfaces: Summary of current knowledge and recommendations for further research</article-title><source>Antivir. Res.</source><year>2009</year><volume>82</volume><fpage>A99</fpage><lpage>A109</lpage><pub-id pub-id-type="doi">10.1016/j.antiviral.2008.12.013</pub-id><pub-id pub-id-type="pmid">19176219</pub-id>
</element-citation></ref><ref id="B99-tropicalmed-10-00045"><label>99.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ellis</surname><given-names>R.J.</given-names></name>
<name><surname>Letendre</surname><given-names>S.</given-names></name>
<name><surname>Vaida</surname><given-names>F.</given-names></name>
<name><surname>Grant</surname><given-names>I.</given-names></name>
<name><surname>Atkinson</surname><given-names>J.H.</given-names></name>
<name><surname>McCutchan</surname><given-names>J.A.</given-names></name>
<name><surname>Clifford</surname><given-names>D.B.</given-names></name>
<name><surname>Everall</surname><given-names>I.P.</given-names></name>
<name><surname>Morgello</surname><given-names>S.</given-names></name>
<name><surname>Simpson</surname><given-names>D.M.</given-names></name>
</person-group><article-title>Randomized trial of central nervous system-targeted antiretrovirals for HIV-associated neurocognitive disorder</article-title><source>Clin. Infect. Dis.</source><year>2014</year><volume>58</volume><fpage>1015</fpage><lpage>1022</lpage><pub-id pub-id-type="doi">10.1093/cid/cit921</pub-id><pub-id pub-id-type="pmid">24352352</pub-id>
</element-citation></ref><ref id="B100-tropicalmed-10-00045"><label>100.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ferrara</surname><given-names>M.</given-names></name>
<name><surname>Bumpus</surname><given-names>N.N.</given-names></name>
<name><surname>Ma</surname><given-names>Q.</given-names></name>
<name><surname>Ellis</surname><given-names>R.J.</given-names></name>
<name><surname>Soontornniyomkij</surname><given-names>V.</given-names></name>
<name><surname>Fields</surname><given-names>J.A.</given-names></name>
<name><surname>Bharti</surname><given-names>A.</given-names></name>
<name><surname>Achim</surname><given-names>C.L.</given-names></name>
<name><surname>Moore</surname><given-names>D.J.</given-names></name>
<name><surname>Letendre</surname><given-names>S.L.</given-names></name>
</person-group><article-title>Antiretroviral drug concentrations in brain tissue of adult decedents</article-title><source>AIDS</source><year>2020</year><volume>34</volume><fpage>1907</fpage><lpage>1914</lpage><pub-id pub-id-type="doi">10.1097/QAD.0000000000002628</pub-id><pub-id pub-id-type="pmid">32694413</pub-id>
</element-citation></ref><ref id="B101-tropicalmed-10-00045"><label>101.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Caniglia</surname><given-names>E.C.</given-names></name>
<name><surname>Cain</surname><given-names>L.E.</given-names></name>
<name><surname>Justice</surname><given-names>A.</given-names></name>
<name><surname>Tate</surname><given-names>J.</given-names></name>
<name><surname>Logan</surname><given-names>R.</given-names></name>
<name><surname>Sabin</surname><given-names>C.</given-names></name>
<name><surname>Winston</surname><given-names>A.</given-names></name>
<name><surname>van Sighem</surname><given-names>A.</given-names></name>
<name><surname>Miro</surname><given-names>J.M.</given-names></name>
<name><surname>Podzamczer</surname><given-names>D.</given-names></name>
<etal/>
</person-group><article-title>Antiretroviral penetration into the CNS and incidence of AIDS-defining neurologic conditions</article-title><source>Neurology</source><year>2014</year><volume>83</volume><fpage>134</fpage><lpage>141</lpage><pub-id pub-id-type="doi">10.1212/WNL.0000000000000564</pub-id><pub-id pub-id-type="pmid">24907236</pub-id>
</element-citation></ref><ref id="B102-tropicalmed-10-00045"><label>102.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lanman</surname><given-names>T.</given-names></name>
<name><surname>Letendre</surname><given-names>S.</given-names></name>
<name><surname>Ma</surname><given-names>Q.</given-names></name>
<name><surname>Bang</surname><given-names>A.</given-names></name>
<name><surname>Ellis</surname><given-names>R.</given-names></name>
</person-group><article-title>CNS Neurotoxicity of Antiretrovirals</article-title><source>J. Neuroimmune Pharmacol.</source><year>2021</year><volume>16</volume><fpage>130</fpage><lpage>143</lpage><pub-id pub-id-type="doi">10.1007/s11481-019-09886-7</pub-id><pub-id pub-id-type="pmid">31823251</pub-id>
</element-citation></ref><ref id="B103-tropicalmed-10-00045"><label>103.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Jenny-Avital</surname><given-names>E.</given-names></name>
<name><surname>Hoffman</surname><given-names>J.</given-names></name>
<name><surname>Katz</surname><given-names>M.</given-names></name>
<name><surname>Leider</surname><given-names>J.</given-names></name>
<name><surname>Apfelroth</surname><given-names>S.</given-names></name>
</person-group><article-title>HIV Central Nervous System Escape (CNSE): Finding the Needle in the Haystack Using Cerebrospinal Fluid (CSF) HIV Viral Load</article-title><source>Open Forum Infect. Dis.</source><year>2015</year><volume>2</volume><issue>(Suppl. S1)</issue><fpage>1658</fpage><pub-id pub-id-type="doi">10.1093/ofid/ofv133.1211</pub-id></element-citation></ref><ref id="B104-tropicalmed-10-00045"><label>104.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Dahl</surname><given-names>V.</given-names></name>
<name><surname>Lee</surname><given-names>E.</given-names></name>
<name><surname>Peterson</surname><given-names>J.</given-names></name>
<name><surname>Spudich</surname><given-names>S.S.</given-names></name>
<name><surname>Leppla</surname><given-names>I.</given-names></name>
<name><surname>Sinclair</surname><given-names>E.</given-names></name>
<name><surname>Fuchs</surname><given-names>D.</given-names></name>
<name><surname>Palmer</surname><given-names>S.</given-names></name>
<name><surname>Price</surname><given-names>R.W.</given-names></name>
</person-group><article-title>Raltegravir treatment intensification does not alter cerebrospinal fluid hiv-1 infection or immunoactivation in subjects on suppressive therapy</article-title><source>J. Infect. Dis.</source><year>2011</year><volume>204</volume><fpage>1936</fpage><lpage>1945</lpage><pub-id pub-id-type="doi">10.1093/infdis/jir667</pub-id><pub-id pub-id-type="pmid">22021620</pub-id>
</element-citation></ref><ref id="B105-tropicalmed-10-00045"><label>105.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Yilmaz</surname><given-names>A.</given-names></name>
<name><surname>Gissl&#x000e9;n</surname><given-names>M.</given-names></name>
<name><surname>Spudich</surname><given-names>S.</given-names></name>
<name><surname>Lee</surname><given-names>E.</given-names></name>
<name><surname>Jayewardene</surname><given-names>A.</given-names></name>
<name><surname>Aweeka</surname><given-names>F.</given-names></name>
<name><surname>Price</surname><given-names>R.W.</given-names></name>
</person-group><article-title>Raltegravir cerebrospinal fluid concentrations in HIV-1 infection</article-title><source>PLoS ONE</source><year>2009</year><volume>4</volume><elocation-id>e6877</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0006877</pub-id><pub-id pub-id-type="pmid">19721718</pub-id>
</element-citation></ref><ref id="B106-tropicalmed-10-00045"><label>106.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Mora-Peris</surname><given-names>B.</given-names></name>
<name><surname>MacKie</surname><given-names>N.E.</given-names></name>
<name><surname>Suan</surname><given-names>D.</given-names></name>
<name><surname>Cooper</surname><given-names>D.A.</given-names></name>
<name><surname>Brew</surname><given-names>B.J.</given-names></name>
<name><surname>Winston</surname><given-names>A.</given-names></name>
</person-group><article-title>Raltegravir resistance in the cerebrospinal fluid</article-title><source>Infection</source><year>2013</year><volume>41</volume><fpage>731</fpage><lpage>734</lpage><pub-id pub-id-type="doi">10.1007/s15010-013-0409-z</pub-id><pub-id pub-id-type="pmid">23378293</pub-id>
</element-citation></ref><ref id="B107-tropicalmed-10-00045"><label>107.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Dravid</surname><given-names>A.N.</given-names></name>
<name><surname>Gawali</surname><given-names>R.</given-names></name>
<name><surname>Betha</surname><given-names>T.P.</given-names></name>
<name><surname>Sharma</surname><given-names>A.K.</given-names></name>
<name><surname>Medisetty</surname><given-names>M.</given-names></name>
<name><surname>Natrajan</surname><given-names>K.</given-names></name>
<name><surname>Kulkarni</surname><given-names>M.M.</given-names></name>
<name><surname>Saraf</surname><given-names>C.K.</given-names></name>
<name><surname>Kore</surname><given-names>S.D.</given-names></name>
<name><surname>Rathod</surname><given-names>N.M.</given-names></name>
<etal/>
</person-group><article-title>Two treatment strategies for management of Neurosymptomatic cerebrospinal fluid HIV escape in Pune, India</article-title><source>Medicine</source><year>2020</year><volume>99</volume><fpage>e20516</fpage><pub-id pub-id-type="doi">10.1097/MD.0000000000020516</pub-id><pub-id pub-id-type="pmid">32541474</pub-id>
</element-citation></ref><ref id="B108-tropicalmed-10-00045"><label>108.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Nickoloff-Bybel</surname><given-names>E.A.</given-names></name>
<name><surname>Festa</surname><given-names>L.</given-names></name>
<name><surname>Meucci</surname><given-names>O.</given-names></name>
<name><surname>Gaskill</surname><given-names>P.J.</given-names></name>
</person-group><article-title>Co-receptor signaling in the pathogenesis of neuroHIV</article-title><source>Retrovirology</source><year>2021</year><volume>18</volume><fpage>24</fpage><pub-id pub-id-type="doi">10.1186/s12977-021-00569-x</pub-id><pub-id pub-id-type="pmid">34429135</pub-id>
</element-citation></ref><ref id="B109-tropicalmed-10-00045"><label>109.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Rao</surname><given-names>V.R.</given-names></name>
<name><surname>Ruiz</surname><given-names>A.P.</given-names></name>
<name><surname>Prasad</surname><given-names>V.R.</given-names></name>
</person-group><article-title>Viral and cellular factors underlying neuropathogenesis in HIV associated neurocognitive disorders (HAND)</article-title><source>AIDS Res. Ther.</source><year>2014</year><volume>11</volume><fpage>13</fpage><pub-id pub-id-type="doi">10.1186/1742-6405-11-13</pub-id><pub-id pub-id-type="pmid">24894206</pub-id>
</element-citation></ref><ref id="B110-tropicalmed-10-00045"><label>110.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Yilmaz</surname><given-names>A.</given-names></name>
<name><surname>Watson</surname><given-names>V.</given-names></name>
<name><surname>Else</surname><given-names>L.</given-names></name>
<name><surname>Gissl&#x000e8;n</surname><given-names>M.</given-names></name>
</person-group><article-title>Cerebrospinal fluid maraviroc concentrations in HIV-1 infected patients</article-title><source>AIDS</source><year>2009</year><volume>23</volume><fpage>2537</fpage><lpage>2540</lpage><pub-id pub-id-type="doi">10.1097/QAD.0b013e328333ae0e</pub-id><pub-id pub-id-type="pmid">19855252</pub-id>
</element-citation></ref><ref id="B111-tropicalmed-10-00045"><label>111.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Melica</surname><given-names>G.</given-names></name>
<name><surname>Canestri</surname><given-names>A.</given-names></name>
<name><surname>Peytavin</surname><given-names>G.</given-names></name>
<name><surname>Lelievre</surname><given-names>J.D.</given-names></name>
<name><surname>Bouvier-Alias</surname><given-names>M.</given-names></name>
<name><surname>Clavel</surname><given-names>C.</given-names></name>
<name><surname>Calvez</surname><given-names>V.</given-names></name>
<name><surname>Lascaux</surname><given-names>A.S.</given-names></name>
<name><surname>Katlama</surname><given-names>C.</given-names></name>
<name><surname>Levy</surname><given-names>Y.</given-names></name>
</person-group><article-title>Maraviroc-containing regimen suppresses HIV replication in the cerebrospinal fluid of patients with neurological symptoms</article-title><source>AIDS</source><year>2010</year><volume>24</volume><fpage>2130</fpage><lpage>2133</lpage><pub-id pub-id-type="doi">10.1097/QAD.0b013e32833c9353</pub-id><pub-id pub-id-type="pmid">20601852</pub-id>
</element-citation></ref><ref id="B112-tropicalmed-10-00045"><label>112.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Tiraboschi</surname><given-names>J.M.</given-names></name>
<name><surname>Niubo</surname><given-names>J.</given-names></name>
<name><surname>Curto</surname><given-names>J.</given-names></name>
<name><surname>Podzamczer</surname><given-names>D.</given-names></name>
</person-group><article-title>Maraviroc concentrations in cerebrospinal fluid in HIV-infected patients</article-title><source>J. Acquir. Immune Defic. Syndr.</source><year>2010</year><volume>55</volume><fpage>606</fpage><lpage>609</lpage><pub-id pub-id-type="doi">10.1097/QAI.0b013e3181ef70fe</pub-id><pub-id pub-id-type="pmid">20706127</pub-id>
</element-citation></ref><ref id="B113-tropicalmed-10-00045"><label>113.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Souli&#x000e9;</surname><given-names>C.</given-names></name>
<name><surname>Tubiana</surname><given-names>R.</given-names></name>
<name><surname>Simon</surname><given-names>A.</given-names></name>
<name><surname>Lambert-Niclot</surname><given-names>S.</given-names></name>
<name><surname>Malet</surname><given-names>I.</given-names></name>
<name><surname>Canestri</surname><given-names>A.</given-names></name>
<name><surname>Brunet</surname><given-names>C.</given-names></name>
<name><surname>Murphy</surname><given-names>R.</given-names></name>
<name><surname>Katlama</surname><given-names>C.</given-names></name>
<name><surname>Calvez</surname><given-names>V.</given-names></name>
<etal/>
</person-group><article-title>Presence of hiv-1 r5 viruses in cerebrospinal fluid even in patients harboring r5x4/x4 viruses in plasma</article-title><source>J. Acquir. Immune Defic. Syndr.</source><year>2009</year><volume>51</volume><fpage>60</fpage><lpage>64</lpage><pub-id pub-id-type="doi">10.1097/QAI.0b013e31819fb903</pub-id><pub-id pub-id-type="pmid">19390328</pub-id>
</element-citation></ref><ref id="B114-tropicalmed-10-00045"><label>114.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Spudich</surname><given-names>S.S.</given-names></name>
<name><surname>Huang</surname><given-names>W.</given-names></name>
<name><surname>Nilsson</surname><given-names>A.C.</given-names></name>
<name><surname>Petropoulos</surname><given-names>C.J.</given-names></name>
<name><surname>Liegler</surname><given-names>T.J.</given-names></name>
<name><surname>Whitcomb</surname><given-names>J.M.</given-names></name>
<name><surname>Price</surname><given-names>R.W.</given-names></name>
</person-group><article-title>HIV-1 chemokine coreceptor utilization in paired cerebrospinal fluid and plasma samples: A survey of subjects with viremia</article-title><source>J. Infect. Dis.</source><year>2005</year><volume>191</volume><fpage>890</fpage><lpage>898</lpage><pub-id pub-id-type="doi">10.1086/428095</pub-id><pub-id pub-id-type="pmid">15717264</pub-id>
</element-citation></ref><ref id="B115-tropicalmed-10-00045"><label>115.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kelly</surname><given-names>K.M.</given-names></name>
<name><surname>Beck</surname><given-names>S.E.</given-names></name>
<name><surname>Pate</surname><given-names>K.A.</given-names></name>
<name><surname>Queen</surname><given-names>S.E.</given-names></name>
<name><surname>Dorsey</surname><given-names>J.L.</given-names></name>
<name><surname>Adams</surname><given-names>R.J.</given-names></name>
<name><surname>Avery</surname><given-names>L.B.</given-names></name>
<name><surname>Hubbard</surname><given-names>W.</given-names></name>
<name><surname>Tarwater</surname><given-names>P.M.</given-names></name>
<name><surname>Mankowski</surname><given-names>J.L.</given-names></name>
</person-group><article-title>Neuroprotective maraviroc monotherapy in simian immunodeficiency virus-infected macaques: Reduced replicating and latent SIV in the brain</article-title><source>AIDS</source><year>2013</year><volume>27</volume><fpage>F21</fpage><lpage>F28</lpage><pub-id pub-id-type="doi">10.1097/QAD.0000000000000074</pub-id><pub-id pub-id-type="pmid">24051706</pub-id>
</element-citation></ref><ref id="B116-tropicalmed-10-00045"><label>116.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Gates</surname><given-names>T.M.</given-names></name>
<name><surname>Cysique</surname><given-names>L.A.</given-names></name>
<name><surname>Siefried</surname><given-names>K.J.</given-names></name>
<name><surname>Chaganti</surname><given-names>J.</given-names></name>
<name><surname>Moffat</surname><given-names>K.J.</given-names></name>
<name><surname>Brew</surname><given-names>B.J.</given-names></name>
</person-group><article-title>Maraviroc-intensified combined antiretroviral therapy improves cognition in virally suppressed HIV-associated neurocognitive disorder</article-title><source>AIDS</source><year>2016</year><volume>30</volume><fpage>591</fpage><lpage>600</lpage><pub-id pub-id-type="doi">10.1097/QAD.0000000000000951</pub-id><pub-id pub-id-type="pmid">26825032</pub-id>
</element-citation></ref><ref id="B117-tropicalmed-10-00045"><label>117.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ndhlovu</surname><given-names>L.C.</given-names></name>
<name><surname>Umaki</surname><given-names>T.</given-names></name>
<name><surname>Chew</surname><given-names>G.M.</given-names></name>
<name><surname>Chow</surname><given-names>D.C.</given-names></name>
<name><surname>Agsalda</surname><given-names>M.</given-names></name>
<name><surname>Kallianpur</surname><given-names>K.J.</given-names></name>
<name><surname>Paul</surname><given-names>R.</given-names></name>
<name><surname>Zhang</surname><given-names>G.</given-names></name>
<name><surname>Ho</surname><given-names>E.</given-names></name>
<name><surname>Hanks</surname><given-names>N.</given-names></name>
<etal/>
</person-group><article-title>Treatment intensification with maraviroc (CCR5 antagonist) leads to declines in CD16-expressing monocytes in cART-suppressed chronic HIV-infected subjects and is associated with improvements in neurocognitive test performance: Implications for HIV-associated neurocognitive disease (HAND)</article-title><source>J. Neurovirol.</source><year>2014</year><volume>20</volume><fpage>571</fpage><lpage>582</lpage><pub-id pub-id-type="pmid">25227930</pub-id>
</element-citation></ref><ref id="B118-tropicalmed-10-00045"><label>118.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Shikuma</surname><given-names>C.M.</given-names></name>
<name><surname>Wojna</surname><given-names>V.</given-names></name>
<name><surname>De Gruttola</surname><given-names>V.</given-names></name>
<name><surname>Siriwardhana</surname><given-names>C.</given-names></name>
<name><surname>Souza</surname><given-names>S.A.</given-names></name>
<name><surname>Rodriguez-Benitez</surname><given-names>R.J.</given-names></name>
<name><surname>Turner</surname><given-names>E.H.</given-names></name>
<name><surname>Kallianpur</surname><given-names>K.</given-names></name>
<name><surname>Bolzenius</surname><given-names>J.</given-names></name>
<name><surname>Chow</surname><given-names>D.</given-names></name>
<etal/>
</person-group><article-title>Impact of antiretroviral therapy intensification with C-C motif chemokine receptor 5 antagonist maraviroc on HIV-associated neurocognitive impairment</article-title><source>AIDS</source><year>2023</year><volume>37</volume><fpage>1987</fpage><lpage>1995</lpage><pub-id pub-id-type="doi">10.1097/QAD.0000000000003650</pub-id><pub-id pub-id-type="pmid">37418541</pub-id>
</element-citation></ref><ref id="B119-tropicalmed-10-00045"><label>119.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ndhlovu</surname><given-names>L.C.</given-names></name>
<name><surname>D&#x02019;Antoni</surname><given-names>M.L.</given-names></name>
<name><surname>Ananworanich</surname><given-names>J.</given-names></name>
<name><surname>Byron</surname><given-names>M.M.</given-names></name>
<name><surname>Chalermchai</surname><given-names>T.</given-names></name>
<name><surname>Sithinamsuwan</surname><given-names>P.</given-names></name>
<name><surname>Tipsuk</surname><given-names>S.</given-names></name>
<name><surname>Ho</surname><given-names>E.</given-names></name>
<name><surname>Slike</surname><given-names>B.M.</given-names></name>
<name><surname>Schuetz</surname><given-names>A.</given-names></name>
<etal/>
</person-group><article-title>Loss of CCR2 expressing non-classical monocytes are associated with cognitive impairment in antiretroviral therapy-na&#x000ef;ve HIV-infected Thais</article-title><source>J. Neuroimmunol.</source><year>2015</year><volume>288</volume><fpage>25</fpage><lpage>33</lpage><pub-id pub-id-type="doi">10.1016/j.jneuroim.2015.08.020</pub-id><pub-id pub-id-type="pmid">26531691</pub-id>
</element-citation></ref><ref id="B120-tropicalmed-10-00045"><label>120.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kamat</surname><given-names>A.</given-names></name>
<name><surname>Lyons</surname><given-names>J.L.</given-names></name>
<name><surname>Misra</surname><given-names>V.</given-names></name>
<name><surname>Uno</surname><given-names>H.</given-names></name>
<name><surname>Morgello</surname><given-names>S.</given-names></name>
<name><surname>Singer</surname><given-names>E.J.</given-names></name>
<name><surname>Gabuzda</surname><given-names>D.</given-names></name>
</person-group><article-title>Monocyte activation markers in cerebrospinal fluid associated with impaired neurocognitive testing in advanced HIV infection</article-title><source>J. Acquir. Immune Defic. Syndr.</source><year>2012</year><volume>60</volume><fpage>234</fpage><lpage>243</lpage><pub-id pub-id-type="doi">10.1097/QAI.0b013e318256f3bc</pub-id><pub-id pub-id-type="pmid">22569268</pub-id>
</element-citation></ref><ref id="B121-tropicalmed-10-00045"><label>121.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Williams</surname><given-names>D.</given-names></name>
<name><surname>Veenstra</surname><given-names>M.</given-names></name>
<name><surname>Gaskill</surname><given-names>P.</given-names></name>
<name><surname>Morgello</surname><given-names>S.</given-names></name>
<name><surname>Calderon</surname><given-names>T.</given-names></name>
<name><surname>Berman</surname><given-names>J.</given-names></name>
</person-group><article-title>Monocytes Mediate HIV Neuropathogenesis: Mechanisms that Contribute to HIV Associated Neurocognitive Disorders</article-title><source>Curr. HIV Res.</source><year>2014</year><volume>12</volume><fpage>85</fpage><lpage>96</lpage><pub-id pub-id-type="doi">10.2174/1570162X12666140526114526</pub-id><pub-id pub-id-type="pmid">24862333</pub-id>
</element-citation></ref><ref id="B122-tropicalmed-10-00045"><label>122.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Williams</surname><given-names>D.W.</given-names></name>
<name><surname>Calderon</surname><given-names>T.M.</given-names></name>
<name><surname>Lopez</surname><given-names>L.</given-names></name>
<name><surname>Carvallo-Torres</surname><given-names>L.</given-names></name>
<name><surname>Gaskill</surname><given-names>P.J.</given-names></name>
<name><surname>Eugenin</surname><given-names>E.A.</given-names></name>
<name><surname>Morgello</surname><given-names>S.</given-names></name>
<name><surname>Berman</surname><given-names>J.W.</given-names></name>
</person-group><article-title>Mechanisms of HIV Entry into the CNS: Increased Sensitivity of HIV Infected CD14+CD16+ Monocytes to CCL2 and Key Roles of CCR2, JAM-A, and ALCAM in Diapedesis</article-title><source>PLoS ONE</source><year>2013</year><volume>8</volume><elocation-id>e69270</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0069270</pub-id><pub-id pub-id-type="pmid">23922698</pub-id>
</element-citation></ref><ref id="B123-tropicalmed-10-00045"><label>123.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>D&#x02019;Antoni</surname><given-names>M.L.</given-names></name>
<name><surname>Paul</surname><given-names>R.H.</given-names></name>
<name><surname>Mitchell</surname><given-names>B.I.</given-names></name>
<name><surname>Kohorn</surname><given-names>L.</given-names></name>
<name><surname>Fischer</surname><given-names>L.</given-names></name>
<name><surname>Lefebvre</surname><given-names>E.</given-names></name>
<name><surname>Seyedkazemi</surname><given-names>S.</given-names></name>
<name><surname>Nakamoto</surname><given-names>B.K.</given-names></name>
<name><surname>Walker</surname><given-names>M.</given-names></name>
<name><surname>Kallianpur</surname><given-names>K.J.</given-names></name>
<etal/>
</person-group><article-title>Improved cognitive performance and reduced monocyte activation in virally suppressed chronic HIV after dual CCR2 and CCR5 antagonism</article-title><source>Am. J. Ther.</source><year>2018</year><volume>79</volume><fpage>108</fpage><lpage>116</lpage><pub-id pub-id-type="doi">10.1097/QAI.0000000000001752</pub-id><pub-id pub-id-type="pmid">29781885</pub-id>
</element-citation></ref><ref id="B124-tropicalmed-10-00045"><label>124.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Letendre</surname><given-names>S.L.</given-names></name>
<name><surname>Mills</surname><given-names>A.</given-names></name>
<name><surname>Hagins</surname><given-names>D.</given-names></name>
<name><surname>Swindells</surname><given-names>S.</given-names></name>
<name><surname>Felizarta</surname><given-names>F.</given-names></name>
<name><surname>Devente</surname><given-names>J.</given-names></name>
<name><surname>Bettacchi</surname><given-names>C.</given-names></name>
<name><surname>Lou</surname><given-names>Y.</given-names></name>
<name><surname>Ford</surname><given-names>S.</given-names></name>
<name><surname>Sutton</surname><given-names>K.</given-names></name>
<etal/>
</person-group><article-title>Pharmacokinetics and antiviral activity of cabotegravir and rilpivirine in cerebrospinal fluid following long-acting injectable administration in HIV-infected adults</article-title><source>J. Antimicrob. Chemother.</source><year>2020</year><volume>75</volume><fpage>648</fpage><lpage>655</lpage><pub-id pub-id-type="doi">10.1093/jac/dkz504</pub-id><pub-id pub-id-type="pmid">31873746</pub-id>
</element-citation></ref><ref id="B125-tropicalmed-10-00045"><label>125.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Gabuzda</surname><given-names>D.</given-names></name>
<name><surname>McArthur</surname><given-names>J.C.</given-names></name>
<name><surname>Letendre</surname><given-names>S.L.</given-names></name>
</person-group><article-title>Efficacy and Safety of Two-drug Regimens for Treatment of HIV in the Central Nervous System</article-title><source>AIDS</source><year>2020</year><volume>34</volume><fpage>1975</fpage><pub-id pub-id-type="doi">10.1097/QAD.0000000000002665</pub-id><pub-id pub-id-type="pmid">33009012</pub-id>
</element-citation></ref><ref id="B126-tropicalmed-10-00045"><label>126.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Gallicchio</surname><given-names>V.S.</given-names></name>
<name><surname>Cibul</surname><given-names>M.L.</given-names></name>
<name><surname>Hughes</surname><given-names>N.K.</given-names></name>
<name><surname>Tse</surname><given-names>K.F.</given-names></name>
</person-group><article-title>Effect of lithium in murine immunodeficiency virus infected animals</article-title><source>Pathobiology</source><year>1993</year><volume>61</volume><fpage>216</fpage><lpage>221</lpage><pub-id pub-id-type="doi">10.1159/000163797</pub-id><pub-id pub-id-type="pmid">8216844</pub-id>
</element-citation></ref><ref id="B127-tropicalmed-10-00045"><label>127.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Letendre</surname><given-names>S.L.</given-names></name>
<name><surname>Woods</surname><given-names>S.P.</given-names></name>
<name><surname>Ellis</surname><given-names>R.J.</given-names></name>
<name><surname>Atkinson</surname><given-names>J.H.</given-names></name>
<name><surname>Masliah</surname><given-names>E.</given-names></name>
<name><surname>Brande</surname><given-names>G.v.D.</given-names></name>
<name><surname>Durelle</surname><given-names>J.</given-names></name>
<name><surname>Grant</surname><given-names>I.</given-names></name>
<name><surname>Everall</surname><given-names>I.</given-names></name>
</person-group><article-title>Lithium improves HIV-associated neurocognitive impairment</article-title><source>AIDS</source><year>2006</year><volume>20</volume><fpage>1885</fpage><lpage>1888</lpage><pub-id pub-id-type="doi">10.1097/01.aids.0000244208.49123.1b</pub-id><pub-id pub-id-type="pmid">16954730</pub-id>
</element-citation></ref><ref id="B128-tropicalmed-10-00045"><label>128.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Decloedt</surname><given-names>E.H.</given-names></name>
<name><surname>Freeman</surname><given-names>C.</given-names></name>
<name><surname>Howells</surname><given-names>F.</given-names></name>
<name><surname>Casson-Crook</surname><given-names>M.</given-names></name>
<name><surname>Lesosky</surname><given-names>M.</given-names></name>
<name><surname>Koutsilieri</surname><given-names>E.</given-names></name>
<name><surname>Lovestone</surname><given-names>S.</given-names></name>
<name><surname>Maartens</surname><given-names>G.</given-names></name>
<name><surname>Joska</surname><given-names>J.A.</given-names></name>
</person-group><article-title>Moderate to severe HIV-associated neurocognitive impairment A randomized placebo-controlled trial of lithium</article-title><source>Medicine</source><year>2016</year><volume>95</volume><fpage>e5401</fpage><pub-id pub-id-type="doi">10.1097/MD.0000000000005401</pub-id><pub-id pub-id-type="pmid">27861379</pub-id>
</element-citation></ref><ref id="B129-tropicalmed-10-00045"><label>129.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Thela</surname><given-names>L.</given-names></name>
<name><surname>Decloedt</surname><given-names>E.</given-names></name>
<name><surname>Zetterberg</surname><given-names>H.</given-names></name>
<name><surname>Gissl&#x000e9;n</surname><given-names>M.</given-names></name>
<name><surname>Lesosky</surname><given-names>M.</given-names></name>
<name><surname>Gleich</surname><given-names>M.</given-names></name>
<name><surname>Koutsilieri</surname><given-names>E.</given-names></name>
<name><surname>Scheller</surname><given-names>C.</given-names></name>
<name><surname>Hye</surname><given-names>A.</given-names></name>
<name><surname>Joska</surname><given-names>J.</given-names></name>
</person-group><article-title>Blood and cerebrospinal fluid biomarker changes in patients with HIV-associated neurocognitive impairment treated with lithium: Analysis from a randomised placebo-controlled trial</article-title><source>J. Neurovirol.</source><year>2023</year><volume>29</volume><fpage>156</fpage><lpage>166</lpage><pub-id pub-id-type="doi">10.1007/s13365-023-01116-4</pub-id><pub-id pub-id-type="pmid">36790601</pub-id>
</element-citation></ref><ref id="B130-tropicalmed-10-00045"><label>130.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Schifitto</surname><given-names>G.</given-names></name>
<name><surname>Zhong</surname><given-names>J.</given-names></name>
<name><surname>Gill</surname><given-names>D.</given-names></name>
<name><surname>Peterson</surname><given-names>D.R.</given-names></name>
<name><surname>Gaugh</surname><given-names>M.D.</given-names></name>
<name><surname>Zhu</surname><given-names>T.</given-names></name>
<name><surname>Tivarus</surname><given-names>M.</given-names></name>
<name><surname>Cruttenden</surname><given-names>K.</given-names></name>
<name><surname>Maggirwar</surname><given-names>S.B.</given-names></name>
<name><surname>E Gendelman</surname><given-names>H.</given-names></name>
<etal/>
</person-group><article-title>Lithium therapy for human immunodeficiency virus type 1-associated neurocognitive impairment</article-title><source>J. Neurovirol.</source><year>2009</year><volume>15</volume><fpage>176</fpage><lpage>186</lpage><pub-id pub-id-type="doi">10.1080/13550280902758973</pub-id><pub-id pub-id-type="pmid">19306230</pub-id>
</element-citation></ref><ref id="B131-tropicalmed-10-00045"><label>131.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Masvekar</surname><given-names>R.R.</given-names></name>
<name><surname>El-Hage</surname><given-names>N.</given-names></name>
<name><surname>Hauser</surname><given-names>K.F.</given-names></name>
<name><surname>Knapp</surname><given-names>P.E.</given-names></name>
</person-group><article-title>GSK3&#x003b2;-activation is a point of convergence for HIV-1 and opiate-mediated interactive neurotoxicity</article-title><source>Mol. Cell. Neurosci.</source><year>2015</year><volume>65</volume><fpage>11</fpage><lpage>20</lpage><pub-id pub-id-type="doi">10.1016/j.mcn.2015.01.001</pub-id><pub-id pub-id-type="pmid">25616162</pub-id>
</element-citation></ref><ref id="B132-tropicalmed-10-00045"><label>132.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lehrman</surname><given-names>G.</given-names></name>
<name><surname>Hogue</surname><given-names>I.B.</given-names></name>
<name><surname>Palmer</surname><given-names>S.</given-names></name>
<name><surname>Jennings</surname><given-names>C.</given-names></name>
<name><surname>Spina</surname><given-names>C.A.</given-names></name>
<name><surname>Wiegand</surname><given-names>A.</given-names></name>
<name><surname>Landay</surname><given-names>A.L.</given-names></name>
<name><surname>Coombs</surname><given-names>R.W.</given-names></name>
<name><surname>Richman</surname><given-names>D.D.</given-names></name>
<name><surname>Mellors</surname><given-names>J.W.</given-names></name>
</person-group><article-title>Depletion of latent HIV-1 infection in vivo: A proof-of-concept study</article-title><source>Lancet</source><year>2005</year><volume>366</volume><fpage>549</fpage><lpage>555</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(05)67098-5</pub-id><pub-id pub-id-type="pmid">16099290</pub-id>
</element-citation></ref><ref id="B133-tropicalmed-10-00045"><label>133.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Archin</surname><given-names>N.M.</given-names></name>
<name><surname>Cheema</surname><given-names>M.</given-names></name>
<name><surname>Parker</surname><given-names>D.</given-names></name>
<name><surname>Wiegand</surname><given-names>A.</given-names></name>
<name><surname>Bosch</surname><given-names>R.J.</given-names></name>
<name><surname>Coffin</surname><given-names>J.M.</given-names></name>
<name><surname>Eron</surname><given-names>J.</given-names></name>
<name><surname>Cohen</surname><given-names>M.</given-names></name>
<name><surname>Margolis</surname><given-names>D.M.</given-names></name>
</person-group><article-title>Antiretroviral intensification and valproic acid lack sustained effect on residual HIV-1 viremia or resting CD4+ cell infection</article-title><source>PLoS ONE</source><year>2010</year><volume>5</volume><elocation-id>e9390</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0009390</pub-id><pub-id pub-id-type="pmid">20186346</pub-id>
</element-citation></ref><ref id="B134-tropicalmed-10-00045"><label>134.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Routy</surname><given-names>J.P.</given-names></name>
<name><surname>Tremblay</surname><given-names>C.L.</given-names></name>
<name><surname>Angel</surname><given-names>J.B.</given-names></name>
<name><surname>Trottier</surname><given-names>B.</given-names></name>
<name><surname>Rouleau</surname><given-names>D.</given-names></name>
<name><surname>Baril</surname><given-names>J.G.</given-names></name>
<name><surname>Harris</surname><given-names>M.</given-names></name>
<name><surname>Trottier</surname><given-names>S.</given-names></name>
<name><surname>Singer</surname><given-names>J.</given-names></name>
<name><surname>Chomont</surname><given-names>N.</given-names></name>
<etal/>
</person-group><article-title>Valproic acid in association with highly active antiretroviral therapy for reducing systemic HIV-1 reservoirs: Results from a multicentre randomized clinical study</article-title><source>HIV Med.</source><year>2012</year><volume>13</volume><fpage>291</fpage><lpage>296</lpage><pub-id pub-id-type="doi">10.1111/j.1468-1293.2011.00975.x</pub-id><pub-id pub-id-type="pmid">22276680</pub-id>
</element-citation></ref><ref id="B135-tropicalmed-10-00045"><label>135.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Schifitto</surname><given-names>G.</given-names></name>
<name><surname>Peterson</surname><given-names>D.R.</given-names></name>
<name><surname>Zhong</surname><given-names>J.</given-names></name>
<name><surname>Ni</surname><given-names>H.</given-names></name>
<name><surname>Cruttenden</surname><given-names>K.</given-names></name>
<name><surname>Gaugh</surname><given-names>M.</given-names></name>
<name><surname>Gendelman</surname><given-names>H.E.</given-names></name>
<name><surname>Boska</surname><given-names>M.</given-names></name>
<name><surname>Gelbard</surname><given-names>H.</given-names></name>
</person-group><article-title>Valproic acid adjunctive therapy for HIV-associated cognitive impairment: A first report</article-title><source>Neurology</source><year>2006</year><volume>66</volume><fpage>919</fpage><lpage>921</lpage><pub-id pub-id-type="doi">10.1212/01.wnl.0000204294.28189.03</pub-id><pub-id pub-id-type="pmid">16510768</pub-id>
</element-citation></ref><ref id="B136-tropicalmed-10-00045"><label>136.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Cysique</surname><given-names>L.A.</given-names></name>
<name><surname>Maruff</surname><given-names>P.</given-names></name>
<name><surname>Brew</surname><given-names>B.J.</given-names></name>
</person-group><article-title>Valproic acid is associated with cognitive decline in HIV-infected individuals: A clinical observational study</article-title><source>BMC Neurol.</source><year>2006</year><volume>6</volume><elocation-id>42</elocation-id><pub-id pub-id-type="doi">10.1186/1471-2377-6-42</pub-id><pub-id pub-id-type="pmid">17150108</pub-id>
</element-citation></ref><ref id="B137-tropicalmed-10-00045"><label>137.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ances</surname><given-names>B.M.</given-names></name>
<name><surname>Letendre</surname><given-names>S.</given-names></name>
<name><surname>Buzzell</surname><given-names>M.</given-names></name>
<name><surname>Marquie-Beck</surname><given-names>J.</given-names></name>
<name><surname>Lazaretto</surname><given-names>D.</given-names></name>
<name><surname>Marcotte</surname><given-names>T.D.</given-names></name>
<name><surname>Grant</surname><given-names>I.</given-names></name>
<name><surname>Ellis</surname><given-names>R.J.</given-names></name>
<collab>the HNRC Group</collab>
</person-group><article-title>Valproic acid does not affect markers of human immunodeficiency virus disease progression</article-title><source>J. Neurovirol.</source><year>2006</year><volume>12</volume><fpage>403</fpage><lpage>406</lpage><pub-id pub-id-type="doi">10.1080/13550280600981695</pub-id><pub-id pub-id-type="pmid">17065134</pub-id>
</element-citation></ref><ref id="B138-tropicalmed-10-00045"><label>138.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>del Real</surname><given-names>G.</given-names></name>
<name><surname>Jim&#x000e9;nez-Baranda</surname><given-names>S.</given-names></name>
<name><surname>Mira</surname><given-names>E.</given-names></name>
<name><surname>Lacalle</surname><given-names>R.A.</given-names></name>
<name><surname>Lucas</surname><given-names>P.</given-names></name>
<name><surname>G&#x000f3;mez-Mout&#x000f3;n</surname><given-names>C.</given-names></name>
<name><surname>Alegret</surname><given-names>M.</given-names></name>
<name><surname>Pe&#x000f1;a</surname><given-names>J.M.</given-names></name>
<name><surname>Rodri&#x000ed;guez-Zapata</surname><given-names>M.</given-names></name>
<name><surname>Alvarez-Mon</surname><given-names>M.</given-names></name>
<etal/>
</person-group><article-title>Statins inhibit HIV-1 infection by down-regulating Rho activity</article-title><source>J. Exp. Med.</source><year>2004</year><volume>200</volume><fpage>541</fpage><lpage>547</lpage><pub-id pub-id-type="doi">10.1084/jem.20040061</pub-id><pub-id pub-id-type="pmid">15314078</pub-id>
</element-citation></ref><ref id="B139-tropicalmed-10-00045"><label>139.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hillyard</surname><given-names>D.Z.</given-names></name>
<name><surname>Nutt</surname><given-names>C.D.</given-names></name>
<name><surname>Thomson</surname><given-names>J.</given-names></name>
<name><surname>McDonald</surname><given-names>K.J.</given-names></name>
<name><surname>Wan</surname><given-names>R.K.</given-names></name>
<name><surname>Cameron</surname><given-names>A.J.</given-names></name>
<name><surname>Mark</surname><given-names>P.B.</given-names></name>
<name><surname>Jardine</surname><given-names>A.G.</given-names></name>
</person-group><article-title>Statins inhibit NK cell cytotoxicity by membrane raft depletion rather than inhibition of isoprenylation</article-title><source>Atherosclerosis</source><year>2007</year><volume>191</volume><fpage>319</fpage><lpage>325</lpage><pub-id pub-id-type="doi">10.1016/j.atherosclerosis.2006.05.037</pub-id><pub-id pub-id-type="pmid">16814295</pub-id>
</element-citation></ref><ref id="B140-tropicalmed-10-00045"><label>140.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Goebel</surname><given-names>J.</given-names></name>
<name><surname>Logan</surname><given-names>B.</given-names></name>
<name><surname>Forrest</surname><given-names>K.</given-names></name>
<name><surname>Mieczkowski</surname><given-names>A.</given-names></name>
<name><surname>Roszman</surname><given-names>T.L.</given-names></name>
<name><surname>Wills-Karp</surname><given-names>M.</given-names></name>
</person-group><article-title>Atorvastatin affects interleukin-2 signaling by altering the lipid raft enrichment of the interleukin-2 receptor &#x003b2; chain</article-title><source>J. Investig. Med.</source><year>2005</year><volume>53</volume><fpage>322</fpage><lpage>328</lpage><pub-id pub-id-type="doi">10.2310/6650.2005.53610</pub-id></element-citation></ref><ref id="B141-tropicalmed-10-00045"><label>141.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Popik</surname><given-names>W.</given-names></name>
<name><surname>Alce</surname><given-names>T.M.</given-names></name>
<name><surname>Au</surname><given-names>W.C.</given-names></name>
</person-group><article-title>Human Immunodeficiency Virus Type 1 Uses Lipid Raft-Colocalized CD4 and Chemokine Receptors for Productive Entry into CD4 + T Cells</article-title><source>J. Virol.</source><year>2002</year><volume>76</volume><fpage>4709</fpage><lpage>4722</lpage><pub-id pub-id-type="doi">10.1128/JVI.76.10.4709-4722.2002</pub-id><pub-id pub-id-type="pmid">11967288</pub-id>
</element-citation></ref><ref id="B142-tropicalmed-10-00045"><label>142.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Letendre</surname><given-names>S.L.</given-names></name>
<name><surname>Marquie-Beck</surname><given-names>J.</given-names></name>
<name><surname>Ellis</surname><given-names>R.J.</given-names></name>
<name><surname>Woods</surname><given-names>S.P.</given-names></name>
<name><surname>Best</surname><given-names>B.</given-names></name>
<name><surname>Clifford</surname><given-names>D.B.</given-names></name>
<name><surname>Collier</surname><given-names>A.C.</given-names></name>
<name><surname>Gelman</surname><given-names>B.B.</given-names></name>
<name><surname>Marra</surname><given-names>C.</given-names></name>
<name><surname>McArthur</surname><given-names>J.C.</given-names></name>
<etal/>
</person-group><article-title>The role of cohort studies in drug development: Clinical evidence of antiviral activity of serotonin reuptake inhibitors and HMG-CoA reductase inhibitors in the central nervous system</article-title><source>J. Neuroimmune Pharmacol.</source><year>2007</year><volume>2</volume><fpage>120</fpage><lpage>127</lpage><pub-id pub-id-type="doi">10.1007/s11481-006-9054-y</pub-id><pub-id pub-id-type="pmid">18040835</pub-id>
</element-citation></ref><ref id="B143-tropicalmed-10-00045"><label>143.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kristiansen</surname><given-names>J.E.</given-names></name>
<name><surname>Hansen</surname><given-names>J.B.</given-names></name>
</person-group><article-title>Inhibition of HIV replication by neuroleptic agents and their potential use in HIV infected patients with AIDS related dementia</article-title><source>Int. J. Antimicrob. Agents</source><year>2000</year><volume>14</volume><fpage>209</fpage><lpage>213</lpage><pub-id pub-id-type="doi">10.1016/S0924-8579(99)00157-0</pub-id><pub-id pub-id-type="pmid">10773489</pub-id>
</element-citation></ref><ref id="B144-tropicalmed-10-00045"><label>144.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Si</surname><given-names>Q.</given-names></name>
<name><surname>A Cosenza</surname><given-names>M.</given-names></name>
<name><surname>Kim</surname><given-names>M.-O.</given-names></name>
<name><surname>Zhao</surname><given-names>M.-L.</given-names></name>
<name><surname>Brownlee</surname><given-names>M.</given-names></name>
<name><surname>Goldstein</surname><given-names>H.</given-names></name>
<name><surname>Lee</surname><given-names>S.C.</given-names></name>
</person-group><article-title>A novel action of minocycline: Inhibition of human immunodeficiency virus type 1 infection in microglia</article-title><source>J. NeuroVirology</source><year>2004</year><volume>10</volume><fpage>284</fpage><lpage>292</lpage><pub-id pub-id-type="doi">10.1080/13550280490499533</pub-id><pub-id pub-id-type="pmid">15385251</pub-id>
</element-citation></ref><ref id="B145-tropicalmed-10-00045"><label>145.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ratai</surname><given-names>E.-M.</given-names></name>
<name><surname>Bombardier</surname><given-names>J.P.</given-names></name>
<name><surname>Joo</surname><given-names>C.-G.</given-names></name>
<name><surname>Annamalai</surname><given-names>L.</given-names></name>
<name><surname>Burdo</surname><given-names>T.H.</given-names></name>
<name><surname>Campbell</surname><given-names>J.</given-names></name>
<name><surname>Fell</surname><given-names>R.</given-names></name>
<name><surname>Hakimelahi</surname><given-names>R.</given-names></name>
<name><surname>He</surname><given-names>J.</given-names></name>
<name><surname>Autissier</surname><given-names>P.</given-names></name>
<etal/>
</person-group><article-title>Proton magnetic resonance spectroscopy reveals neuroprotection by oral minocycline in a nonhuman primate model of accelerated NeuroAIDS</article-title><source>PLoS ONE</source><year>2010</year><volume>5</volume><elocation-id>e10523</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0010523</pub-id><pub-id pub-id-type="pmid">20479889</pub-id>
</element-citation></ref><ref id="B146-tropicalmed-10-00045"><label>146.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Clements</surname><given-names>J.</given-names></name>
<name><surname>Mankowski</surname><given-names>J.</given-names></name>
<name><surname>Gama</surname><given-names>L.</given-names></name>
<name><surname>Zink</surname><given-names>M.C.</given-names></name>
</person-group><article-title>The accelerated simian immunodeficiency virus macaque model of human immunodeficiency virus-associated neurological disease: From mechanism to treatment</article-title><source>J. NeuroVirology</source><year>2008</year><volume>14</volume><fpage>309</fpage><lpage>317</lpage><pub-id pub-id-type="doi">10.1080/13550280802132832</pub-id><pub-id pub-id-type="pmid">18780232</pub-id>
</element-citation></ref><ref id="B147-tropicalmed-10-00045"><label>147.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Follstaedt</surname><given-names>S.C.</given-names></name>
<name><surname>Barber</surname><given-names>S.A.</given-names></name>
<name><surname>Zink</surname><given-names>M.C.</given-names></name>
</person-group><article-title>Mechanisms of minocycline-induced suppression of simian immunodeficiency virus encephalitis: Inhibition of apoptosis signal-regulating kinase 1</article-title><source>J. NeuroVirology</source><year>2008</year><volume>14</volume><fpage>376</fpage><lpage>388</lpage><pub-id pub-id-type="doi">10.1080/13550280802199898</pub-id><pub-id pub-id-type="pmid">19003592</pub-id>
</element-citation></ref><ref id="B148-tropicalmed-10-00045"><label>148.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Szeto</surname><given-names>G.L.</given-names></name>
<name><surname>Brice</surname><given-names>A.</given-names></name>
<name><surname>Yang</surname><given-names>H.C.</given-names></name>
<name><surname>Barber</surname><given-names>S.A.</given-names></name>
<name><surname>Siliciano</surname><given-names>R.F.</given-names></name>
<name><surname>Clements</surname><given-names>J.E.</given-names></name>
</person-group><article-title>Minocycline attenuates HIV infection and reactivation by suppressing cellular activation in human CD4+ T cells</article-title><source>J. Infect. Dis.</source><year>2010</year><volume>201</volume><fpage>1132</fpage><lpage>1140</lpage><pub-id pub-id-type="doi">10.1086/651277</pub-id><pub-id pub-id-type="pmid">20205570</pub-id>
</element-citation></ref><ref id="B149-tropicalmed-10-00045"><label>149.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ho</surname><given-names>E.L.</given-names></name>
<name><surname>Spudich</surname><given-names>S.S.</given-names></name>
<name><surname>Lee</surname><given-names>E.</given-names></name>
<name><surname>Fuchs</surname><given-names>D.</given-names></name>
<name><surname>Sinclair</surname><given-names>E.</given-names></name>
<name><surname>Price</surname><given-names>R.W.</given-names></name>
</person-group><article-title>Minocycline fails to modulate cerebrospinal fluid HIV infection or immune activation in chronic untreated HIV-1 infection: Results of a pilot study</article-title><source>AIDS Res. Ther.</source><year>2011</year><volume>8</volume><fpage>17</fpage><pub-id pub-id-type="doi">10.1186/1742-6405-8-17</pub-id><pub-id pub-id-type="pmid">21569420</pub-id>
</element-citation></ref><ref id="B150-tropicalmed-10-00045"><label>150.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Marconi</surname><given-names>V.C.</given-names></name>
<name><surname>Moser</surname><given-names>C.</given-names></name>
<name><surname>Gavegnano</surname><given-names>C.</given-names></name>
<name><surname>Deeks</surname><given-names>S.G.</given-names></name>
<name><surname>Lederman</surname><given-names>M.M.</given-names></name>
<name><surname>Overton</surname><given-names>E.T.</given-names></name>
<name><surname>Tsibris</surname><given-names>A.</given-names></name>
<name><surname>Hunt</surname><given-names>P.W.</given-names></name>
<name><surname>Kantor</surname><given-names>A.</given-names></name>
<name><surname>Sekaly</surname><given-names>R.-P.</given-names></name>
<etal/>
</person-group><article-title>Randomized Trial of Ruxolitinib in Antiretroviral-Treated Adults with Human Immunodeficiency Virus</article-title><source>Clin. Infect. Dis.</source><year>2022</year><volume>74</volume><fpage>95</fpage><lpage>104</lpage><pub-id pub-id-type="doi">10.1093/cid/ciab212</pub-id><pub-id pub-id-type="pmid">33693561</pub-id>
</element-citation></ref><ref id="B151-tropicalmed-10-00045"><label>151.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>De Armas</surname><given-names>L.R.</given-names></name>
<name><surname>Gavegnano</surname><given-names>C.</given-names></name>
<name><surname>Pallikkuth</surname><given-names>S.</given-names></name>
<name><surname>Rinaldi</surname><given-names>S.</given-names></name>
<name><surname>Pan</surname><given-names>L.</given-names></name>
<name><surname>Battivelli</surname><given-names>E.</given-names></name>
<name><surname>Verdin</surname><given-names>E.</given-names></name>
<name><surname>Younis</surname><given-names>R.T.</given-names></name>
<name><surname>Pahwa</surname><given-names>R.</given-names></name>
<name><surname>Williams</surname><given-names>S.L.</given-names></name>
<etal/>
</person-group><article-title>The Effect of JAK1/2 Inhibitors on HIV Reservoir Using Primary Lymphoid Cell Model of HIV Latency</article-title><source>Front. Immunol.</source><year>2021</year><volume>12</volume><elocation-id>720697</elocation-id><pub-id pub-id-type="doi">10.3389/fimmu.2021.720697</pub-id><pub-id pub-id-type="pmid">34531866</pub-id>
</element-citation></ref><ref id="B152-tropicalmed-10-00045"><label>152.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Gavegnano</surname><given-names>C.</given-names></name>
<name><surname>Haile</surname><given-names>W.B.</given-names></name>
<name><surname>Hurwitz</surname><given-names>S.</given-names></name>
<name><surname>Tao</surname><given-names>S.</given-names></name>
<name><surname>Jiang</surname><given-names>Y.</given-names></name>
<name><surname>Schinazi</surname><given-names>R.F.</given-names></name>
<name><surname>Tyor</surname><given-names>W.R.</given-names></name>
</person-group><article-title>Baricitinib reverses HIV-associated neurocognitive disorders in a SCID mouse model and reservoir seeding in vitro</article-title><source>J. Neuroinflammation</source><year>2019</year><volume>16</volume><fpage>182</fpage><pub-id pub-id-type="doi">10.1186/s12974-019-1565-6</pub-id><pub-id pub-id-type="pmid">31561750</pub-id>
</element-citation></ref><ref id="B153-tropicalmed-10-00045"><label>153.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bertrand</surname><given-names>L.</given-names></name>
<name><surname>Velichkovska</surname><given-names>M.</given-names></name>
<name><surname>Toborek</surname><given-names>M.</given-names></name>
</person-group><article-title>Cerebral Vascular Toxicity of Antiretroviral Therapy</article-title><source>J. Neuroimmune Pharmacol.</source><year>2019</year><volume>16</volume><fpage>74</fpage><lpage>89</lpage><pub-id pub-id-type="doi">10.1007/s11481-019-09858-x</pub-id><pub-id pub-id-type="pmid">31209776</pub-id>
</element-citation></ref><ref id="B154-tropicalmed-10-00045"><label>154.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Velichkovska</surname><given-names>M.</given-names></name>
<name><surname>Surnar</surname><given-names>B.</given-names></name>
<name><surname>Nair</surname><given-names>M.</given-names></name>
<name><surname>Dhar</surname><given-names>S.</given-names></name>
<name><surname>Toborek</surname><given-names>M.</given-names></name>
</person-group><article-title>Targeted Mitochondrial COQ 10 Delivery Attenuates Antiretroviral-Drug-Induced Senescence of Neural Progenitor Cells</article-title><source>Mol. Pharm.</source><year>2019</year><volume>16</volume><fpage>724</fpage><lpage>736</lpage><pub-id pub-id-type="doi">10.1021/acs.molpharmaceut.8b01014</pub-id><pub-id pub-id-type="pmid">30592424</pub-id>
</element-citation></ref><ref id="B155-tropicalmed-10-00045"><label>155.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Apostolova</surname><given-names>N.</given-names></name>
<name><surname>Funes</surname><given-names>H.A.</given-names></name>
<name><surname>Blas-Garcia</surname><given-names>A.</given-names></name>
<name><surname>Galindo</surname><given-names>M.J.</given-names></name>
<name><surname>Alvarez</surname><given-names>A.</given-names></name>
<name><surname>Esplugues</surname><given-names>J.V.</given-names></name>
</person-group><article-title>Efavirenz and the CNS: What we already know and questions that need to be answered</article-title><source>J. Antimicrob. Chemother.</source><year>2015</year><volume>70</volume><fpage>2693</fpage><lpage>2708</lpage><pub-id pub-id-type="doi">10.1093/jac/dkv183</pub-id><pub-id pub-id-type="pmid">26203180</pub-id>
</element-citation></ref><ref id="B156-tropicalmed-10-00045"><label>156.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ros&#x000e1;s-Umbert</surname><given-names>M.</given-names></name>
<name><surname>Mothe</surname><given-names>B.</given-names></name>
<name><surname>Noguera-Julian</surname><given-names>M.</given-names></name>
<name><surname>Bellido</surname><given-names>R.</given-names></name>
<name><surname>Puertas</surname><given-names>M.C.</given-names></name>
<name><surname>Carrillo</surname><given-names>J.</given-names></name>
<name><surname>Rodriguez</surname><given-names>C.</given-names></name>
<name><surname>Perez-Alvarez</surname><given-names>N.</given-names></name>
<name><surname>Cobars&#x000ed;</surname><given-names>P.</given-names></name>
<name><surname>Gomez</surname><given-names>C.E.</given-names></name>
<etal/>
</person-group><article-title>Virological and immunological outcome of treatment interruption in HIV-1-infected subjects vaccinated with MVA-B</article-title><source>PLoS ONE</source><year>2017</year><volume>12</volume><elocation-id>e0184929</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0184929</pub-id><pub-id pub-id-type="pmid">28953921</pub-id>
</element-citation></ref><ref id="B157-tropicalmed-10-00045"><label>157.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Salantes</surname><given-names>D.B.</given-names></name>
<name><surname>Zheng</surname><given-names>Y.</given-names></name>
<name><surname>Mampe</surname><given-names>F.</given-names></name>
<name><surname>Srivastava</surname><given-names>T.</given-names></name>
<name><surname>Beg</surname><given-names>S.</given-names></name>
<name><surname>Lai</surname><given-names>J.</given-names></name>
<name><surname>Li</surname><given-names>J.Z.</given-names></name>
<name><surname>Tressler</surname><given-names>R.L.</given-names></name>
<name><surname>Koup</surname><given-names>R.A.</given-names></name>
<name><surname>Hoxie</surname><given-names>J.</given-names></name>
<etal/>
</person-group><article-title>HIV-1 latent reservoir size and diversity are stable following brief treatment interruption</article-title><source>J. Clin. Investig.</source><year>2018</year><volume>128</volume><fpage>3102</fpage><lpage>3115</lpage><pub-id pub-id-type="doi">10.1172/JCI120194</pub-id><pub-id pub-id-type="pmid">29911997</pub-id>
</element-citation></ref><ref id="B158-tropicalmed-10-00045"><label>158.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Osborne</surname><given-names>O.</given-names></name>
<name><surname>Peyravian</surname><given-names>N.</given-names></name>
<name><surname>Nair</surname><given-names>M.</given-names></name>
<name><surname>Daunert</surname><given-names>S.</given-names></name>
<name><surname>Toborek</surname><given-names>M.</given-names></name>
</person-group><article-title>The Paradox of HIV Blood&#x02013;Brain Barrier Penetrance and Antiretroviral Drug Delivery Deficiencies</article-title><source>Trends Neurosci.</source><year>2020</year><volume>43</volume><fpage>695</fpage><lpage>708</lpage><pub-id pub-id-type="doi">10.1016/j.tins.2020.06.007</pub-id><pub-id pub-id-type="pmid">32682564</pub-id>
</element-citation></ref><ref id="B159-tropicalmed-10-00045"><label>159.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Nair</surname><given-names>M.</given-names></name>
<name><surname>Jayant</surname><given-names>R.D.</given-names></name>
<name><surname>Kaushik</surname><given-names>A.</given-names></name>
<name><surname>Sagar</surname><given-names>V.</given-names></name>
</person-group><article-title>Getting into the brain: Potential of nanotechnology in the management of NeuroAIDS</article-title><source>Adv. Drug Deliv. Rev.</source><year>2016</year><volume>103</volume><fpage>202</fpage><lpage>217</lpage><pub-id pub-id-type="doi">10.1016/j.addr.2016.02.008</pub-id><pub-id pub-id-type="pmid">26944096</pub-id>
</element-citation></ref><ref id="B160-tropicalmed-10-00045"><label>160.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Garrido</surname><given-names>C.</given-names></name>
<name><surname>A Simpson</surname><given-names>C.</given-names></name>
<name><surname>Dahl</surname><given-names>N.P.</given-names></name>
<name><surname>Bresee</surname><given-names>J.</given-names></name>
<name><surname>Whitehead</surname><given-names>D.C.</given-names></name>
<name><surname>A Lindsey</surname><given-names>E.</given-names></name>
<name><surname>Harris</surname><given-names>T.L.</given-names></name>
<name><surname>A Smith</surname><given-names>C.</given-names></name>
<name><surname>Carter</surname><given-names>C.J.</given-names></name>
<name><surname>Feldheim</surname><given-names>D.L.</given-names></name>
<etal/>
</person-group><article-title>Gold nanoparticles to improve HIV drug delivery</article-title><source>Future Med. Chem.</source><year>2015</year><volume>7</volume><fpage>1097</fpage><lpage>1107</lpage><pub-id pub-id-type="doi">10.4155/fmc.15.57</pub-id><pub-id pub-id-type="pmid">26132521</pub-id>
</element-citation></ref><ref id="B161-tropicalmed-10-00045"><label>161.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wan</surname><given-names>L.</given-names></name>
<name><surname>Pooyan</surname><given-names>S.</given-names></name>
<name><surname>Hu</surname><given-names>P.</given-names></name>
<name><surname>Leibowitz</surname><given-names>M.J.</given-names></name>
<name><surname>Stein</surname><given-names>S.</given-names></name>
<name><surname>Sinko</surname><given-names>P.J.</given-names></name>
</person-group><article-title>Peritoneal macrophage uptake, pharmacokinetics and biodistribution of macrophage-targeted PEG-fMLF (N-formyl-methionyl-leucyl-phenylalanine) nanocarriers for improving HIV drug delivery</article-title><source>Pharm. Res.</source><year>2007</year><volume>24</volume><fpage>2110</fpage><lpage>2119</lpage><pub-id pub-id-type="doi">10.1007/s11095-007-9402-5</pub-id><pub-id pub-id-type="pmid">17701325</pub-id>
</element-citation></ref><ref id="B162-tropicalmed-10-00045"><label>162.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Gong</surname><given-names>Y.</given-names></name>
<name><surname>Chowdhury</surname><given-names>P.</given-names></name>
<name><surname>Nagesh</surname><given-names>P.K.B.</given-names></name>
<name><surname>Rahman</surname><given-names>M.A.</given-names></name>
<name><surname>Zhi</surname><given-names>K.</given-names></name>
<name><surname>Yallapu</surname><given-names>M.M.</given-names></name>
<name><surname>Kumar</surname><given-names>S.</given-names></name>
</person-group><article-title>Novel elvitegravir nanoformulation for drug delivery across the blood-brain barrier to achieve HIV-1 suppression in the CNS macrophages</article-title><source>Sci. Rep.</source><year>2020</year><volume>10</volume><elocation-id>3835</elocation-id><pub-id pub-id-type="doi">10.1038/s41598-020-60684-1</pub-id><pub-id pub-id-type="pmid">32123217</pub-id>
</element-citation></ref><ref id="B163-tropicalmed-10-00045"><label>163.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Roy</surname><given-names>U.</given-names></name>
<name><surname>Drozd</surname><given-names>V.</given-names></name>
<name><surname>Durygin</surname><given-names>A.</given-names></name>
<name><surname>Rodriguez</surname><given-names>J.</given-names></name>
<name><surname>Barber</surname><given-names>P.</given-names></name>
<name><surname>Atluri</surname><given-names>V.</given-names></name>
<name><surname>Liu</surname><given-names>X.</given-names></name>
<name><surname>Voss</surname><given-names>T.G.</given-names></name>
<name><surname>Saxena</surname><given-names>S.</given-names></name>
<name><surname>Nair</surname><given-names>M.</given-names></name>
</person-group><article-title>Characterization of Nanodiamond-based anti-HIV drug Delivery to the Brain</article-title><source>Sci. Rep.</source><year>2018</year><volume>8</volume><elocation-id>1603</elocation-id><pub-id pub-id-type="doi">10.1038/s41598-017-16703-9</pub-id><pub-id pub-id-type="pmid">29371638</pub-id>
</element-citation></ref><ref id="B164-tropicalmed-10-00045"><label>164.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Singh</surname><given-names>D.</given-names></name>
<name><surname>McMillan</surname><given-names>J.</given-names></name>
<name><surname>Hilaire</surname><given-names>J.</given-names></name>
<name><surname>Gautam</surname><given-names>N.</given-names></name>
<name><surname>Palandri</surname><given-names>D.</given-names></name>
<name><surname>Alnouti</surname><given-names>Y.</given-names></name>
<name><surname>E Gendelman</surname><given-names>H.</given-names></name>
<name><surname>Edagwa</surname><given-names>B.</given-names></name>
</person-group><article-title>Development and characterization of a long-acting nanoformulated abacavir prodrug</article-title><source>Nanomedicine</source><year>2016</year><volume>11</volume><fpage>1913</fpage><lpage>1927</lpage><pub-id pub-id-type="doi">10.2217/nnm-2016-0164</pub-id><pub-id pub-id-type="pmid">27456759</pub-id>
</element-citation></ref><ref id="B165-tropicalmed-10-00045"><label>165.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sillman</surname><given-names>B.</given-names></name>
<name><surname>Bade</surname><given-names>A.N.</given-names></name>
<name><surname>Dash</surname><given-names>P.K.</given-names></name>
<name><surname>Bhargavan</surname><given-names>B.</given-names></name>
<name><surname>Kocher</surname><given-names>T.</given-names></name>
<name><surname>Mathews</surname><given-names>S.</given-names></name>
<name><surname>Su</surname><given-names>H.</given-names></name>
<name><surname>Kanmogne</surname><given-names>G.D.</given-names></name>
<name><surname>Poluektova</surname><given-names>L.Y.</given-names></name>
<name><surname>Gorantla</surname><given-names>S.</given-names></name>
<etal/>
</person-group><article-title>Creation of a long-acting nanoformulated dolutegravir</article-title><source>Nat. Commun.</source><year>2018</year><volume>9</volume><fpage>443</fpage><pub-id pub-id-type="doi">10.1038/s41467-018-02885-x</pub-id><pub-id pub-id-type="pmid">29402886</pub-id>
</element-citation></ref><ref id="B166-tropicalmed-10-00045"><label>166.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Mamo</surname><given-names>T.</given-names></name>
<name><surname>Moseman</surname><given-names>E.A.</given-names></name>
<name><surname>Kolishetti</surname><given-names>N.</given-names></name>
<name><surname>Salvador-Morales</surname><given-names>C.</given-names></name>
<name><surname>Shi</surname><given-names>J.</given-names></name>
<name><surname>Kuritzkes</surname><given-names>D.R.</given-names></name>
<name><surname>Langer</surname><given-names>R.</given-names></name>
<name><surname>von Andrian</surname><given-names>U.</given-names></name>
<name><surname>Farokhzad</surname><given-names>O.C.</given-names></name>
</person-group><article-title>Emerging nanotechnology approaches for HIV/AIDS treatment and prevention</article-title><source>Nanomedicine</source><year>2010</year><volume>5</volume><fpage>269</fpage><lpage>285</lpage><pub-id pub-id-type="doi">10.2217/nnm.10.1</pub-id><pub-id pub-id-type="pmid">20148638</pub-id>
</element-citation></ref><ref id="B167-tropicalmed-10-00045"><label>167.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>N&#x000fc;hn</surname><given-names>M.M.</given-names></name>
<name><surname>Gumbs</surname><given-names>S.B.</given-names></name>
<name><surname>Buchholtz</surname><given-names>N.V.</given-names></name>
<name><surname>Jannink</surname><given-names>L.M.</given-names></name>
<name><surname>Gharu</surname><given-names>L.</given-names></name>
<name><surname>de Witte</surname><given-names>L.D.</given-names></name>
<name><surname>Wensing</surname><given-names>A.M.</given-names></name>
<name><surname>Lewin</surname><given-names>S.R.</given-names></name>
<name><surname>Nijhuis</surname><given-names>M.</given-names></name>
<name><surname>Symons</surname><given-names>J.</given-names></name>
</person-group><article-title>Shock and Kill within the CNS: A Promising HIV Eradication Approach?</article-title><source>J. Leukoc. Biol.</source><year>2022</year><volume>112</volume><fpage>1297</fpage><lpage>1315</lpage><pub-id pub-id-type="doi">10.1002/JLB.5VMR0122-046RRR</pub-id><pub-id pub-id-type="pmid">36148896</pub-id>
</element-citation></ref><ref id="B168-tropicalmed-10-00045"><label>168.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kim</surname><given-names>Y.</given-names></name>
<name><surname>Anderson</surname><given-names>J.L.</given-names></name>
<name><surname>Lewin</surname><given-names>S.R.</given-names></name>
</person-group><article-title>Getting the &#x0201c;Kill&#x0201d; into &#x0201c;Shock and Kill&#x0201d;: Strategies to Eliminate Latent HIV</article-title><source>Cell Host Microbe</source><year>2018</year><volume>23</volume><fpage>14</fpage><lpage>26</lpage><pub-id pub-id-type="doi">10.1016/j.chom.2017.12.004</pub-id><pub-id pub-id-type="pmid">29324227</pub-id>
</element-citation></ref><ref id="B169-tropicalmed-10-00045"><label>169.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Gama</surname><given-names>L.</given-names></name>
<name><surname>Abreu</surname><given-names>C.M.</given-names></name>
<name><surname>Shirk</surname><given-names>E.N.</given-names></name>
<name><surname>Price</surname><given-names>S.L.</given-names></name>
<name><surname>Li</surname><given-names>M.</given-names></name>
<name><surname>Laird</surname><given-names>G.M.</given-names></name>
<name><surname>Pate</surname><given-names>K.A.M.</given-names></name>
<name><surname>Wietgrefe</surname><given-names>S.W.</given-names></name>
<name><surname>O&#x02019;connor</surname><given-names>S.L.</given-names></name>
<name><surname>Pianowski</surname><given-names>L.</given-names></name>
<etal/>
</person-group><article-title>Reactivation of simian immunodeficiency virus reservoirs in the brain of virally suppressed macaques</article-title><source>AIDS</source><year>2017</year><volume>31</volume><fpage>5</fpage><lpage>14</lpage><pub-id pub-id-type="doi">10.1097/QAD.0000000000001267</pub-id><pub-id pub-id-type="pmid">27898590</pub-id>
</element-citation></ref><ref id="B170-tropicalmed-10-00045"><label>170.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Giri</surname><given-names>M.S.</given-names></name>
<name><surname>Nebozyhn</surname><given-names>M.</given-names></name>
<name><surname>Raymond</surname><given-names>A.</given-names></name>
<name><surname>Gekonge</surname><given-names>B.</given-names></name>
<name><surname>Hancock</surname><given-names>A.</given-names></name>
<name><surname>Creer</surname><given-names>S.</given-names></name>
<name><surname>Nicols</surname><given-names>C.</given-names></name>
<name><surname>Yousef</surname><given-names>M.</given-names></name>
<name><surname>Foulkes</surname><given-names>A.S.</given-names></name>
<name><surname>Mounzer</surname><given-names>K.</given-names></name>
<etal/>
</person-group><article-title>Circulating Monocytes in HIV-1-Infected Viremic Subjects Exhibit an Antiapoptosis Gene Signature and Virus- and Host-Mediated Apoptosis Resistance</article-title><source>J. Immunol.</source><year>2009</year><volume>182</volume><fpage>4459</fpage><lpage>4470</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.0801450</pub-id><pub-id pub-id-type="pmid">19299747</pub-id>
</element-citation></ref><ref id="B171-tropicalmed-10-00045"><label>171.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hendricks</surname><given-names>C.M.</given-names></name>
<name><surname>Cordeiro</surname><given-names>T.</given-names></name>
<name><surname>Gomes</surname><given-names>A.P.</given-names></name>
<name><surname>Stevenson</surname><given-names>M.</given-names></name>
</person-group><article-title>The Interplay of HIV-1 and Macrophages in Viral Persistence</article-title><source>Front. Microbiol.</source><year>2021</year><volume>12</volume><elocation-id>646447</elocation-id><pub-id pub-id-type="doi">10.3389/fmicb.2021.646447</pub-id><pub-id pub-id-type="pmid">33897659</pub-id>
</element-citation></ref><ref id="B172-tropicalmed-10-00045"><label>172.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Clayton</surname><given-names>K.L.</given-names></name>
<name><surname>Collins</surname><given-names>D.R.</given-names></name>
<name><surname>Lengieza</surname><given-names>J.</given-names></name>
<name><surname>Ghebremichael</surname><given-names>M.</given-names></name>
<name><surname>Dotiwala</surname><given-names>F.</given-names></name>
<name><surname>Lieberman</surname><given-names>J.</given-names></name>
<name><surname>Walker</surname><given-names>B.D.</given-names></name>
</person-group><article-title>Resistance of HIV-infected macrophages to CD8 + T lymphocyte-mediated killing drives activation of the immune system article</article-title><source>Nat. Immunol.</source><year>2018</year><volume>19</volume><fpage>475</fpage><lpage>486</lpage><pub-id pub-id-type="doi">10.1038/s41590-018-0085-3</pub-id><pub-id pub-id-type="pmid">29670239</pub-id>
</element-citation></ref><ref id="B173-tropicalmed-10-00045"><label>173.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Gray</surname><given-names>L.R.</given-names></name>
<name><surname>On</surname><given-names>H.</given-names></name>
<name><surname>Roberts</surname><given-names>E.</given-names></name>
<name><surname>Lu</surname><given-names>H.K.</given-names></name>
<name><surname>Moso</surname><given-names>M.A.</given-names></name>
<name><surname>Raison</surname><given-names>J.A.</given-names></name>
<name><surname>Papaioannou</surname><given-names>C.</given-names></name>
<name><surname>Cheng</surname><given-names>W.-J.</given-names></name>
<name><surname>Ellett</surname><given-names>A.M.</given-names></name>
<name><surname>Jacobson</surname><given-names>J.C.</given-names></name>
<etal/>
</person-group><article-title>Toxicity and in vitro activity of HIV-1 latency-reversing agents in primary CNS cells</article-title><source>J. Neurovirol.</source><year>2016</year><volume>22</volume><fpage>455</fpage><lpage>463</lpage><pub-id pub-id-type="doi">10.1007/s13365-015-0413-4</pub-id><pub-id pub-id-type="pmid">26727904</pub-id>
</element-citation></ref><ref id="B174-tropicalmed-10-00045"><label>174.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Edara</surname><given-names>V.V.</given-names></name>
<name><surname>Ghorpade</surname><given-names>A.</given-names></name>
<name><surname>Borgmann</surname><given-names>K.</given-names></name>
</person-group><article-title>Insights into the Gene Expression Profiles of Active and Restricted Red/Green-HIV + Human Astrocytes: Implications for Shock or Lock Therapies in the Brain</article-title><source>J. Virol.</source><year>2020</year><volume>94</volume><fpage>1110</fpage><lpage>1128</lpage><pub-id pub-id-type="doi">10.1128/JVI.01563-19</pub-id><pub-id pub-id-type="pmid">31896591</pub-id>
</element-citation></ref><ref id="B175-tropicalmed-10-00045"><label>175.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Terry</surname><given-names>R.L.</given-names></name>
<name><surname>Getts</surname><given-names>D.R.</given-names></name>
<name><surname>Deffrasnes</surname><given-names>C.</given-names></name>
<name><surname>van Vreden</surname><given-names>C.</given-names></name>
<name><surname>Campbell</surname><given-names>I.L.</given-names></name>
<name><surname>King</surname><given-names>N.J.C.</given-names></name>
</person-group><article-title>Inflammatory monocytes and the pathogenesis of viral encephalitis</article-title><source>J. Neuroinflammation</source><year>2012</year><volume>9</volume><fpage>270</fpage><pub-id pub-id-type="doi">10.1186/1742-2094-9-270</pub-id><pub-id pub-id-type="pmid">23244217</pub-id>
</element-citation></ref><ref id="B176-tropicalmed-10-00045"><label>176.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Carvalhal</surname><given-names>A.</given-names></name>
<name><surname>Gill</surname><given-names>M.J.</given-names></name>
<name><surname>Letendre</surname><given-names>S.L.</given-names></name>
<name><surname>Rachlis</surname><given-names>A.</given-names></name>
<name><surname>Bekele</surname><given-names>T.</given-names></name>
<name><surname>Raboud</surname><given-names>J.</given-names></name>
<name><surname>Burchell</surname><given-names>A.</given-names></name>
<name><surname>Rourke</surname><given-names>S.B.</given-names></name>
</person-group><article-title>Central nervous system penetration effectiveness of antiretroviral drugs and neuropsychological impairment in the Ontario HIV Treatment Network Cohort Study</article-title><source>J. Neurovirol.</source><year>2016</year><volume>22</volume><fpage>349</fpage><lpage>357</lpage><pub-id pub-id-type="doi">10.1007/s13365-015-0404-5</pub-id><pub-id pub-id-type="pmid">26572786</pub-id>
</element-citation></ref><ref id="B177-tropicalmed-10-00045"><label>177.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ciccarelli</surname><given-names>N.</given-names></name>
<name><surname>Fabbiani</surname><given-names>M.</given-names></name>
<name><surname>Colafigli</surname><given-names>M.</given-names></name>
<name><surname>Trecarichi</surname><given-names>E.M.</given-names></name>
<name><surname>Silveri</surname><given-names>M.C.</given-names></name>
<name><surname>Cauda</surname><given-names>R.</given-names></name>
<name><surname>Murri</surname><given-names>R.</given-names></name>
<name><surname>De Luca</surname><given-names>A.</given-names></name>
<name><surname>Di Giambenedetto</surname><given-names>S.</given-names></name>
</person-group><article-title>Revised central nervous system neuropenetrationeffectiveness score is associated with cognitive disorders in HIV-infected patients with controlled plasma viraemia</article-title><source>Antivir. Ther.</source><year>2013</year><volume>18</volume><fpage>153</fpage><lpage>160</lpage><pub-id pub-id-type="doi">10.3851/IMP2560</pub-id><pub-id pub-id-type="pmid">23486721</pub-id>
</element-citation></ref><ref id="B178-tropicalmed-10-00045"><label>178.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Vassallo</surname><given-names>M.</given-names></name>
<name><surname>Durant</surname><given-names>J.</given-names></name>
<name><surname>Biscay</surname><given-names>V.</given-names></name>
<name><surname>Lebrun-Frenay</surname><given-names>C.</given-names></name>
<name><surname>Dunais</surname><given-names>B.</given-names></name>
<name><surname>Laffon</surname><given-names>M.</given-names></name>
<name><surname>Harvey-Langton</surname><given-names>A.</given-names></name>
<name><surname>Cottalorda</surname><given-names>J.</given-names></name>
<name><surname>Ticchioni</surname><given-names>M.</given-names></name>
<name><surname>Carsenti</surname><given-names>H.</given-names></name>
<etal/>
</person-group><article-title>Can high central nervous system penetrating antiretroviral regimens protect against the onset of HIV-associated neurocognitive disorders</article-title><source>AIDS</source><year>2014</year><volume>28</volume><fpage>493</fpage><lpage>501</lpage><pub-id pub-id-type="doi">10.1097/QAD.0000000000000096</pub-id><pub-id pub-id-type="pmid">24472743</pub-id>
</element-citation></ref><ref id="B179-tropicalmed-10-00045"><label>179.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Cross</surname><given-names>H.M.</given-names></name>
<name><surname>Combrinck</surname><given-names>M.I.</given-names></name>
<name><surname>Joska</surname><given-names>J.A.</given-names></name>
</person-group><article-title>HIV-associated neurocognitive disorders: Antiretroviral regimen, central nervous system penetration effectiveness, and cognitive outcomes</article-title><source>S. Afr. Med. J.</source><year>2013</year><volume>103</volume><fpage>758</fpage><lpage>762</lpage><pub-id pub-id-type="doi">10.7196/SAMJ.6677</pub-id><pub-id pub-id-type="pmid">24079630</pub-id>
</element-citation></ref><ref id="B180-tropicalmed-10-00045"><label>180.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Chan</surname><given-names>T.Y.H.</given-names></name>
<name><surname>Marta</surname><given-names>M.</given-names></name>
<name><surname>Rackstraw</surname><given-names>S.</given-names></name>
</person-group><article-title>Relapse of neurosymptomatic cerebrospinal fluid HIV RNA escape</article-title><source>HIV Med.</source><year>2023</year><volume>24</volume><fpage>1158</fpage><lpage>1163</lpage><pub-id pub-id-type="doi">10.1111/hiv.13527</pub-id><pub-id pub-id-type="pmid">37487714</pub-id>
</element-citation></ref><ref id="B181-tropicalmed-10-00045"><label>181.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kouamou</surname><given-names>V.</given-names></name>
<name><surname>Ndhlovu</surname><given-names>C.E.</given-names></name>
<name><surname>Katzenstein</surname><given-names>D.</given-names></name>
<name><surname>Manasa</surname><given-names>J.</given-names></name>
</person-group><article-title>Rapid hiv-1 drug resistance testing in a resource limited setting: The pan degenerate amplification and adaptation assay (pandaa)</article-title><source>Pan Afr. Med. J.</source><year>2021</year><volume>40</volume><fpage>57</fpage><pub-id pub-id-type="pmid">34795836</pub-id>
</element-citation></ref><ref id="B182-tropicalmed-10-00045"><label>182.</label><element-citation publication-type="book"><person-group person-group-type="author">
<collab>World Health Organization</collab>
</person-group><source>Global Action Plan on HIV Drug Resistance 2017&#x02013;2021</source><publisher-name>WHO Press</publisher-name><publisher-loc>Geneva, Switzerland</publisher-loc><year>2017</year></element-citation></ref></ref-list></back><floats-group><fig position="float" id="tropicalmed-10-00045-f001"><label>Figure 1</label><caption><p>A schema to explain the mechanism of secondary CSF HIV RNA escape.</p></caption><graphic xlink:href="tropicalmed-10-00045-g001" position="float"/></fig></floats-group></article>